U.S. patent application number 16/989184 was filed with the patent office on 2021-06-10 for compositions and methods for treatment of metabolic disorders and diseases.
The applicant listed for this patent is NGM Biopharmaceuticals, Inc.. Invention is credited to Darrin Anthony Lindhout, Lei Ling.
Application Number | 20210169983 16/989184 |
Document ID | / |
Family ID | 1000005406058 |
Filed Date | 2021-06-10 |
United States Patent
Application |
20210169983 |
Kind Code |
A1 |
Ling; Lei ; et al. |
June 10, 2021 |
Compositions and Methods for Treatment of Metabolic Disorders and
Diseases
Abstract
The invention relates to variants and fusions of fibroblast
growth factor 19 (FGF19), variants and fusions of fibroblast growth
factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or
fusions of FGF19 and/or FGF21 proteins and peptide sequences (and
peptidomimetics), having one or more activities, such as glucose
lowering activity, and methods for and uses in treatment of
hyperglycemia and other disorders.
Inventors: |
Ling; Lei; (Foster City,
CA) ; Lindhout; Darrin Anthony; (Mountain View,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NGM Biopharmaceuticals, Inc. |
South San Francisco |
CA |
US |
|
|
Family ID: |
1000005406058 |
Appl. No.: |
16/989184 |
Filed: |
August 10, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15950050 |
Apr 10, 2018 |
10758590 |
|
|
16989184 |
|
|
|
|
14647627 |
May 27, 2015 |
9963494 |
|
|
PCT/US13/71803 |
Nov 26, 2013 |
|
|
|
15950050 |
|
|
|
|
61730777 |
Nov 28, 2012 |
|
|
|
61887108 |
Oct 4, 2013 |
|
|
|
61893720 |
Oct 21, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2319/00 20130101;
A61K 45/06 20130101; G01N 33/66 20130101; C07K 14/50 20130101; A61K
38/1825 20130101 |
International
Class: |
A61K 38/18 20060101
A61K038/18; C07K 14/50 20060101 C07K014/50; A61K 45/06 20060101
A61K045/06 |
Claims
1-79. (canceled)
80. A method of reducing body mass in a subject, comprising
administering to the subject an effective amount of a peptide,
wherein the peptide comprises: a) an N-terminal region comprising
at least seven amino acid residues, the N-terminal region having a
first amino acid position and a last amino acid position, wherein
the N-terminal region comprises DSSPL (SEQ ID NO:121), DASPH (SEQ
ID NO:122), or DAGPH (amino acids 7 to 11 of SEQ ID NO:99 [FGF19]);
and b) a C-terminal region comprising a first amino acid position
and a last amino acid position, wherein the C-terminal region
comprises (i) a first C-terminal region sequence comprising
WGDPIRQRHLYTSG (SEQ ID NO:169 with a L7Q substitution), wherein the
W residue corresponds to the first amino acid position of the
C-terminal region; and (ii) a second C-terminal region sequence
comprising PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIK
GVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNV
YRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:188); wherein
the second C-terminal region sequence comprises a EILPD (amino
acids 103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ
ID NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED
(amino acids 103-107 of SEQ ID NO:196), or LLLED (amino acids
98-102 of SEQ ID NO:100) sequence substituted for the EIRPD
sequence (amino acids 74 to 78 of SEQ ID NO:188); and wherein the
peptide (i) binds to fibroblast growth factor receptor 4 (FGFR4)
with an affinity equal to or greater than FGF19 binding affinity
for FGFR4; (ii) activates FGFR4 to an extent or amount equal to or
greater than FGF19 activates FGFR4; (iii) has at least one of
reduced hepatocellular carcinoma (HCC) formation; greater glucose
lowering activity, less lipid increasing activity, less
triglyceride activity, less cholesterol activity, less non-HDL
activity or less HDL increasing activity, as compared to FGF19, or
as compared to an FGF19 variant sequence having any of GQV, GDI,
WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173),
GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID
NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ
ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ
ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the FGF19 WGDPI (SEQ ID NO:170) sequence at amino
acids 16-20; and/or (iv) has less lean mass reducing activity as
compared to FGF21; thereby reducing body mass in said subject.
81. The method of claim 80, wherein the second C-terminal region
sequence comprises a EILPD (amino acids 103-107 of SEQ ID NO:193)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188).
82. The method of claim 80, wherein the second C-terminal region
sequence comprises a EIRED (amino acids 103-107 of SEQ ID NO:194)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188).
83. The method of claim 80, wherein the second C-terminal region
sequence comprises a), EILCD (amino acids 103-107 of SEQ ID NO:195)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188).
84. The method of claim 80, wherein the second C-terminal region
sequence comprises a EILED (amino acids 103-107 of SEQ ID NO:196)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188).
85. The method of claim 80, wherein the second C-terminal region
sequence comprises a LLLED (amino acids 98-102 of SEQ ID NO:100)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188).
86. The method of claim 80, wherein the second C-terminal region
sequence comprises from 2 to 5 amino acid substitutions, deletions
or insertions.
87. The method of claim 80, wherein the peptide is less than about
250 amino acids in length.
88. The method of claim 80, wherein (i) the N-terminal region
comprises amino acid residues VHYG (SEQ ID NO:101), DASPHVHYG (SEQ
ID NO:102), or DSSPLVHYG (SEQ ID NO:103), wherein the G corresponds
to the last position of the N-terminal region; (ii) the N-terminal
region comprises amino acid residues DSSPLLQ (SEQ ID NO:104), and
wherein the Q residue is the last amino acid position of the
N-terminal region; (iii) the N-terminal region comprises amino acid
residues DSSPLLQFGGQV (SEQ ID NO:105), and wherein the V residue
corresponds to the last position of the N-terminal region; or (iv)
the N-terminal region comprises any one of the following amino acid
sequences: MDSSPL (SEQ ID NO:119), MSDSSPL (SEQ ID NO:120), or
SDSSPL (SEQ ID NO:112).
89. The method of claim 80, wherein the N-terminal region comprises
amino acid residues DAGPHVH (amino acids 7-13 of SEQ ID NO:16),
wherein the last H residue corresponds to the last amino acid
position of the N-terminal region; DAGPHVG (amino acids 7-13 of SEQ
ID NO:17), wherein the last G residue corresponds to the last amino
acid position of the N-terminal region; DAGPHYG (amino acids 7-13
of SEQ ID NO:18), wherein the last G residue corresponds to the
last amino acid position of the N-terminal region; DAGPHVHG (amino
acids 7-14 of SEQ ID NO:22), wherein the last G residue corresponds
to the last amino acid position of the N-terminal region; DAGPHHG
(amino acids 7-13 of SEQ ID NO:23), wherein the last G residue
corresponds to the last amino acid position of the N-terminal
region; DAGPHHY (amino acids 7-13 of SEQ ID NO:24), wherein the Y
residue corresponds to the last amino acid position of the
N-terminal region; DAGPHVY (amino acids 7-13 of SEQ ID NO:25),
wherein the Y residue corresponds to the last amino acid position
of the N-terminal region; DAGPHV (amino acids 7-12 of SEQ ID
NO:28), wherein the V residue corresponds to the last amino acid
position of the N-terminal region; DAGPHVHY (amino acids 7-14 of
SEQ ID NO:29), wherein the Y residue corresponds to the last amino
acid position of the N-terminal region; DAGPHVHYA (amino acids 7-15
of SEQ ID NO:4), wherein the last A residue corresponds to the last
amino acid position of the N-terminal region; DAGPHLQ (amino acids
7-13 of SEQ ID NO:66), wherein the Q residue corresponds to the
last amino acid position of the N-terminal region; or DAGPHVHYG
(amino acids 7-15 of SEQ ID NO:196), wherein the last G residue
corresponds to the last amino acid position of the N-terminal
region.
90. The method of claim 80, wherein the N-terminal region further
comprises: RHPIP (SEQ ID NO:106), wherein R is the first amino acid
position of the N-terminal region; HPIP (SEQ ID NO:107), wherein H
is the first amino acid position of the N-terminal region; RPLAF
(SEQ ID NO:108), wherein R is the first amino acid position of the
N-terminal region; PLAF (SEQ ID NO:109), wherein P is the first
amino acid position of the N-terminal region; or R, wherein R is
the first amino acid position of the N-terminal region.
91. The method of claim 80, wherein the first position of the
N-terminal region is a R or M residue; the first and second
positions of the N-terminal region is a MR, RM, RD, DS, MD or MS
sequence; the first through third positions of the N-terminal
region is a MDS, RDS, MSD, MSS, or DSS sequence; the first through
fourth positions of the N-terminal region is a RDSS (SEQ ID NO:115)
or MDSS (SEQ ID NO:116) sequence; the first through fifth positions
of the N-terminal region is an MRDSS (SEQ ID NO:117) sequence; the
first through sixth positions of the N-terminal region is an MDSSPL
(SEQ ID NO:119) sequence; or the first through seventh positions of
the N-terminal region is an MSDSSPL (SEQ ID NO:120) sequence.
92. The method of claim 80, wherein the N-terminal region has an
amino acid sequence comprising or consisting of any of:
TABLE-US-00020 (M1) (amino acids 1-15 of SEQ ID NO: 1)
RPLAFSDASPHVHYG; (M1-R) (amino acids 2-15 of SEQ ID NO: 1)
PLAFSDASPHVHYG; (M2) (amino acids 1-15 of SEQ ID NO: 2)
RPLAFSDSSPLVHYG; (M2-R) (amino acids 2-15 of SEQ ID NO: 2)
PLAFSDSSPLVHYG; (M8) (amino acids 1-12 of SEQ ID NO: 8)
RHPIPDSSPLLQ; (M9) (amino acids 1-12 of SEQ ID NO: 9)
RHPIPDSSPLLQFG; (M26) (amino acids 1-13 of SEQ ID NO: 26)
RPLAFSDSSPLVH; (M26-R) (amino acids 2-13 of SEQ ID NO: 26)
PLAFSDSSPLVH; (M47) (amino acids 1-11 of SEQ ID NO: 47)
HPIPDSSPLLQ; (M52) (amino acids 1-8 of SEQ ID NO: 52) RDSSPLLQ;
(M52-R) (amino acids 2-8 of SEQ ID NO: 52) DSSPLLQ; (M53) (amino
acids 1-10 of SEQ ID NO: 53) MDSSPLVHYG; (M69) (amino acids 1-10 of
SEQ ID NO: 69) RDSSPLVHYG; (M69-R) (amino acids 2-10 of SEQ ID NO:
69) DSSPLVHYG; (M70) (amino acids 1-11 of SEQ ID NO: 70)
MRDSSPLVHYG; (M9-R) (amino acids 1-9 of SEQ ID NO: 141) DSSPLVHYG;
(amino acids 1-13 of SEQ ID NO: 163) HPIPDSSPLLQFG; (M16) (amino
acids 1-13 of SEQ ID NO: 16) RPLAFSDAGPHVH; (M16-R) (amino acids
2-13 of SEQ ID NO: 16) PLAFSDAGPHVH; (M17) (amino acids 1-13 of SEQ
ID NO: 17) RPLAFSDAGPHVG; (M17-R) (amino acids 2-13 of SEQ ID NO:
17) PLAFSDAGPHVG; (M18) (amino acids 1-13 of SEQ ID NO: 18)
RPLAFSDAGPHYG; (M18-R) (amino acids 2-13 of SEQ ID NO: 18)
PLAFSDAGPHYG; (M22) (amino acids 1-14 of SEQ ID NO: 22)
RPLAFSDAGPHVHG; (M22-R) (amino acids 2-14 of SEQ ID NO: 22)
PLAFSDAGPHVHG; (M23) (amino acids 1-13 of SEQ ID NO: 23)
RPLAFSDAGPHHG; (M23-R) (amino acids 2-13 of SEQ ID NO: 23)
PLAFSDAGPHHG; (M24) (amino acids 1-13 of SEQ ID NO: 24)
RPLAFSDAGPHHY; (M24-R) (amino acids 2-13 of SEQ ID NO: 24)
PLAFSDAGPHHY; (M25) (amino acids 1-13 of SEQ ID NO: 25)
RPLAFSDAGPHVY; (M25-R) (amino acids 2-13 of SEQ ID NO: 25)
PLAFSDAGPHVY; (M28) (amino acids 1-12 of SEQ ID NO: 28)
RPLAFSDAGPHV; (M28-R) (amino acids 2-12 of SEQ ID NO: 28)
PLAFSDAGPHV; (M29) (amino acids 1-14 of SEQ ID NO: 29)
RPLAFSDAGPHVHY; (M29-R) (amino acids 2-14 of SEQ ID NO: 29)
PLAFSDAGPHVHY; (M4) (amino acids 1-15 of SEQ ID NO: 4)
RPLAFSDAGPHVHYA; (M4-R) (amino acids 2-15 of SEQ ID NO: 4)
PLAFSDAGPHVHYA; (M66) (amino acids 1-13 of SEQ ID NO: 66)
RPLAFSDAGPHLQ; (M66-R) (amino acids 2-13 of SEQ ID NO: 66)
PLAFSDAGPHLQ; (M160) (amino acids 1-15 of SEQ ID NO: 196)
RPLAFSDAGPHVHYG; or (M160-R) (amino acids 2-15 of SEQ ID NO: 196)
PLAFSDAGPHVHYG.
93. The method of claim 80, wherein the N-terminal region first
amino acid position is a methionine (M), arginine (R), serine (S),
histidine (H), proline (P), leucine (L) or aspartic acid (D)
residue.
94. The method of claim 80, wherein the N-terminal region does not
have a methionine (M) or arginine (R) residue at the first amino
acid position of the N-terminal region.
95. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of: i. SEQ ID NO:1 (M1) with a
L22Q substitution and a EILPD (amino acids 103-107 of SEQ ID
NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino
acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ
ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); ii. SEQ ID NO:2 (M2) with a L22Q substitution and a EILPD
(amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids 103-107
of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195),
EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED (amino acids
98-102 of SEQ ID NO:100) sequence substituted for the EIRPD
sequence (amino acids 74-78 of SEQ ID NO:188); iii. SEQ ID NO:8
(M8) with a L19Q substitution and a EILPD (amino acids 103-107 of
SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD
(amino acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107
of SEQ ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188); iv. SEQ ID NO:9 (M9) with a L21Q substitution and a
EILPD (amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids
103-107 of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID
NO:195), EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED
(amino acids 98-102 of SEQ ID NO:100) sequence substituted for the
EIRPD sequence (amino acids 74-78 of SEQ ID NO:188); v. SEQ ID
NO:26 (M26) with a L20Q substitution and a EILPD (amino acids
103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID
NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED (amino
acids 103-107 of SEQ ID NO:196), or LLLED (amino acids 98-102 of
SEQ ID NO:100) sequence substituted for the EIRPD sequence (amino
acids 74-78 of SEQ ID NO:188); vi. SEQ ID NO:47 (M47) with a L18Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); vii. SEQ ID NO:52 (M52) with a L15Q substitution and a
EILPD (amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids
103-107 of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID
NO:195), EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED
(amino acids 98-102 of SEQ ID NO:100) sequence substituted for the
EIRPD sequence (amino acids 74-78 of SEQ ID NO:188); viii. SEQ ID
NO:192 (M53) with a L15Q substitution and a EILPD (amino acids
103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID
NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED (amino
acids 103-107 of SEQ ID NO:196), or LLLED (amino acids 98-102 of
SEQ ID NO:100) sequence substituted for the EIRPD sequence (amino
acids 74-78 of SEQ ID NO:188); ix. SEQ ID NO:69 (M69) with a L17Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); x. SEQ ID NO:70 (M70) with a L18Q substitution and a EILPD
(amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids 103-107
of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195),
EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED (amino acids
98-102 of SEQ ID NO:100) sequence substituted for the EIRPD
sequence (amino acids 74-78 of SEQ ID NO:188); xi. SEQ ID NO:141
with a L16Q substitution a EILPD (amino acids 103-107 of SEQ ID
NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino
acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ
ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); xii. SEQ ID NO:163 with a L20Q substitution and a EILPD
(amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids 103-107
of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195),
EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED (amino acids
98-102 of SEQ ID NO:100) sequence substituted for the EIRPD
sequence (amino acids 74-78 of SEQ ID NO:188); xiii. SEQ ID NO:4
(M4) with a L22Q substitution and a EILPD (amino acids 103-107 of
SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD
(amino acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107
of SEQ ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188); xiv. SEQ ID NO:16 (M16) with a L20Q substitution a
EILPD (amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids
103-107 of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID
NO:195), EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED
(amino acids 98-102 of SEQ ID NO:100) sequence substituted for the
EIRPD sequence (amino acids 74-78 of SEQ ID NO:188); xv. SEQ ID
NO:17 (M17) with a L20Q substitution and a EILPD (amino acids
103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID
NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED (amino
acids 103-107 of SEQ ID NO:196), or LLLED (amino acids 98-102 of
SEQ ID NO:100) sequence substituted for the EIRPD sequence (amino
acids 74-78 of SEQ ID NO:188); xvi. SEQ ID NO:18 (M18) with a L20Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); xvii. SEQ ID NO:22 (M22) with a L21Q substitution and a
EILPD (amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids
103-107 of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID
NO:195), EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED
(amino acids 98-102 of SEQ ID NO:100) sequence substituted for the
EIRPD sequence (amino acids 74-78 of SEQ ID NO:188); xviii. SEQ ID
NO:23 (M23) with a L20Q substitution and a EILPD (amino acids
103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID
NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED (amino
acids 103-107 of SEQ ID NO:196), or LLLED (amino acids 98-102 of
SEQ ID NO:100) sequence substituted for the EIRPD sequence (amino
acids 74-78 of SEQ ID NO:188); xix. SEQ ID NO:24 (M24) with a L20Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188); xx. SEQ ID NO:25 (M25) with a L20Q substitution a EILPD
(amino acids 103-107 of SEQ ID NO:193), EIRED (amino acids 103-107
of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195),
EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED (amino acids
98-102 of SEQ ID NO:100) sequence substituted for the EIRPD
sequence (amino acids 74-78 of SEQ ID NO:188); xxi. SEQ ID NO:28
(M28) with a L19Q substitution and a EILPD (amino acids 103-107 of
SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD
(amino acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107
of SEQ ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100)
sequence substituted for the EIRPD sequence (amino acids 74-78 of
SEQ ID NO:188); xxii. SEQ ID NO:29 (M29) with a L21Q substitution
and a EILPD (amino acids 103-107 of SEQ ID NO:193), EIRED (amino
acids 103-107 of SEQ ID NO:194), EILCD (amino acids 103-107 of SEQ
ID NO:195), EILED (amino acids 103-107 of SEQ ID NO:196), or LLLED
(amino acids 98-102 of SEQ ID NO:100) sequence substituted for the
EIRPD sequence (amino acids 74-78 of SEQ ID NO:188); xxiii. SEQ ID
NO:66 (M66) with a L20Q substitution and a EILPD (amino acids
103-107 of SEQ ID NO:193), EIRED (amino acids 103-107 of SEQ ID
NO:194), EILCD (amino acids 103-107 of SEQ ID NO:195), EILED (amino
acids 103-107 of SEQ ID NO:196), or LLLED (amino acids 98-102 of
SEQ ID NO:100) sequence substituted for the EIRPD sequence (amino
acids 74-78 of SEQ ID NO:188); xxiv. SEQ ID NO:193 (M139) with a
L22Q substitution; xxv. SEQ ID NO:194 (M140) with a L22Q
substitution; xxvi. SEQ ID NO:195 (M141) with a L22Q substitution;
or xxvii. SEQ ID NO:196 (M160).
96. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:52 (M52) with a L15Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188).
97. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:192 (M53) with a
L15Q substitution and a EILPD (amino acids 103-107 of SEQ ID
NO:193), EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino
acids 103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ
ID NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188).
98. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:69 (M69) with a L17Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188).
99. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:70 (M70) with a L18Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188).
100. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:4 (M4) with a L22Q
substitution and a EILPD (amino acids 103-107 of SEQ ID NO:193),
EIRED (amino acids 103-107 of SEQ ID NO:194), EILCD (amino acids
103-107 of SEQ ID NO:195), EILED (amino acids 103-107 of SEQ ID
NO:196), or LLLED (amino acids 98-102 of SEQ ID NO:100) sequence
substituted for the EIRPD sequence (amino acids 74-78 of SEQ ID
NO:188);
101. The method of claim 80, wherein the peptide has an amino acid
sequence comprising or consisting of SEQ ID NO:196 (M160).
102. The method of claim 95, wherein the arginine (R) residue at
the first amino acid position of the N-terminal region of the
sequence of claim 95 (i)-(v), (vii), (ix), and (xiii)-(xxvii) is
deleted.
103. The method of claim 80, wherein the peptide has at least one
of reduced HCC formation; greater glucose lowering activity, or
less lipid increasing activity as compared to FGF19, or as compared
to an FGF19 variant having any of GQV, GDI, WGPI (SEQ ID NO:171),
WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174),
GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID
NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ
ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ
ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ
ID NO:170) sequence at amino acids 16-20 of FGF19 (SEQ ID
NO:99).
104. The method of claim 103, wherein the HCC formation, glucose
lowering activity, or lipid increasing activity is ascertained in a
db/db mouse.
105. The method of claim 80, wherein the peptide has less lean mass
reducing activity as compared to the lean mass reducing activity of
FGF21.
106. The method of claim 105, wherein the lean mass reducing
activity is ascertained in a db/db mouse.
107. The method of claim 80, wherein the peptide is formulated as a
pharmaceutical composition, wherein the pharmaceutical composition
further comprises a pharmaceutically acceptable carrier.
108. The method of claim 80, wherein the method further comprises
administration of a supplemental therapy.
109. The method of claim 108, wherein said supplemental therapy is
a weight loss surgery, gastric bypass, gastrectomy, gastric
banding, gastric balloon, or gastric sleeve.
110. The method of claim 108, wherein said supplemental therapy is
a glucose lowering agent, insulin, GLP1 analogue, biguanide,
sulphonylurea, thiazolidinedione, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, a bromocriptine formulation, a bile acid sequestrant,
metformin, a thiazolidinedione (TZD), a SGLT-2 inhibitor, or any
combination thereof.
111. The method of claim 110, wherein said biguanide or
sulphonylurea is selected from the group consisting of tolbutamide,
chlorpropamide, acetohexamide, tolazamide, glibenclamide, glipizide
or any combination thereof.
112. The method of claim 110, wherein said thiazolidinedione is
rosiglitazone or pioglitazone, or combination thereof.
113. The method of claim 110, wherein said bile acid sequestrant is
colesevelam.
114. The method of claim 110, wherein said insulin is bolus
insulin, basal insulin, or an analogue thereof.
115. The method of claim 110, wherein said metformin is metformin
hydrochloride.
116. The method of claim 108, wherein said supplemental therapy is
administered prior to said method.
117. The method of claim 108, wherein said supplemental therapy is
administered contemporaneously with said method.
118. The method of claim 108, wherein said supplemental therapy is
administered following said method.
119. The method of claim 80, wherein the subject has a metabolic
disorder.
120. The method of claim 80, wherein the subject has an insulin
resistance disorder.
121. The method of claim 80, wherein the subject has
hyperinsulinemia.
122. The method of claim 80, wherein the subject has glucose
intolerance.
123. The method of claim 80, wherein the subject has a
hyperglycemic disorder or is at risk of developing a hyperglycemic
disorder.
124. The method of claim 80, wherein the subject has diabetes.
125. The method of claim 80, wherein the subject has
insulin-dependent (type I) diabetes.
126. The method of claim 80, wherein the subject has type II
diabetes.
127. The method of claim 80, wherein the subject has gestational
diabetes.
128. The method of claim 80, wherein the subject is obese.
129. The method of claim 80, wherein the subject has a body mass
index greater than 25.
130. The method of claim 80, wherein the subject has a body mass
index greater than 40.
131. The method of claim 80, wherein the subject has nonalcoholic
fatty liver disease (NAFLD).
132. The method of claim 80, wherein the subject has nonalcoholic
steatohepatitis (NASH).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a division of U.S. application Ser. No.
15/950,050, filed Apr. 10, 2018, which is a division of U.S.
application Ser. No. 14/647,627, filed May 27, 2015, now U.S. Pat.
No. 9,963,494, which is a 371 national stage application of
international application Serial No. PCT/US2013/071803, filed on
Nov. 26, 2013, which claims the benefit of U.S. Application No.
61/730,777 filed Nov. 28, 2012, U.S. Application No. 61/887,108
filed Oct. 4, 2013 and U.S. Application No. 61/893,720 filed Oct.
21, 2013, each of which is incorporated herein by reference in its
entirety.
FIELD OF THE INVENTION
[0002] The invention relates to variants of fibroblast growth
factor 19 (FGF19) proteins and peptide sequences (and
peptidomimetics) and fusions of FGF19 and/or fibroblast growth
factor 21 (FGF21) proteins and peptide sequences (and
peptidomimetics), and variants of fusions of FGF19 and/or FGF21
proteins and peptide sequences (and peptidomimetics) having glucose
lowering activity, and methods for and uses in treatment of
hyperglycemia and other disorders.
INTRODUCTION
[0003] Diabetes mellitus is a debilitating metabolic disease caused
by absent insulin production (type 1) or insulin resistance or
insufficient insulin production (type 2) from pancreatic
.beta.-cells. .beta.-cells are specialized endocrine cells that
manufacture and store insulin for release following a meal. Insulin
is a hormone that facilitates the transfer of glucose from the
blood into tissues where it is needed. Patients with diabetes must
frequently monitor blood glucose levels and many require multiple
daily insulin injections to survive. However, such patients rarely
attain ideal glucose levels by insulin injection (Turner, R. C. et
al. JAMA 281:2005(1999)). Furthermore, prolonged elevation of
insulin levels can result in detrimental side effects such as
hypoglycemic shock and desensitization of the body's response to
insulin. Consequently, diabetic patients still develop long-term
complications, such as cardiovascular diseases, kidney disease,
blindness, nerve damage and wound healing disorders (UK Prospective
Diabetes Study (UKPDS) Group, Lancet 352:837 (1998)).
[0004] Bariatric surgery has been proposed as a potential treatment
for diabetes. It has been postulated that changes in gut hormone
secretion after the surgery are responsible for the resolution of
diabetic conditions. The underlying molecular mechanism has yet to
be elucidated, although glucagon-like peptide 1 (GLP-1) has been
speculated as a possible candidate (Rubino, F. Diabetes Care 32
Suppl 2:S368(2009)). FGF19 is highly expressed in the distal small
intestine and transgenic over-expression of FGF19 improves glucose
homeostasis (Tomlinson, E. Endocrinology 143(5):1741-7(2002)).
Serum levels of FGF19 in humans are elevated following gastric
bypass surgery. Augmented expression and secretion of FGF19 could
at least partially explain the diabetes remission experienced
following surgery.
[0005] Accordingly, there is a need for alternative treatments of
hyperglycemic conditions such as diabetes, prediabetes, insulin
resistance, hyperinsulinemia, glucose intolerance or metabolic
syndrome, and other disorders and diseases associated with elevated
glucose levels, in humans. The invention satisfies this need and
provides related advantages.
SUMMARY
[0006] The invention is based, in part, on variants of FGF19
peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences
and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide
sequences having one or more activities, such as glucose lowering
activity. Such variants and fusions (chimeras) of FGF19 and/or
FGF21 peptide sequences include sequences that do not increase or
induce hepatocellular carcinoma (HCC) formation or HCC
tumorigenesis. Such variants and fusions (chimeras) of FGF19 and/or
FGF21 peptide sequences also include sequences that do not induce a
substantial elevation or increase in lipid profile.
[0007] In one embodiment, a chimeric peptide sequence includes or
consists of: a) an N-terminal region comprising at least seven
amino acid residues, the N-terminal region having a first amino
acid position and a last amino acid position, wherein the
N-terminal region comprises a DSSPL (SEQ ID NO:121) or DASPH (SEQ
ID NO:122); and b) a C-terminal region comprising a portion of SEQ
ID NO:99 [FGF19], the C-terminal region having a first amino acid
position and a last amino acid position, wherein the C-terminal
region comprises amino acid residues 16-29 of SEQ ID NO:99 [FGF19]
(WGDPIRLRHLYTSG; SEQ ID NO:169), wherein the W residue corresponds
to the first amino acid position of the C-terminal region.
[0008] In another embodiment, a chimeric peptide sequence includes
or consists of: a) an N-terminal region comprising a portion of SEQ
ID NO:100 [FGF21], the N-terminal region having a first amino acid
position and a last amino acid position, wherein the N-terminal
region comprises amino acid residues GQV, and wherein the V residue
corresponds to the last amino acid position of the N-terminal
region; and b) a C-terminal region comprising a portion of SEQ ID
NO:99 [FGF19], the C-terminal region having a first amino acid
position and a last amino acid position, wherein the C-terminal
region comprises amino acid residues 21-29 of SEQ ID NO:99 [FGF19],
RLRHLYTSG (SEQ ID NO:185), and wherein the R residue corresponds to
the first position of the C-terminal region.
[0009] In a further embodiment, a chimeric peptide sequence
includes or consists of any of: a) an N-terminal region comprising
a portion of SEQ ID NO:100 [FGF21], the N-terminal region having a
first amino acid position and a last amino acid position,
[0010] wherein the N-terminal region comprises at least 5
contiguous amino acids of SEQ ID NO:100 [FGF21] including the amino
acid residues GQV, and wherein the V residue corresponds to the
last amino acid position of the N-terminal region; and b) a
C-terminal region comprising a portion of SEQ ID NO:99 [FGF19], the
C-terminal region having a first amino acid position and a last
amino acid position, wherein the C-terminal region comprises amino
acid residues 21-29 of SEQ ID NO:99 [FGF19], RLRHLYTSG (SEQ ID
NO:185), and wherein the R residue corresponds to the first
position of the C-terminal region.
[0011] In an additional embodiment, a peptide sequence includes or
consists of any of: a) a FGF19 sequence variant having one or more
amino acid substitutions, insertions or deletions compared to a
reference or wild type FGF19; b) a FGF21 sequence variant having
one or more amino acid substitutions, insertions or deletions
compared to a reference or wild type FGF21; c) a portion of an
FGF19 sequence fused to a portion of an FGF21 sequence; or d) a
portion of an FGF19 sequence fused to a portion of an FGF21
sequence, wherein the FGF19 and/or FGF21 sequence portion(s) have
one or more amino acid substitutions, insertions or deletions
compared to a reference or wild type FGF19 and/or FGF21.
[0012] In particular aspects, the N-terminal region comprises at
least 6 contiguous amino acids (or more, e.g., 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-40, 40-50, 50-75,
75-100 contiguous amino acids) of SEQ ID NO:100 [FGF21] including
the amino acid residues GQV.
[0013] In still further embodiments, a peptide sequence or a
chimeric peptide sequence includes or consists of amino-terminal
amino acids 1-16 of SEQ ID NO:100 [FGF21] fused to carboxy-terminal
amino acids 21-194 of SEQ ID NO:99 [FGF19], or the peptide sequence
has amino-terminal amino acids 1-147 of SEQ ID NO:99 [FGF19] fused
to carboxy-terminal amino acids 147-181 of SEQ ID NO:100 [FGF21]
(M41), or the peptide sequence has amino-terminal amino acids 1-20
of SEQ ID NO:99 [FGF19] fused to carboxy-terminal amino acids
17-181 of SEQ ID NO:100 [FGF21] (M44), or the peptide sequence has
amino-terminal amino acids 1-146 of SEQ ID NO:100 [FGF21] fused to
carboxy-terminal amino acids 148-194 of SEQ ID NO:99 [FGF19] (M45),
or the peptide sequence has amino-terminal amino acids 1-20 of SEQ
ID NO:99 [FGF19] fused to internal amino acids 17-146 of SEQ ID
NO:100 [FGF21] or fused to carboxy-terminal amino acids 148-194 of
SEQ ID NO:99 [FGF19] (M46).
[0014] In various further embodiments, a peptide sequence has at
least one amino acid substitution to amino acid residues 125-129 of
SEQ ID NO:99 [FGF19], EIRPD; at least one amino acid substitution
to amino acid residues 126-128 of SEQ ID NO:99 [FGF19], IRP; or at
least one amino acid substitution to amino acid residues 127-128 of
SEQ ID NO:99 [FGF19], RP, or at least one amino acid substitution
to amino acid residues 1-124 of SEQ ID NO:99 [FGF19] and/or to
amino acid residues 130-194 of SEQ ID NO:99 [FGF19]. More
specifically, for example, a peptide sequence with a substitution
to one of amino acid residues 127-128 of SEQ ID NO:99 [FGF19], IRP,
wherein at least one amino acid substitution is R127L or P128E.
[0015] Methods and uses of the invention can be practiced using a
peptide or chimeric sequence, as set forth herein. For example, a
sequence that includes or consists of any peptide sequence set
forth herein as M1 to M98, or M101 to M160, or SEQ ID NOs:1 to 98,
101 to 135, or 138 to 196, a peptide sequence that includes or
consists of any sequence set forth in Tables 1-9, or a peptide
sequence that includes or consists of any sequence set forth in the
Sequence Listing herein.
[0016] Methods and uses of the invention can be practiced using a
peptide or chimeric sequence of any suitable length. In particular
embodiments, the N-terminal or C-terminal region of the peptide or
chimeric sequence is from about 20 to about 200 amino acid residues
in length. In other particular aspects, a peptide or chimeric
sequence has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20 or more amino acid deletions from the amino
terminus, the carboxy-terminus or internally. In further particular
embodiments, a peptide or chimeric sequence has an N-terminal
region, or a C-terminal region that includes or consists of an
amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40,
40 to 50, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino
acids. In additional more particular embodiments, a peptide or
chimeric sequence has an FGF19 sequence portion, or an FGF21
sequence portion that includes or consists of an amino acid
sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50,
50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino
acids of FGF19 or FGF21.
[0017] In yet additional embodiments, a peptide sequence or a
chimeric peptide sequence has a WGDPI (SEQ ID NO:170) sequence
motif corresponding to the WGDPI sequence of amino acids 16-20 of
SEQ ID NO:99 [FGF19]; has a substituted, mutated or absent WGDPI
(SEQ ID NO:170) sequence motif corresponding to FGF19 WGDPI (SEQ ID
NO:170) sequence of amino acids 16-20 of FGF19; has a WGDPI (SEQ ID
NO:170) sequence with one or more amino acids substituted, mutated
or absent. In various other further aspects, the peptide sequence
is distinct from an FGF 19 variant sequence having any of GQV, GDI,
WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173),
GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID
NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ
ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ
ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the FGF19 WGDPI (SEQ ID NO:170) sequence at amino
acids 16-20.
[0018] In yet further embodiments, a peptide sequence or a chimeric
peptide sequence has N-terminal region comprises amino acid
residues VHYG (SEQ ID NO:101), wherein the N-terminal region
comprises amino acid residues DASPHVHYG (SEQ ID NO:102), or the
N-terminal region comprises amino acid residues DSSPLVHYG (SEQ ID
NO:103). More particularly, in one aspect the G corresponds to the
last position of the N-terminal region.
[0019] In various additional aspects, the N-terminal region
comprises amino acid residues DSSPLLQ (SEQ ID NO:104), where the Q
residue is the last amino acid position of the N-terminal region,
or comprises amino acid residues DSSPLLQFGGQV (SEQ ID NO:105),
where the V residue corresponds to the last position of the
N-terminal region.
[0020] In still additional embodiments, a peptide sequence or a
chimeric peptide sequence has an N-terminal region that includes or
consists of: RHPIP (SEQ ID NO:106), where R is the first amino acid
position of the N-terminal region; or HPIP (SEQ ID NO:107) (e.g.,
where HPIP are the first 4 amino acid residues of the N-terminal
region), where H is the first amino acid position of the N-terminal
region; or RPLAF (SEQ ID NO:108), where R is the first amino acid
position of the N-terminal region; or PLAF (SEQ ID NO:109), where P
is the first amino acid position of the N-terminal region; or R,
where R is the first amino acid position of the N-terminal
region.
[0021] In various other aspects, a peptide or chimeric sequence
has: amino acid residues HPIP (SEQ ID NO:107), which are the first
4 amino acid residues of the N-terminal region. In various still
further aspects, a peptide or chimeric sequence has: an R residue
at the first position of the N-terminal region, or the first
position of the N-terminal region is an M residue, or the first and
second positions of the N-terminal region is an MR sequence, or the
first and second positions of the N-terminal region is an RM
sequence, or the first and second positions of the N-terminal
region is an RD sequence, or the first and second positions of the
N-terminal region is an DS sequence, or the first and second
positions of the N-terminal region is an MD sequence, or the first
and second positions of the N-terminal region is an MS sequence, or
the first through third positions of the N-terminal region is an
MDS sequence, or the first through third positions of the
N-terminal region is an RDS sequence, or the first through third
positions of the N-terminal region is an MSD sequence, or the first
through third positions of the N-terminal region is an MSS
sequence, or the first through third positions of the N-terminal
region is an DSS sequence, or the first through fourth positions of
the N-terminal region is an RDSS (SEQ ID NO:115), sequence, or the
first through fourth positions of the N-terminal region is an MDSS
(SEQ ID NO:116), sequence, or the first through fifth positions of
the N-terminal region is an MRDSS (SEQ ID NO:117), sequence, or the
first through fifth positions of the N-terminal region is an MSSPL
(SEQ ID NO:113) sequence, or the first through sixth positions of
the N-terminal region is an MDSSPL (SEQ ID NO:110) sequence, or the
first through seventh positions of the N-terminal region is an
MSDSSPL (SEQ ID NO:111) sequence.
[0022] In various other particular aspects, a peptide or chimeric
sequence has at the N-terminal region first amino acid position an
"M" residue, an "R" residue, a "S" residue, a "H" residue, a "P"
residue, a "L" residue or an "D" residue. In various alternative
particular aspects, a peptide or chimeric sequence peptide sequence
does not have a "M" residue or an "R" residue at the first amino
acid position of the N-terminal region.
[0023] In further various other aspects, a peptide or chimeric
sequence has an N-terminal region with any one of the following
sequences: MDSSPL (SEQ ID NO:110), MSDSSPL (SEQ ID NO:111), SDSSPL
(SEQ ID NO:112), MSSPL (SEQ ID NO:113) or SSPL (SEQ ID NO:114).
[0024] In still other embodiments, a peptide sequence or a chimeric
peptide sequence an addition of amino acid residues 30-194 of SEQ
ID NO:99 [FGF19] at the C-terminus, resulting in a chimeric
polypeptide having at the last position of the C-terminal region
that corresponds to about residue 194 of SEQ ID NO:99 [FGF19]. In
further other embodiments, a chimeric peptide sequence or peptide
sequence comprises all or a portion of an FGF19 sequence (e.g., SEQ
ID NO:99), positioned at the C-terminus of the peptide, or where
the amino terminal "R" residue is deleted from the peptide.
[0025] In more particular embodiments, a chimeric peptide sequence
or peptide sequence includes or consists of any of M1-M98 variant
peptide sequences, or a subsequence or fragment of any of the
M1-M98 variant peptide sequences. Methods and uses of the invention
can also be practiced using a peptide or chimeric sequence, as set
forth herein. For example, a sequence that includes or consists of
any peptide sequence set forth herein as M1 to M98, or M101 to
M160, or SEQ ID NOs:1 to 98, 101 to 135, or 138 to 196, a peptide
sequence that includes or consists of any sequence set forth in
Tables 1-9, or a peptide sequence that includes or consists of any
sequence set forth in the Sequence Listing herein.
[0026] Methods and uses of the invention can be practiced using a
peptide or chimeric sequence of any suitable length. In particular
embodiments, the N-terminal or C-terminal region of the peptide or
chimeric sequence is from about 20 to about 200 amino acid residues
in length. In further particular embodiments, a chimeric peptide
sequence or peptide sequence has at least one amino acid deletion.
In other particular aspects, a peptide or chimeric sequence has 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
or more amino acid deletions from the amino terminus, the
carboxy-terminus or internally. In a particular non-limiting
aspect, the amino acid substitution, or deletion is at any of amino
acid positions 8-20 of FGF19 (AGPHVHYGWGDPI) (AGPHVHYGWGDPI) (SEQ
ID NO:187). In further particular embodiments, a peptide or
chimeric sequence has an N-terminal region, or a C-terminal region
that includes or consists of an amino acid sequence of about 5 to
10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 60 to 70, 70 to 80, 80
to 90, 90 to 100 or more amino acids. In additional more particular
embodiments, a peptide or chimeric sequence has an FGF19 sequence
portion, or an FGF21 sequence portion that includes or consists of
an amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to
40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or
more amino acids of FGF19 or FGF21.
[0027] In further particular embodiments, chimeric peptide
sequences and peptide sequences have particular functions or
activities. In one aspect, a chimeric peptide sequence or peptide
sequence maintains or increases an FGFR4 mediated activity. In
additional aspects, a chimeric peptide sequence or peptide sequence
binds to fibroblast growth factor receptor 4 (FGFR4) or activates
FGFR4, or does not detectably bind to FGFR4 or activate FGFR4, or
binds to FGFR4 with an affinity less than, comparable to or greater
than FGF19 binding affinity for FGFR4, or activates FGFR4 to an
extent or amount less than, comparable to or greater than FGF19
activates FGFR4. In further aspects, a chimeric peptide sequence or
peptide sequence has reduced HCC formation compared to FGF19, or an
FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID
NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID
NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI
(SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179),
WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182),
WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the
WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; or
has greater glucose lowering activity compared to FGF19, or an FGF
19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171),
WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174),
GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID
NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ
ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ
ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ
ID NO:170) sequence at amino acids 16-20 of FGF19; has less lipid
increasing activity compared to FGF19, or an FGF 19 variant
sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ
ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI
(SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177),
WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID
NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID
NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID
NO:170) sequence at amino acids 16-20 of FGF19; or has less
triglyceride, cholesterol, non-HDL or HDL increasing activity
compared to FGF19, or an FGF 19 variant sequence having any of GQV,
GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID
NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI
(SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178),
WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181),
WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids
16-20 of FGF19; or the peptide sequence has less lean mass reducing
activity compared to FGF21. Such functions and activities can be
ascertained in vitro or in vivo, for example, in a db/db mouse.
[0028] In still additional embodiments, chimeric peptide sequences
and peptide sequences isolated or purified, and/or chimeric peptide
sequences and peptide sequences can be included in compositions. In
one embodiment, a chimeric peptide sequence or peptide sequence is
included in a pharmaceutical composition. Such compositions include
combinations of inactive or other active ingredients. In one
embodiment, a compositions, such as a pharmaceutical composition
includes chimeric peptide sequence or peptide sequence and a
glucose lowering agent.
[0029] In yet further embodiments, nucleic acid molecules encoding
the chimeric peptide sequence or peptide sequence are provided.
Such molecules can further include an expression control element in
operable linkage that confers expression of the nucleic acid
molecule encoding the peptide in vitro, in a cell or in vivo, or a
vector comprising the nucleic acid molecule (e.g., a viral vector).
Transformed and host cells that express the chimeric peptide
sequences and peptide sequences are also provided.
[0030] Uses and methods of treatment that include administration or
delivery of any chimeric peptide sequence or peptide sequence are
also provided. In particular embodiments, a use or method of
treatment of a subject includes administering an invention chimeric
peptide or peptide sequence to a subject, such as a subject having,
or at risk of having, a disease or disorder treatable by an
invention peptide sequence, in an amount effective for treating the
disease or disorder. In a further embodiment, a method includes
administering an invention chimeric peptide or peptide sequence to
a subject, such as a subject having a hyperglycemic condition
(e.g., diabetes, such as insulin-dependent (type I) diabetes, type
II diabetes, or gestational diabetes), insulin resistance,
hyperinsulinemia, glucose intolerance or metabolic syndrome, or is
obese or has an undesirable body mass.
[0031] In particular aspects of the methods and uses, a chimeric
peptide sequence or peptide sequence is administered to a subject
in an amount effective to improve glucose metabolism in the
subject. In more particular aspects, a subject has a fasting plasma
glucose level greater than 100 mg/dl or has a hemoglobin A1c
(HbA1c) level above 6%, prior to administration.
[0032] In further embodiments, a use or method of treatment of a
subject is intended to or results in reduced glucose levels,
increased insulin sensitivity, reduced insulin resistance, reduced
glucagon, an improvement in glucose tolerance, or glucose
metabolism or homeostasis, improved pancreatic function, or reduced
triglyceride, cholesterol, IDL, LDL or VLDL levels, or a decrease
in blood pressure, a decrease in intimal thickening of the blood
vessel, or a decrease in body mass or weight gain.
[0033] Methods of analyzing and/or identifying a chimeric peptide
sequence or peptide sequence are also provided, such as chimeric
peptide sequences and peptide sequences that have glucose lowering
activity without substantial HCC activity. In one embodiment, a
method includes: a) providing a candidate chimeric peptide sequence
or peptide sequence; b) administering the candidate peptide
sequence to a test animal (e.g., a db/db mouse); c) measuring
glucose levels of the animal after administration of the candidate
peptide sequence, to determine if the candidate peptide sequence
reduces glucose levels. In a particular aspect, the chimeric
peptide sequence or peptide sequence is also analyzed for induction
of HCC in the animal (e.g., assessing a hepatic tissue sample from
the test animal), or expression of a marker correlating with HCC
activity, wherein a candidate peptide having glucose lowering
activity and not substantial HCC activity. Such methods identify
the candidate as having glucose lowering activity, optionally also
without substantial HCC activity.
DESCRIPTION OF DRAWINGS
[0034] FIG. 1 shows FGF19 and FGF21 protein sequences (SEQ ID
NOs:99 and 100, respectively), and representative variant
sequences, namely variant M5 (SEQ ID NO:5), variant M1 (SEQ ID
NO:1), variant M2 (SEQ ID NO:2), variant M69 (SEQ ID NO:69),
variant M3 (SEQ ID NO:3), variant M48 (SEQ ID NO:48), variant M49
(SEQ ID NO:49), variant M50 (SEQ ID NO:50), variant M51 (SEQ ID
NO:51), variant M52 (SEQ ID NO:52), variant M53 (SEQ ID NO:192) and
variant M70 (SEQ ID NO:70) peptide sequences. Three additional
allelic (polymorphic) forms of FGF21, namely M71 (SEQ ID NO:71),
M72 (SEQ ID NO:72) and M73 (SEQ ID NO:73), are also shown.
[0035] FIG. 2 shows representative domain exchanges between FGF21
(no shading) and FGF19 (grey shading) protein sequences, and the
resultant fusion (chimeric) sequences. The amino acid regions from
each of FGF21 and FGF19 present in the fusion (chimera) are
indicated by the numbers. Glucose lowering and lipid elevation are
shown for each of the chimeric sequences.
[0036] FIG. 3A-3I show glucose lowering and body weight data. A)
variant M5; B) variant M1; C) variant M2 and variant M69; D)
variant M3; E) variant M48 and variant M49; F) variant M51 and
variant M50; G) variant M52 peptide; H) variant M53 peptide; and I)
variant M70 peptide sequences all have glucose lowering (i.e.,
anti-diabetic) activity in db/db mice. Mice were injected with AAV
vector expressing FGF19, FGF21, the selected variants, and saline
and GFP are negative controls.
[0037] FIG. 4A-4I show serum lipid profile (triglyceride, total
cholesterol, HDL and non-HDL) of db/db mice injected with AAV
vector expressing FGF19, FGF21 or A) variant M5; B) variant M1; C)
variant M2 and variant M69; D) variant M3; E) variant M48 and
variant M49; F) variant M51 and variant M50; G) variant M52
peptide; H) variant M53 peptide; and I) variant M70 peptide
sequences. Variant M5 peptide sequence did not increase or elevate
lipids, in contrast to FGF19, M1, M2 and M69 which increases and
elevates lipids. Serum levels of all variants were comparable.
Saline and GFP are negative controls.
[0038] FIG. 5A-5I show HCC-related data for A) variant M5; B)
variant M1; C) variant M2 and variant M69; D) variant M3; E)
variant M48 and variant M49; F) variant M51 and variant M50; G)
variant M52; H) variant M53 peptide; and I) variant M70 peptide
sequences. All variants did not significantly increase or induce
HCC formation or HCC tumorigenesis, in contrast to FGF19. HCC score
is recorded as the number of HCC nodules on the surface of the
entire liver from variants-injected mice divided by the number of
HCC nodules from wild type FGF19-injected mice.
[0039] FIG. 6A-6I show lean mass or fat mass data for A) variant
M5; B) variant M1; C) variant M2 and variant M69; D) variant M3; E)
variant M48 and variant M49; F) variant M51 and variant M50; G)
variant M52; H) variant M53 peptide; and I) variant M70 peptide
sequences. Except for M2, M5 and M69, the variant peptide sequences
reduce lean mass or fat mass, in contrast to FGF21.
[0040] FIG. 7A-7B show graphical data demonstrating that injection
of the recombinant A) variant M5; and B) variant M69 polypeptides
reduce blood glucose in ob/ob mice.
[0041] FIG. 8 depicts that the expression of FGFR4/.beta.-klotho
complex in L6 cells potentiates activation of intracellular
signaling pathways by FGF19, M3 and M70.
DETAILED DESCRIPTION
[0042] The invention provides chimeric and peptide sequences that
are able to lower or reduce levels of glucose. In one embodiment, a
chimeric peptide sequence includes or consists of an N-terminal
region having at least seven amino acid residues and the N-terminal
region having a first amino acid position and a last amino acid
position, where the N-terminal region has a DSSPL (SEQ ID NO:121)
or DASPH (SEQ ID NO:122) sequence; and a C-terminal region having a
portion of FGF19 and the C-terminal region having a first amino
acid position and a last amino acid position, where the C-terminal
region includes amino acid residues 16-29 of FGF19 (WGDPIRLRHLYTSG;
SEQ ID NO:169) and the W residue corresponds to the first amino
acid position of the C-terminal region.
[0043] In another embodiment, a chimeric peptide sequence includes
or consists of an N-terminal region having a portion of FGF21 and
the N-terminal region having a first amino acid position and a last
amino acid position, where the N-terminal region has a GQV sequence
and the V residue corresponds to the last amino acid position of
the N-terminal region; and a C-terminal region having a portion of
FGF19 and the C-terminal region having a first amino acid position
and a last amino acid position where the C-terminal region includes
amino acid residues 21-29 of FGF19 (RLRHLYTSG; SEQ ID NO: 185) and
the R residue corresponds to the first position of the C-terminal
region.
[0044] In further embodiments, a peptide sequence includes or
consists of a FGF19 sequence variant having one or more amino acid
substitutions, insertions or deletions compared to a reference or
wild type FGF19. In additional embodiments, a peptide sequence
includes or consists of a FGF21 sequence variant having one or more
amino acid substitutions, insertions or deletions compared to a
reference or wild type FGF21. In yet additional embodiments, a
peptide sequence includes or consists of a portion of an FGF19
sequence fused to a portion of an FGF21 sequence. In still
additional embodiments, a peptide sequence includes or consists of
a portion of an FGF19 sequence fused to a portion of an FGF21
sequence, where the FGF19 and/or FGF21 sequence portion(s) have one
or more amino acid substitutions, insertions or deletions compared
to a reference or wild type FGF19 and/or FGF21.
[0045] The invention also provides methods and uses of treating a
subject having or at risk of having a metabolic disorder treatable
using variants and fusions of FGF19 and/or FGF21 peptide sequences.
In one embodiment, a method includes contacting or administering to
a subject one or more variant or fusion FGF19 and/or FGF21 peptide
sequences in an amount effective for treating the disorder. In
another embodiment, a method includes contacting or administering
to a subject one or more nucleic acid molecules encoding a variant
or fusion FGF19 and/or FGF21 peptide sequence (for example, an
expression control element in operable linkage with the nucleic
acid encoding the peptide sequence, optionally including a vector),
in an amount effective for treating the disorder.
[0046] Although an understanding of the underlying mechanism of
action of the invention peptides is not required in order to
practice the invention, without being bound to any particular
theory or hypothesis, it is believed that invention peptides mimic,
at least in part, the effect that bariatric surgery has on, for
example, glucose homeostasis and weight loss. Changes in
gastrointestinal hormone secretion (e.g., glucagon-like peptide 1
(GLP-1)) after bariatric surgery are believed responsible for the
resolution of, for example, diabetic conditions. FGF19 is highly
expressed in the distal small intestine, and transgenic
over-expression of FGF19 improves glucose homeostasis. Because
levels of FGF19 in humans are also elevated following gastric
bypass surgery, the elevated FGF19 might be involved with the
remission of diabetes observed following bariatric surgery.
[0047] A representative reference or wild type FGF19 sequence is
set forth as:
TABLE-US-00001 (SEQ ID NO: 99)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKEIRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK.
[0048] A representative reference or wild type FGF21 sequence is
set forth as:
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (SEQ ID
NO:100). FGF21 allelic variants are illustrated in FIG. 1 (e.g.,
M70, M71 and M72).
[0049] The terms "peptide," "protein," and "polypeptide" sequence
are used interchangeably herein to refer to two or more amino
acids, or "residues," including chemical modifications and
derivatives of amino acids, covalently linked by an amide bond or
equivalent. The amino acids forming all or a part of a peptide may
be from among the known 21 naturally occurring amino acids, which
are referred to by both their single letter abbreviation or common
three-letter abbreviation. In the peptide sequences of the
invention, conventional amino acid residues have their conventional
meaning. Thus, "Leu" is leucine, "Ile" is isoleucine, "Nle" is
norleucine, and so on.
[0050] Exemplified herein are peptide sequences, distinct from
reference FGF19 and FGF21 polypeptides set forth herein, that
reduce or lower glucose, in vivo (e.g., Tables 1-9, FIG. 1 and the
Sequence Listing). Non-limiting particular examples are a peptide
sequence with amino-terminal amino acids 1-16 of FGF21 fused to
carboxy-terminal amino acids 21-194 of FGF19; a peptide sequence
with amino-terminal amino acids 1-147 of FGF19 fused to
carboxy-terminal amino acids 147-181 of FGF21; a peptide sequence
with amino-terminal amino acids 1-20 of FGF19 fused to
carboxy-terminal amino acids 17-181 of FGF21; a peptide sequence
with amino-terminal amino acids 1-146 of FGF21 fused to
carboxy-terminal amino acids 148-194 of FGF19; and a peptide
sequence with amino-terminal amino acids 1-20 of FGF19 fused to
internal amino acids 17-146 of FGF21 fused to carboxy-terminal
amino acids 148-194 of FGF19.
[0051] Additional particular peptides sequences have a WGDPI (SEQ
ID NO:170) sequence motif corresponding to the WGDPI sequence of
amino acids 16-20 of FGF19 (SEQ ID NO:99), lack a WGDPI SEQ ID
NO:170) sequence motif corresponding to the WGDPI sequence of amino
acids 16-20 of FGF19 (SEQ ID NO:99), or have a substituted (i.e.,
mutated) WGDPI SEQ ID NO:170) sequence motif corresponding to the
WGDPI sequence of amino acids 16-20 of FGF19 (SEQ ID NO:99).
[0052] Particular peptide sequences of the invention also include
sequences distinct from FGF19 and FGF21 (e.g., as set forth
herein), and FGF 19 variant sequences having any GQV, GDI, WGPI
(SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI
(SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176),
AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID
NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID
NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted
for FGF19 WGDPI (SEQ ID NO:170) sequence at amino acids 16-20.
Accordingly, the wild-type FGF19 and FGF21 (e.g., as set forth
herein as SEQ ID NOS:99 and 100, respectively) may be excluded
sequences, and FGF19 having any of GQV, GDI, WGPI (SEQ ID NO:171),
WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174),
GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID
NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ
ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ
ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ
ID NO:170) sequence at amino acids 16-20 of FGF19 may also be
excluded. This exclusion, however, does not apply to where a
sequence has, for example, 3 FGF21 residues fused to FGF19 having,
for example, any of GQV, GQV, GDI, or GPI, or 2 FGF21 residues
fused to any of WGPI (SEQ ID NO:171), WGDI (SEQ ID NO:173), GDPI
(SEQ ID NO:174), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), or
WGDP (SEQ ID NO:183).
[0053] Particular non-limiting examples of peptide sequences
include or consist of all or a part of a sequence variant specified
herein as M1-M98 (SEQ ID NOs:1-52, 192, and 54-98, respectively).
More particular non-limiting examples of peptide sequences include
or consist of all or a part of a sequence set forth as:
HPIPDSSPLLQFGGQVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP SFEK
(M5-R) (SEQ ID NO:160) (FGF21 sequences can also include an "R"
residue at the amino terminus);
DSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFS SPLETDSMDPFGLVTGLEAVRSPSFE K
(SEQ ID NO:138 and 161);
RPLAFSDASPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLE SDMFS SPLETDSMDPFGLVTGLE
AVRSPSFEK (M1) (SEQ ID NO:1 or 139);
RPLAFSDSSPLVHYGWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLS
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSFEK (M2) (SEQ ID NO:2 or 140);
DSSPLVHYGWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTV
AIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQR
QLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
(SEQ ID NO:141);
RDSSPLVHYGWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP SFEK
(M69) (SEQ ID NO:69);
RDSSPLLQWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFS SPLETDSMDPFGLVTGLEAVRSPSFE K
(M52) (SEQ ID NO:52);
HPIPDSSPLLQFGGQVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP SFEK
(M5-R) (SEQ ID NO:160);
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHSLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (M71) (SEQ
ID NO:71);
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPAPPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (M72) (SEQ
ID NO:72);
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVVQDELQGVGGEGCHMHPE
NCKTLLTDIDRTHTEKPVWDGITGE (M73) (SEQ ID NO:73);
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M3) (SEQ ID NO:3);
RDSSPLLQFGGQVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFS SPLETDSMDPFGLVTGLEAVRSPSFE K
(M48) (SEQ ID NO:48, 6 or 148);
RPLAFSDSSPLLQFGGQVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVAL
RTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKEIRLPVSLSSA
KQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVR
SPSFEK (M49) (SEQ ID NO:49, 7 or 149);
RHIPIPDSSPLLQFGDQVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEILEDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M50) (SEQ ID NO:50);
RHPIPDSSPLLQFGGNVRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M51) (SEQ ID NO:51, 36 or 155);
MDS SPLLQWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVA
IKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFS SPLETDSMDPFGLVTGLEAVRSPSFE K
(M53) (SEQ ID NO:192);
MRDSSPLVHYGWGDPIRLREILYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M70) (SEQ ID NO:70);
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEILPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M139) (SEQ ID NO:193);
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIREDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M140) (SEQ ID NO:194);
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEILCDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M141) (SEQ ID NO:195); or
RPLAFSDAGPHVHYGWGDPIRQRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLE SDMFS SPLETDSMDPFGLVTGLE
AVRSPSFEK (M160) (SEQ ID NO:196);
[0054] or a subsequence or fragment thereof of any of the foregoing
peptide sequences. In certain embodiments of any of the foregoing
peptide sequences, the R terminal residue is deleted.
[0055] Additional particular non-limiting examples of peptide
sequences, having at the N-terminus, a peptide sequence including
or consisting of all or a part of any of:
HPIPDSSPLLQFGGQVRLRHLYTSG (M5-R) (amino acids 1-25 of SEQ ID
NO:160); DSSPLLQFGGQVRLRHLYTSG (M6) (M6-R) (amino acids 2-22 of SEQ
ID NO:6); RPLAFSDSSPLLQFGGQVRLRHLYTSG (M7) (amino acids 1-27 of SEQ
ID NO:7); HPIPDSSPLLQWGDPIRLRHLYTSG (M8-R) (amino acids 2-26 of SEQ
ID NO:8); HPIPDSSPLLQFGWGDPIRLRHLYTSG (M9-R) (amino acids 2-28 of
SEQ ID NO:9); HPIPDSSPHVHYGWGDPIRLRHLYTSG (M10-R) (amino acids 2-28
of SEQ ID NO:10); RPLAFSDAGPLLQWGDPIRLRHLYTSG (M11) (amino acids
1-27 of SEQ ID NO:11); RPLAFSDAGPLLQFGWGDPIRLRHLYTSG (M12) (amino
acids 1-29 of SEQ ID NO:12); RPLAFSDAGPLLQFGGQVRLRHLYTSG (M13)
(amino acids 1-27 of SEQ ID NO:13); HPIPDSSPHVHYGGQVRLRHLYTSG
(M14-R) (amino acids 2-26 of SEQ ID NO:14);
RPLAFSDAGPHVHYGGQVRLRHLYTSG (M15) (amino acids 1-27 of SEQ ID
NO:15); RPLAFSDAGPHVHWGDPIRLRHLYTSG (M16) (amino acids 1-27 of SEQ
ID NO:16); RPLAFSDAGPHVGWGDPIRLRHLYTSG (M17) (amino acids 1-27 of
SEQ ID NO:17); RPLAFSDAGPHYGWGDPIRLRHLYTSG (M18) (amino acids 1-27
of SEQ ID NO:18); RPLAFSDAGPVYGWGDPIRLRHLYTSG (M19) (amino acids
1-27 of SEQ ID NO:19); RPLAFSDAGPVHGWGDPIRLRHLYTSG (M20) (amino
acids 1-27 of SEQ ID NO:20); RPLAFSDAGPVHYWGDPIRLRHLYTSG (M21)
(amino acids 1-27 of SEQ ID NO:21); RPLAFSDAGPHVHGWGDPIRLRHLYTSG
(M22) (amino acids 1-27 of SEQ ID NO:22);
RPLAFSDAGPHHGWGDPIRLRHLYTSG (M23) (amino acids 1-27 of SEQ ID
NO:23); RPLAFSDAGPHHYWGDPIRLRHLYTSG (M24) (amino acids 1-27 of SEQ
ID NO:24); RPLAFSDAGPHVYWGDPIRLRHLYTSG (M25) (amino acids 1-27 of
SEQ ID NO:25); RPLAFSDSSPLVHWGDPIRLRHLYTSG (M26) (amino acids 1-27
of SEQ ID NO:26); RPLAFSDSSPHVHWGDPIRLRHLYTSG (M27) (amino acids
1-27 of SEQ ID NO:27); RPLAFSDAGPHVWGDPIRLRHLYTSG (M28) (amino
acids 1-26 of SEQ ID NO:28); RPLAFSDAGPHVHYWGDPIRLRHLYTSG (M29)
(amino acids 1-28 of SEQ ID NO:29); RPLAFSDAGPHVHYAWGDPIRLRHLYTSG
(M30) (amino acids 1-29 of SEQ ID NO:30);
RHPIPDSSPLLQFGAQVRLRHLYTSG (M31) (amino acids 1-26 of SEQ ID
NO:31); RHPIPDSSPLLQFGDQVRLRHLYTSG (M32) (amino acids 1-26 of SEQ
ID NO:32); RHPIPDSSPLLQFGPQVRLRHLYTSG (M33) (amino acids 1-26 of
SEQ ID NO:33); RHPIPDSSPLLQFGGAVRLRHLYTSG (M34) (amino acids 1-26
of SEQ ID NO:34); RHPIPDSSPLLQFGGEVRLRHLYTSG (M35) (amino acids
1-26 of SEQ ID NO:35); RHPIPDSSPLLQFGGNVRLRHLYTSG (M36) (amino
acids 1-26 of SEQ ID NO:36); RHPIPDSSPLLQFGGQARLRHLYTSG (M37)
(amino acids 1-26 of SEQ ID NO:37); RHPIPDSSPLLQFGGQIRLRHLYTSG
(M38) (amino acids 1-26 of SEQ ID NO:38);
RHPIPDSSPLLQFGGQTRLRHLYTSG (M39) (amino acids 1-26 of SEQ ID
NO:39); RHPIPDSSPLLQFGWGQPVRLRHLYTSG (M40) (amino acids 1-28 of SEQ
ID NO:40); DAGPHVHYGWGDPIRLRHLYTSG (M74-R) (amino acids 2-24 of SEQ
ID NO:74); VHYGWGDPIRLRHLYTSG (M75-R) (amino acids 2-19 of SEQ ID
NO:75); RLREILYTSG (M77-R) (amino acids 2-10 of SEQ ID NO:77);
REIPIPDSSPLLQFGWGDPIRLREILYTSG (M9) (amino acids 1-28 of SEQ ID
NO:9); RHPIPDSSPLLQWGDPIRLRHLYTSG (M8) (amino acids 1-26 of SEQ ID
NO:8); RPLAFSDAGPLLQFGWGDPIRLRHLYTSG (M12) (amino acids 1-29 of SEQ
ID NO:12); REIPIPDSSPHVHYGWGDPIRLREILYTSG (M10) (amino acids 1-28
of SEQ ID NO:10); RPLAFSDAGPLLQFGGQVRLRHLYTSG (M13) (amino acids
1-27 of SEQ ID NO:13); REIPIPDSSPHVHYGGQVRLREILYTSG (M14) (amino
acids 1-26 of SEQ ID NO:14); RPLAFSDAGPHVHYGGDIRLRHLYTSG (M43)
amino acids 1-27 of SEQ ID NO:43); or RDSSPLLQFGGQVRLRHLYTSG (M6)
(amino acids 1-22 of SEQ ID NO:6); and for any of the foregoing
peptide sequences the amino terminal R residue may be deleted.
[0056] Peptide sequences of the invention additionally include
those with reduced or absent induction or formation of HCC compared
to FGF19, or an FGF 19 variant sequence having any of GQV, GDI,
WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173),
GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID
NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ
ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ
ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids
16-20 of FGF19. Peptide sequences of the invention also include
those with greater glucose lowering activity compared to FGF19, or
an FGF 19 variant sequence having any of GQV, GDI, WGPI, WGPI (SEQ
ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ
ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176),
AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID
NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID
NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted
for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of
FGF19. Peptide sequences of the invention moreover include those
with less lipid (e.g., triglyceride, cholesterol, non-HDL or HDL)
increasing activity compared to FGF19, or an FGF 19 variant
sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ
ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI
(SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177),
WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID
NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID
NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID
NO:170) sequence at amino acids 16-20 of FGF19.
[0057] Typically, the number of amino acids or residues in an
invention peptide sequence will total less than about 250 (e.g.,
amino acids or mimetics thereof). In various particular
embodiments, the number of residues comprise from about 20 up to
about 200 residues (e.g., amino acids or mimetics thereof). In
additional embodiments, the number of residues comprise from about
50 up to about 200 residues (e.g., amino acids or mimetics
thereof). In further embodiments, the number of residues comprise
from about 100 up to about 195 residues (e.g., amino acids or
mimetics thereof) in length.
[0058] Amino acids or residues can be linked by amide or by
non-natural and non-amide chemical bonds including, for example,
those formed with glutaraldehyde, N-hydroxysuccinimide esters,
bifunctional maleimides, or N, N'-dicyclohexylcarbodiimide (DCC).
Non-amide bonds include, for example, ketomethylene,
aminomethylene, olefin, ether, thioether and the like (see, e.g.,
Spatola in Chemistry and Biochemistry of Amino Acids, Peptides and
Proteins, Vol. 7, pp 267-357 (1983), "Peptide and Backbone
Modifications," Marcel Decker, NY). Thus, when a peptide of the
invention includes a portion of an FGF19 sequence and a portion of
an FGF21 sequence, the two portions need not be joined to each
other by an amide bond, but can be joined by any other chemical
moiety or conjugated together via a linker moiety.
[0059] The invention also includes subsequences, variants and
modified forms of the exemplified peptide sequences (including the
FGF19 and FGF21 variants and subsequences listed in Tables 1-9,
FIG. 1 and the Sequence Listing, and the FGF19/FGF21 fusions and
chimeras listed in Tables 1-9, FIG. 1 and the Sequence Listing), so
long as the foregoing retains at least a detectable or measureable
activity or function. For example, certain exemplified variant
peptides have FGF19 C-terminal sequence,
PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGL
LQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:188) at the
C-terminal portion, e.g., following the "TSG" amino acid residues
of the variant.
[0060] Also, certain exemplified variant peptides, for example,
those having all or a portion of FGF21 sequence at the
amino-terminus, have an "R" residue positioned at the N-terminus,
which can be omitted. Similarly, certain exemplified variant
peptides, include an "M" residue positioned at the N-terminus,
which can be appended to or further substituted for an omitted
residue, such as an "R" residue. More particularly, in various
embodiments peptide sequences at the N-terminus include any of:
RDSS (SEQ ID NO:115), DSS, MDSS (SEQ ID NO:116) or MRDSS (SEQ ID
NO:117). Furthermore, in cells when a "M" residue is adjacent to a
"S" residue, the "M" residue may be cleaved such that the "M"
residue is deleted from the peptide sequence, whereas when the "M"
residue is adjacent to a "D" residue, the "M" residue may not be
cleaved. Thus, by way of example, in various embodiments peptide
sequences include those with the following residues at the
N-terminus: MDSSPL (SEQ ID NO:119), MSDSSPL (SEQ ID NO:120)
(cleaved to SDSSPL (SEQ ID NO:112)) and MSSPL (SEQ ID NO:113)
(cleaved to SSPL (SEQ ID NO:114)).
[0061] Accordingly, the "peptide," "polypeptide," and "protein"
sequences of the invention include subsequences, variants and
modified forms of the FGF19 and FGF21 variants and subsequences
listed in Tables 1-9, FIG. 1 and the Sequence Listing, and the
FGF19/FGF21 fusions and chimeras listed in Tables 1-9, FIG. 1 and
the Sequence Listing, so long as the subsequence, variant or
modified form (e.g., fusion or chimera) retains at least a
detectable activity or function.
[0062] As used herein, the term "modify" and grammatical variations
thereof, means that the composition deviates relative to a
reference composition, such as a peptide sequence. Such modified
peptide sequences, nucleic acids and other compositions may have
greater or less activity or function, or have a distinct function
or activity compared with a reference unmodified peptide sequence,
nucleic acid, or other composition, or may have a property
desirable in a protein formulated for therapy (e.g. serum
half-life), to elicit antibody for use in a detection assay, and/or
for protein purification. For example, a peptide sequence of the
invention can be modified to increase serum half-life, to increase
in vitro and/or in vivo stability of the protein, etc.
[0063] Particular examples of such subsequences, variants and
modified forms of the peptide sequences exemplified herein (e.g., a
peptide sequence listed in Tables 1-9, FIG. 1 and the Sequence
Listing) include substitutions, deletions and/or
insertions/additions of one or more amino acids, to or from the
amino terminus, the carboxy-terminus or internally. One example is
a substitution of an amino acid residue for another amino acid
residue within the peptide sequence. Another is a deletion of one
or more amino acid residues from the peptide sequence, or an
insertion or addition of one or more amino acid residues into the
peptide sequence.
[0064] The number of residues substituted, deleted or
inserted/added are one or more amino acids (e.g., 1-3, 3-5, 5-10,
10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100,
100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170,
170-180, 180-190, 190-200, 200-225, 225-250, or more) of a peptide
sequence. Thus, an FGF19 or FGF21 sequence can have few or many
amino acids substituted, deleted or inserted/added (e.g., 1-3, 3-5,
5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90,
90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160,
160-170, 170-180, 180-190, 190-200, 200-225, 225-250, or more). In
addition, an FGF19 amino acid sequence can include or consist of an
amino acid sequence of about 1-3, 3-5, 5-10, 10-20, 20-30, 30-40,
40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120,
120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190,
190-200, 200-225, 225-250, or more amino acids from FGF21; or an
FGF21 amino acid or sequence can include or consist of an amino
acid sequence of about 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50,
50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130,
130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200,
200-225, 225-250, or more amino acids from FGF19.
[0065] Specific examples of substitutions include substituting a D
residue for an L-residue. Accordingly, although residues are listed
in the L-isomer configuration D-amino acids at any particular or
all positions of the peptide sequences of the invention are
included, unless a D-isomer leads to a sequence that has no
detectable or measurable function.
[0066] Additional specific examples are non-conservative and
conservative substitutions. A "conservative substitution" is a
replacement of one amino acid by a biologically, chemically or
structurally similar residue. Biologically similar means that the
substitution is compatible with a biological activity, e.g.,
glucose lowering activity. Structurally similar means that the
amino acids have side chains with similar length, such as alanine,
glycine and serine, or having similar size, or the structure of a
first, second or additional peptide sequence is maintained.
Chemical similarity means that the residues have the same charge or
are both hydrophilic and hydrophobic. Particular examples include
the substitution of one hydrophobic residue, such as isoleucine,
valine, leucine or methionine for another, or the substitution of
one polar residue for another, such as the substitution of arginine
for lysine, glutamic for aspartic acids, or glutamine for
asparagine, serine for threonine, etc. Routine assays can be used
to determine whether a subsequence, variant or modified form has
activity, e.g., glucose lowering activity.
[0067] Particular examples of subsequences, variants and modified
forms of the peptide sequences exemplified herein (e.g., a peptide
sequence listed in Tables 1-9, FIG. 1 and the Sequence Listing)
have 50%-60%, 60%-70%, 70%-75%, 75%-80%, 80%-85%, 85%-90%, 90%-95%,
or 96%, 97%, 98%, or 99% identity to a reference peptide sequence
(for example, a peptide sequence in any of Table 1-9 and FIG. 1).
The term "identity" and "homology" and grammatical variations
thereof mean that two or more referenced entities are the same.
Thus, where two amino acid sequences are identical, they have the
identical amino acid sequence. "Areas, regions or domains of
identity" mean that a portion of two or more referenced entities
are the same. Thus, where two amino acid sequences are identical or
homologous over one or more sequence regions, they share identity
in these regions.
[0068] The extent of identity between two sequences can be
ascertained using a computer program and mathematical algorithm
known in the art. Such algorithms that calculate percent sequence
identity (homology) generally account for sequence gaps and
mismatches over the comparison region. For example, a BLAST (e.g.,
BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol.
Biol. 215:403 (1990), publicly available through NCBI) has
exemplary search parameters as follows: Mismatch -2; gap open 5;
gap extension 2. For peptide sequence comparisons, a BLASTP
algorithm is typically used in combination with a scoring matrix,
such as PAM100, PAM 250, BLOSUM 62 or BLOSUM 50. FASTA (e.g.,
FASTA2 and FASTA3) and SSEARCH sequence comparison programs are
also used to quantitate the extent of identity (Pearson et al.,
Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol
Biol. 132:185 (2000); and Smith et al., J. Mol. Biol. 147:195
(1981)). Programs for quantitating protein structural similarity
using Delaunay-based topological mapping have also been developed
(Bostick et al., Biochem Biophys Res Commun. 304:320 (2003)).
[0069] In the invention peptide sequences, including subsequences,
variants and modified forms of the peptide sequences exemplified
herein (e.g., sequences listed in Table 1-9 and FIG. 1) an "amino
acid" or "residue" includes conventional alpha-amino acids as well
as beta-amino acids, alpha, alpha disubstituted amino acids and
N-substituted amino acids wherein at least one side chain is an
amino acid side chain moiety as defined herein. An "amino acid"
further includes N-alkyl alpha-amino acids, wherein the N-terminus
amino group has a C.sub.1 to C.sub.6 linear or branched alkyl
substituent. The term "amino acid" therefore includes stereoisomers
and modifications of naturally occurring protein amino acids,
non-protein amino acids, post-translationally modified amino acids
(e.g., by glycosylation, phosphorylation, ester or amide cleavage,
etc.), enzymatically modified or synthesized amino acids,
derivatized amino acids, constructs or structures designed to mimic
amino acids, amino acids with a side chain moiety modified,
derivatized from naturally occurring moieties, or synthetic, or not
naturally occurring, etc. Modified and unusual amino acids are
included in the peptide sequences of the invention (see, for
example, in Synthetic Peptides: A User's Guide; Hruby et al.,
Biochem. J. 268:249 (1990); and Toniolo C., Int. J. Peptide Protein
Res. 35:287 (1990)).
[0070] In addition, protecting and modifying groups of amino acids
are included. The term "amino acid side chain moiety" as used
herein includes any side chain of any amino acid, as the term
"amino acid" is defined herein. This therefore includes the side
chain moiety in naturally occurring amino acids. It further
includes side chain moieties in modified naturally occurring amino
acids as set forth herein and known to one of skill in the art,
such as side chain moieties in stereoisomers and modifications of
naturally occurring protein amino acids, non-protein amino acids,
post-translationally modified amino acids, enzymatically modified
or synthesized amino acids, derivatized amino acids, constructs or
structures designed to mimic amino acids, etc. For example, the
side chain moiety of any amino acid disclosed herein or known to
one of skill in the art is included within the definition.
[0071] A "derivative of an amino acid side chain moiety" is
included within the definition of an amino acid side chain moiety.
Non-limiting examples of derivatized amino acid side chain moieties
include, for example: (a) adding one or more saturated or
unsaturated carbon atoms to an existing alkyl, aryl, or aralkyl
chain; (b) substituting a carbon in the side chain with another
atom, preferably oxygen or nitrogen; (c) adding a terminal group to
a carbon atom of the side chain, including methyl (--CH.sub.3),
methoxy (--OCH.sub.3), nitro (--NO.sub.2), hydroxyl (--OH), or
cyano (--C.dbd.N); (d) for side chain moieties including a hydroxy,
thiol or amino groups, adding a suitable hydroxy, thiol or amino
protecting group; or (e) for side chain moieties including a ring
structure, adding one or more ring substituents, including
hydroxyl, halogen, alkyl, or aryl groups attached directly or
through an ether linkage. For amino groups, suitable protecting
groups are known to the skilled artisan. Provided such
derivatization provides a desired activity in the final peptide
sequence (e.g., glucose lowering, improved glucose or lipid
metabolism, anti-diabetic activity, absence of substantial HCC
formation or tumorigenesis, absence of substantial modulation of
lean or fat mass, etc.).
[0072] An "amino acid side chain moiety" includes all such
derivatization, and particular non-limiting examples include:
gamma-amino butyric acid, 12-amino dodecanoic acid,
alpha-aminoisobutyric acid, 6-amino hexanoic acid,
4-(aminomethyl)-cyclohexane carboxylic acid, 8-amino octanoic acid,
biphenylalanine, Boc-t-butoxycarbonyl, benzyl, benzoyl, citrulline,
diaminobutyric acid, pyrrollysine, diaminopropionic acid,
3,3-diphenylalanine, orthonine, citrulline,
1,3-dihydro-2H-isoindolecarboxylic acid, ethyl,
Fmoc--fluorenylmethoxycarbonyl, heptanoyl
(CH.sub.3--(CH.sub.2).sub.5--C(.dbd.O)--), hexanoyl
(CH.sub.3--(CH.sub.2).sub.4--C(.dbd.O)--), homoarginine,
homocysteine, homolysine, homophenylalanine, homoserine, methyl,
methionine sulfoxide, methionine sulfone, norvaline (NVA),
phenylglycine, propyl, isopropyl, sarcosine (SAR),
tert-butylalanine, and benzyloxycarbonyl.
[0073] A single amino acid, including stereoisomers and
modifications of naturally occurring protein amino acids,
non-protein amino acids, post-translationally modified amino acids,
enzymatically synthesized amino acids, non-naturally occurring
amino acids including derivatized amino acids, an alpha, alpha
disubstituted amino acid derived from any of the foregoing (i.e.,
an alpha, alpha disubstituted amino acid, wherein at least one side
chain is the same as that of the residue from which it is derived),
a beta-amino acid derived from any of the foregoing (i.e., a
beta-amino acid which other than for the presence of a beta-carbon
is otherwise the same as the residue from which it is derived)
etc., including all of the foregoing can be referred to herein as a
"residue." Suitable substituents, in addition to the side chain
moiety of the alpha-amino acid, include C1 to C6 linear or branched
alkyl. Aib is an example of an alpha, alpha disubstituted amino
acid. While alpha, alpha disubstituted amino acids can be referred
to using conventional L- and D-isomeric references, it is to be
understood that such references are for convenience, and that where
the substituents at the alpha-position are different, such amino
acid can interchangeably be referred to as an alpha, alpha
disubstituted amino acid derived from the L- or D-isomer, as
appropriate, of a residue with the designated amino acid side chain
moiety. Thus (S)-2-Amino-2-methyl-hexanoic acid can be referred to
as either an alpha, alpha disubstituted amino acid derived from
L-Nle (norleucine) or as an alpha, alpha disubstituted amino acid
derived from D-Ala. Similarly, Aib can be referred to as an alpha,
alpha disubstituted amino acid derived from Ala. Whenever an alpha,
alpha disubstituted amino acid is provided, it is to be understood
as including all (R) and (S) configurations thereof.
[0074] An "N-substituted amino acid" includes any amino acid
wherein an amino acid side chain moiety is covalently bonded to the
backbone amino group, optionally where there are no substituents
other than H in the alpha-carbon position. Sarcosine is an example
of an N-substituted amino acid. By way of example, sarcosine can be
referred to as an N-substituted amino acid derivative of Ala, in
that the amino acid side chain moiety of sarcosine and Ala is the
same, i.e., methyl.
[0075] Covalent modifications of the invention peptide sequences,
including subsequences, variants and modified forms of the peptide
sequences exemplified herein (e.g., sequences listed in Table 1-9
and FIG. 1), are included in the invention. One type of covalent
modification includes reacting targeted amino acid residues with an
organic derivatizing agent that is capable of reacting with
selected side chains or the N- or C-terminal residues of the
peptide. Derivatization with bifunctional agents is useful, for
instance, for cross linking peptide to a water-insoluble support
matrix or surface for use in the method for purifying anti-peptide
antibodies, and vice-versa. Commonly used cross linking agents
include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides
such as bis-N-maleimido-1,8-octane and agents such as
methyl-3-[(p-azidophenyl)dithio]propioimidate.
[0076] Other modifications include deamidation of glutaminyl and
asparaginyl residues to the corresponding glutamyl and aspartyl
residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the alpha-amino groups of lysine, arginine, and
histidine side chains (T. E. Creighton, Proteins: Structure and
Molecular Properties, W.H. Freeman & Co., San Francisco, pp.
79-86 (1983)), acetylation of the N-terminal amine, amidation of
any C-terminal carboxyl group, etc.
[0077] Exemplified peptide sequences, and subsequences, variants
and modified forms of the peptide sequences exemplified herein
(e.g., sequences listed in Table 1-9 and FIG. 1), can also include
alterations of the backbone for stability, derivatives, and
peptidomimetics. The term "peptidomimetic" includes a molecule that
is a mimic of a residue (referred to as a "mimetic"), including but
not limited to piperazine core molecules, keto-piperazine core
molecules and diazepine core molecules. Unless otherwise specified,
an amino acid mimetic of an invention peptide sequence includes
both a carboxyl group and amino group, and a group corresponding to
an amino acid side chain, or in the case of a mimetic of Glycine,
no side chain other than hydrogen.
[0078] By way of example, these would include compounds that mimic
the sterics, surface charge distribution, polarity, etc. of a
naturally occurring amino acid, but need not be an amino acid,
which would impart stability in the biological system. For example,
Proline may be substituted by other lactams or lactones of suitable
size and substitution; Leucine may be substituted by an alkyl
ketone, N-substituted amide, as well as variations in amino acid
side chain length using alkyl, alkenyl or other substituents,
others may be apparent to the skilled artisan. The essential
element of making such substitutions is to provide a molecule of
roughly the same size and charge and configuration as the residue
used to design the molecule. Refinement of these modifications will
be made by analyzing the compounds in a functional (e.g., glucose
lowering) or other assay, and comparing the structure activity
relationship. Such methods are within the scope of the skilled
artisan working in medicinal chemistry and drug development.
[0079] Another type of modification of the invention peptide
sequences, including subsequences, sequence variants and modified
forms of the exemplified peptide sequences (including the peptides
listed in Table 1-9 and FIG. 1), is glycosylation. As used herein,
"glycosylation" broadly refers to the presence, addition or
attachment of one or more sugar (e.g., carbohydrate) moieties to
proteins, lipids or other organic molecules. The use of the term
"deglycosylation" herein is generally intended to mean the removal
or deletion, of one or more sugar (e.g., carbohydrate) moieties. In
addition, the phrase includes qualitative changes in the
glycosylation of the native proteins involving a change in the type
and proportions (amount) of the various sugar (e.g., carbohydrate)
moieties present.
[0080] Glycosylation can be achieved by modification of an amino
acid residue, or by adding one or more glycosylation sites that may
or may not be present in the native sequence. For example, a
typically non-glycosylated residue can be substituted for a residue
that may be glycosylated. Addition of glycosylation sites can be
accomplished by altering the amino acid sequence. The alteration to
the peptide sequence may be made, for example, by the addition of,
or substitution by, one or more serine or threonine residues (for
O-linked glycosylation sites) or asparagine residues (for N-linked
glycosylation sites). The structures of N-linked and O-linked
oligosaccharides and the sugar residues found in each type may be
different. One type of sugar that is commonly found on both is
N-acetylneuraminic acid (hereafter referred to as sialic acid).
Sialic acid is usually the terminal residue of both N-linked and
O-linked oligosaccharides and, by virtue of its negative charge,
may confer acidic properties to the glycoprotein.
[0081] Peptide sequences of the invention may optionally be altered
through changes at the nucleotide (e.g., DNA) level, particularly
by mutating the DNA encoding the peptide at preselected bases such
that codons are generated that will translate into the desired
amino acids. Another means of increasing the number of carbohydrate
moieties on the peptide is by chemical or enzymatic coupling of
glycosides to the polypeptide (see, for example, in WO 87/05330).
De-glycosylation can be accomplished by removing the underlying
glycosylation site, by deleting the glycosylation by chemical
and/or enzymatic means, or by substitution of codons encoding amino
acid residues that are glycosylated. Chemical deglycosylation
techniques are known, and enzymatic cleavage of carbohydrate
moieties on polypeptides can be achieved by the use of a variety of
endo- and exo-glycosidases.
[0082] Various cell lines can be used to produce proteins that are
glycosylated. One non-limiting example is Dihydrofolate reductase
(DHFR)-deficient Chinese Hamster Ovary (CHO) cells, which are a
commonly used host cell for the production of recombinant
glycoproteins. These cells do not express the enzyme
beta-galactoside alpha-2,6-sialyltransferase and therefore do not
add sialic acid in the alpha-2,6 linkage to N-linked
oligosaccharides of glycoproteins produced in these cells.
[0083] Another type of modification is to conjugate (e.g., link)
one or more additional components or molecules at the N- and/or
C-terminus of an invention peptide sequence, such as another
protein (e.g., a protein having an amino acid sequence heterologous
to the subject protein), or a carrier molecule. Thus, an exemplary
peptide sequence can be a conjugate with another component or
molecule.
[0084] In certain embodiments, the amino- or carboxy-terminus of an
invention peptide sequence can be fused with an immunoglobulin Fc
region (e.g., human Fc) to form a fusion conjugate (or fusion
molecule). Fc fusion conjugates can increase the systemic half-life
of biopharmaceuticals, and thus the biopharmaceutical product may
have prolonged activity or require less frequent administration. Fc
binds to the neonatal Fc receptor (FcRn) in endothelial cells that
line the blood vessels, and, upon binding, the Fc fusion molecule
is protected from degradation and re-released into the circulation,
keeping the molecule in circulation longer. This Fc binding is
believed to be the mechanism by which endogenous IgG retains its
long plasma half-life. Well-known and validated Fc-fusion drugs
consist of two copies of a biopharmaceutical linked to the Fc
region of an antibody to improve pharmacokinetics, solubility, and
production efficiency. More recent Fc-fusion technology links a
single copy of a biopharmaceutical to Fc region of an antibody to
optimize the pharmacokinetic and pharmacodynamic properties of the
biopharmaceutical as compared to traditional Fc-fusion
conjugates.
[0085] A conjugate modification can be used to produce a peptide
sequence that retains activity with an additional or complementary
function or activity of the second molecule. For example, a peptide
sequence may be conjugated to a molecule, e.g., to facilitate
solubility, storage, in vivo or shelf half-life or stability,
reduction in immunogenicity, delayed or controlled release in vivo,
etc. Other functions or activities include a conjugate that reduces
toxicity relative to an unconjugated peptide sequence, a conjugate
that targets a type of cell or organ more efficiently than an
unconjugated peptide sequence, or a drug to further counter the
causes or effects associated with a disorder or disease as set
forth herein (e.g., diabetes).
[0086] Clinical effectiveness of protein therapeutics may be
limited by short plasma half-life and susceptibility to
degradation. Studies of various therapeutic proteins have shown
that various modifications, including conjugating or linking the
peptide sequence to any of a variety of nonproteinaceous polymers,
e.g., polyethylene glycol (PEG), polypropylene glycol, or
polyoxyalkylenes (see, for example, typically via a linking moiety
covalently bound to both the protein and the nonproteinaceous
polymer (e.g., a PEG) can prolong half-life. Such PEG-conjugated
biomolecules have been shown to possess clinically useful
properties, including better physical and thermal stability,
protection against susceptibility to enzymatic degradation,
increased solubility, longer in vivo circulating half-life and
decreased clearance, reduced immunogenicity and antigenicity, and
reduced toxicity.
[0087] PEGS suitable for conjugation to an invention peptide
sequence is generally soluble in water at room temperature, and
have the general formula R(O--CH.sub.2--CH.sub.2).sub.nO--R, where
R is hydrogen or a protective group such as an alkyl or an alkanol
group, and where n is an integer from 1 to 1000. When R is a
protective group, it generally has from 1 to 8 carbons. The PEG
conjugated to the peptide sequence can be linear or branched.
Branched PEG derivatives, "star-PEGs" and multi-armed PEGS are
included in the invention. A molecular weight of the PEG used in
the invention is not restricted to any particular range, but
certain embodiments have a molecular weight between 500 and 20,000
while other embodiments have a molecular weight between 4,000 and
10,000.
[0088] The invention includes compositions of conjugates wherein
the PEGS have different "n" values and thus the various different
PEGs are present in specific ratios. For example, some compositions
comprise a mixture of conjugates where n=1, 2, 3 and 4. In some
compositions, the percentage of conjugates where n=1 is 18-25%, the
percentage of conjugates where n=2 is 50-66%, the percentage of
conjugates where n=3 is 12-16%, and the percentage of conjugates
where n=4 is up to 5%. Such compositions can be produced by
reaction conditions and purification methods know in the art.
[0089] PEG may directly or indirectly (e.g., through an
intermediate) bind to the peptide sequences of the invention. For
example, in one embodiment, PEG binds via a terminal reactive group
(a "spacer"). The spacer, is, for example, a terminal reactive
group which mediates a bond between the free amino or carboxyl
groups of one or more of the peptide sequences and polyethylene
glycol. The PEG having the spacer which may be bound to the free
amino group includes N-hydroxysuccinylimide polyethylene glycol
which may be prepared by activating succinic acid ester of
polyethylene glycol with N-hydroxysuccinylimide. Another activated
polyethylene glycol which may be bound to free amino group is
2,4-bis(O-methoxypolyethyleneglycol)-6-chloro-s-triazine which may
be prepared by reacting polyethylene glycol monomethyl ether with
cyanuric chloride. The activated polyethylene glycol which is bound
to the free carboxyl group includes polyoxyethylenediamine.
[0090] Conjugation of one or more of invention peptide sequences to
PEG having a spacer may be carried out by various conventional
methods. For example, the conjugation reaction can be carried out
in solution at a pH of from 5 to 10, at temperature from 4.degree.
C. to room temperature, for 30 minutes to 20 hours, utilizing a
molar ratio of reagent to protein of from 4:1 to 30:1. Reaction
conditions may be selected to direct the reaction towards producing
predominantly a desired degree of substitution. In general, low
temperature, low pH (e.g., pH=5), and short reaction time tend to
decrease the number of PEGs attached, whereas high temperature,
neutral to high pH (e.g., pH.gtoreq.7), and longer reaction time
tend to increase the number of PEGS attached. Various methods known
in the art may be used to terminate the reaction. In some
embodiments the reaction is terminated by acidifying the reaction
mixture and freezing at, e.g., -20.degree. C.
[0091] Invention peptide sequences including subsequences, sequence
variants and modified forms of the exemplified peptide sequences
(including the peptides listed in Table 1-9 and FIG. 1), further
include conjugation to large, slowly metabolized macromolecules
such as proteins; polysaccharides, such as sepharose, agarose,
cellulose, cellulose beads; polymeric amino acids such as
polyglutamic acid, polylysine; amino acid copolymers; inactivated
virus particles; inactivated bacterial toxins such as toxoid from
diphtheria, tetanus, cholera, leukotoxin molecules; inactivated
bacteria; and dendritic cells. Such conjugated forms, if desired,
can be used to produce antibodies against peptide sequences of the
invention.
[0092] Additional suitable components and molecules for conjugation
include, for example, thyroglobulin; albumins such as human serum
albumin (HSA); tetanus toxoid; Diphtheria toxoid; polyamino acids
such as poly(D-lysine:D-glutamic acid); VP6 polypeptides of
rotaviruses; influenza virus hemagglutinin, influenza virus
nucleoprotein; Keyhole Limpet Hemocyanin (KLH); and hepatitis B
virus core protein and surface antigen; or any combination of the
foregoing.
[0093] Fusion of albumin to an invention peptide sequence can, for
example, be achieved by genetic manipulation, such that the DNA
coding for HSA (human serum albumin), or a fragment thereof, is
joined to the DNA coding for a peptide sequence. Thereafter, a
suitable host can be transformed or transfected with the fused
nucleotide sequence in the form of, for example, a suitable
plasmid, so as to express a fusion polypeptide. The expression may
be effected in vitro from, for example, prokaryotic or eukaryotic
cells, or in vivo from, for example, a transgenic organism. In some
embodiments of the invention, the expression of the fusion protein
is performed in mammalian cell lines, for example, CHO cell
lines.
[0094] Further means for genetically fusing target proteins or
peptides to albumin include a technology known as Albufuse.RTM.
(Novozymes Biopharma A/S; Denmark), and the conjugated therapeutic
peptide sequences frequently become much more effective with better
uptake in the body. The technology has been utilized commercially
to produce Albuferon.RTM. (Human Genome Sciences), a combination of
albumin and interferon .alpha.-2B used to treat hepatitis C
infection.
[0095] Another embodiment entails the use of one or more human
domain antibodies (dAb). dAbs are the smallest functional binding
units of human antibodies (IgGs) and have favorable stability and
solubility characteristics. The technology entails a dAb(s)
conjugated to HSA (thereby forming a "AlbudAb"; see, e.g.,
EP1517921B, WO2005/118642 and WO2006/051288) and a molecule of
interest (e.g., a peptide sequence of the invention). AlbudAbs are
often smaller and easier to manufacture in microbial expression
systems, such as bacteria or yeast, than current technologies used
for extending the serum half-life of peptides. As HSA has a
half-life of about three weeks, the resulting conjugated molecule
improves the half-life. Use of the dAb technology may also enhance
the efficacy of the molecule of interest.
[0096] Additional suitable components and molecules for conjugation
include those suitable for isolation or purification. Particular
non-limiting examples include binding molecules, such as biotin
(biotin-avidin specific binding pair), an antibody, a receptor, a
ligand, a lectin, or molecules that comprise a solid support,
including, for example, plastic or polystyrene beads, plates or
beads, magnetic beads, test strips, and membranes.
[0097] Purification methods such as cation exchange chromatography
may be used to separate conjugates by charge difference, which
effectively separates conjugates into their various molecular
weights. For example, the cation exchange column can be loaded and
then washed with .about.20 mM sodium acetate, pH.about.4, and then
eluted with a linear (0 M to 0.5 M) NaCl gradient buffered at a pH
from 3 to 5.5, preferably at pH.about.4.5. The content of the
fractions obtained by cation exchange chromatography may be
identified by molecular weight using conventional methods, for
example, mass spectroscopy, SDS-PAGE, or other known methods for
separating molecular entities by molecular weight. A fraction is
then accordingly identified which contains the conjugate having the
desired number of PEGS attached, purified free from unmodified
protein sequences and from conjugates having other numbers of PEGs
attached.
[0098] In still other embodiments, an invention peptide sequence is
linked to a chemical agent (e.g., an immunotoxin or
chemotherapeutic agent), including, but are not limited to, a
cytotoxic agent, including taxol, cytochalasin B, gramicidin D,
mitomycin, etoposide, tenoposide, vincristine, vinblastine,
colchicin, doxorubicin, daunorubicin, and analogs or homologs
thereof. Other chemical agents include, for example,
antimetabolites (e.g., methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, 5-fluorouracil decarbazine); alkylating
agents (e.g., mechlorethamine, carmustine and lomustine,
cyclothosphamide, busulfan, dibromomannitol, streptozotocin,
mitomycin C, and cisplatin); antibiotics (e.g., bleomycin); and
anti-mitotic agents (e.g., vincristine and vinblastine). Cytotoxins
can be conjugated to a peptide of the invention using linker
technology known in the art and described herein.
[0099] Further suitable components and molecules for conjugation
include those suitable for detection in an assay. Particular
non-limiting examples include detectable labels, such as a
radioisotope (e.g., .sup.125I; .sup.35S; .sup.32P; .sup.33P), an
enzyme which generates a detectable product (e.g., luciferase,
.beta.-galactosidase, horse radish peroxidase and alkaline
phosphatase), a fluorescent protein, a chromogenic protein, dye
(e.g., fluorescein isothiocyanate); fluorescence emitting metals
(e.g., .sup.152Eu); chemiluminescent compounds (e.g., luminol and
acridinium salts); bioluminescent compounds (e.g., luciferin); and
fluorescent proteins. Indirect labels include labeled or detectable
antibodies that bind to a peptide sequence, where the antibody may
be detected.
[0100] In certain embodiments, a peptide sequence of the invention
is conjugated to a radioactive isotope to generate a cytotoxic
radiopharmaceutical (radioimmunoconjugates) useful as a diagnostic
or therapeutic agent. Examples of such radioactive isotopes
include, but are not limited to, iodine.sup.131, indium.sup.111,
yttrium.sup.90 and lutetium.sup.177. Methods for preparing
radioimmunoconjugates are known to the skilled artisan. Examples of
radioimmunoconjugates that are commercially available include
ibritumomab, tiuxetan, and tositumomab.
[0101] Other means and methods included in the invention for
prolonging the circulation half-life, increasing stability,
reducing clearance, or altering immunogenicity or allergenicity of
a peptide sequence of the invention involves modification of the
peptide sequence by hesylation, which utilizes hydroxyethyl starch
derivatives linked to other molecules in order to modify the
molecule's characteristics. Various aspects of hesylation are
described in, for example, U.S. Patent Appln. Nos. 2007/0134197 and
2006/0258607.
[0102] Any of the foregoing components and molecules used to modify
peptide sequences of the invention may optionally be conjugated via
a linker. Suitable linkers include "flexible linkers" which are
generally of sufficient length to permit some movement between the
modified peptide sequences and the linked components and molecules.
The linker molecules are generally about 6-50 atoms long. The
linker molecules may also be, for example, aryl acetylene, ethylene
glycol oligomers containing 2-10 monomer units, diamines, diacids,
amino acids, or combinations thereof. Suitable linkers can be
readily selected and can be of any suitable length, such as 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30, 30-50 amino acids (e.g.,
Gly).
[0103] Exemplary flexible linkers include glycine polymers (G)n,
glycine-serine polymers (for example, (GS).sub.n, GSGGS.sub.n (SEQ
ID NO:129) and GGGS.sub.n (SEQ ID NO:130), where n is an integer of
at least one), glycine-alanine polymers, alanine-serine polymers,
and other flexible linkers. Glycine and glycine-serine polymers are
relatively unstructured, and therefore may serve as a neutral
tether between components. Exemplary flexible linkers include, but
are not limited to GGSG (SEQ ID NO:131), GGSGG (SEQ ID NO:132),
GSGSG (SEQ ID NO:133), GSGGG (SEQ ID NO:134), GGGSG (SEQ ID
NO:189), and GSSSG (SEQ ID NO:135).
[0104] Peptide sequences of the invention, including the FGF19 and
FGF21 variants and subsequences and the FGF19/FGF21 fusions and
chimeras listed in Table 1-9 and FIG. 1, as well as subsequences,
sequence variants and modified forms of the sequences listed in
Table 1-9 and FIG. 1 have one or more activities as set forth
herein. One example of an activity is glucose lowering activity.
Another example of an activity is reduced stimulation or formation
of HCC, for example, as compared to FGF19. An additional example of
an activity is lower or reduced lipid (e.g., triglyceride,
cholesterol, non-HDL) or HDL increasing activity, for example, as
compared to FGF21. A further example of an activity is a lower or
reduced lean muscle mass reducing activity, for example, as
compared to FGF21. Yet another example of an activity is binding to
FGFR4, or activating FGFR4, for example, peptide sequences that
bind to FGFR4 with an affinity comparable to or greater than FGF19
binding affinity for FGFR4; and peptide sequences that activate
FGFR4 to an extent or amount comparable to or greater than FGF19
activates FGFR4. Still further examples of activities include
down-regulation or reduction of aldo-keto reductase gene
expression, for example, compared to FGF19; up-regulation or
increased Slc1a2 gene expression compared to FGF21.
[0105] More particularly, peptide sequences of the invention,
including the FGF19 and FGF21 variants and subsequences and the
FGF19/FGF21 fusions and chimeras listed in Table 1-9 and FIG. 1, as
well as subsequences, variants and modified forms of the sequences
listed in Table 1-9 and FIG. 1 include those with the following
activities: peptide sequences having reduced HCC formation compared
to FGF19, or an FGF 19 variant sequence having any of GQV, GDI,
WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173),
GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID
NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ
ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ
ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids
16-20 of FGF19; peptide sequences having greater glucose lowering
activity compared to FGF19, or FGF 19 variant sequence having any
of GQV, GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ
ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI
(SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178),
WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181),
WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184)
substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids
16-20 of FGF19; peptide sequences having less lipid increasing
activity (e.g., less triglyceride, cholesterol, non-HDL) or more
HDL increasing activity compared to FGF19, or an FGF 19 variant
sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ
ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI
(SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177),
WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID
NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID
NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID
NO:170) sequence at amino acids 16-20 of FGF19; and peptide
sequences having less lean mass reducing activity as compared to
FGF21.
[0106] More particularly, peptide sequences of the invention,
including the FGF19 and FGF21 variants and subsequences and the
FGF19/FGF21 fusions and chimeras listed in Table 1-9 and FIG. 1, as
well as subsequences, variants and modified forms of the sequences
listed in Table 1-9 and FIG. 1 include those with the following
activities: peptide sequences that bind to FGFR4, or activate
FGFR4, such as peptide sequences that bind to FGFR4 with an
affinity comparable to or greater than FGF19 binding affinity for
FGFR4; peptide sequences that activate FGFR4 to an extent or amount
comparable to or greater than FGF19 activates FGFR4; peptide
sequences that down-regulate or reduce aldo-keto reductase gene
expression, for example, compared to FGF19; and peptide sequences
that up-regulate or increase solute carrier family 1, member 2
(Slc1a2) gene expression as compared to FGF21.
[0107] As disclosed herein, variants include various N-terminal
modifications and/or truncations of FGF19, including variants in
which there has been a substitution of one or several N-terminal
FGF19 amino acids with amino acids from FGF21. Such variants
include variants having glucose lowering activity, as well as a
favorable lipid profile and are not measurably or detectably
tumorigenic.
[0108] In various particular aspects, modifications to the Loop-8
region of FGF19 (residues 127-129 are defined as constituting the
Loop-8 region) are disclosed herein that have glucose lowering
activity and also possess favorable metabolic parameters without
exhibiting substantial tumorigenicity. Herein, FGF19 residues
127-129 are defined as constituting the Loop-8 region, although in
the literature the Loop-8 region is sometimes defined as including
or consisting of other residues (e.g., residues 125-129). As set
forth in Example 9 and Table 8, certain combinations of R127L and
P128E substitutions to the FGF19 framework had an unexpectedly
positive effect on HCC formation. Even more surprisingly, a
combination of R127L and P128E substitutions and a substitution of
Gln (Q) for Leu (L) in the FGF19 core region (see, e.g., core
region sequence denoted in Tables 1-4, 8 and 9) had an even more
significant effect on preventing HCC formation. Accordingly,
variants of FGF19 Loop-8 region are included since they can reduce
or eliminate substantial, measurable or detectable HCC formation.
Furthermore, the effect of reducing HCC formation may be enhanced
by modifications to amino acid residues outside of the Loop 8
region (e.g., substitutions of amino acid residues in the core
region).
[0109] Activities such as, for example, HCC formation or
tumorigenesis, glucose lowering activity, lipid increasing
activity, or lean mass reducing activity can be ascertained in an
animal, such as a db/db mouse. Measurement of binding to FGFR4 or
activation of FGFR4 can be ascertained by assays disclosed herein
(see, for example, Example 1) or known to the skilled artisan.
[0110] The term "bind," or "binding," when used in reference to a
peptide sequence, means that the peptide sequence interacts at the
molecular level. Thus, a peptide sequence that binds to FGFR4 binds
to all or a part of the FGFR4 sequence. Specific and selective
binding can be distinguished from non-specific binding using assays
known in the art (e.g., competition binding, immunoprecipitation,
ELISA, flow cytometry, Western blotting).
[0111] Peptides and peptidomimetics can be produced and isolated
using methods known in the art. Peptides can be synthesized, in
whole or in part, using chemical methods (see, e.g., Caruthers
(1980). Nucleic Acids Res. Symp. Ser. 215; Horn (1980); and Banga,
A. K., Therapeutic Peptides and Proteins, Formulation, Processing
and Delivery Systems (1995) Technomic Publishing Co., Lancaster,
Pa.). Peptide synthesis can be performed using various solid-phase
techniques (see, e.g., Roberge Science 269:202 (1995); Merrifield,
Methods Enzymol. 289:3 (1997)) and automated synthesis may be
achieved, e.g., using the ABI 431A Peptide Synthesizer (Perkin
Elmer) in accordance with the manufacturer's instructions. Peptides
and peptide mimetics can also be synthesized using combinatorial
methodologies. Synthetic residues and polypeptides incorporating
mimetics can be synthesized using a variety of procedures and
methodologies known in the art (see, e.g., Organic Syntheses
Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons,
Inc., NY). Modified peptides can be produced by chemical
modification methods (see, for example, Belousov, Nucleic Acids
Res. 25:3440 (1997); Frenkel, Free Radic. Biol. Med. 19:373 (1995);
and Blommers, Biochemistry 33:7886 (1994)). Peptide sequence
variations, derivatives, substitutions and modifications can also
be made using methods such as oligonucleotide-mediated
(site-directed) mutagenesis, alanine scanning, and PCR based
mutagenesis. Site-directed mutagenesis (Carter et al., Nucl. Acids
Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res. 10:6487
(1987)), cassette mutagenesis (Wells et al., Gene 34:315 (1985)),
restriction selection mutagenesis (Wells et al., Philos. Trans. R.
Soc. London SerA 317:415 (1986)) and other techniques can be
performed on cloned DNA to produce invention peptide sequences,
variants, fusions and chimeras, and variations, derivatives,
substitutions and modifications thereof.
[0112] A "synthesized" or "manufactured" peptide sequence is a
peptide made by any method involving manipulation by the hand of
man. Such methods include but are not limited to the
aforementioned, such as chemical synthesis, recombinant DNA
technology, biochemical or enzymatic fragmentation of larger
molecules, and combinations of the foregoing.
[0113] Peptide sequences of the invention including subsequences,
sequence variants and modified forms of the exemplified peptide
sequences (e.g., sequences listed in Table 1-9 and FIG. 1), can
also be modified to form a chimeric molecule. In accordance with
the invention, there are provided peptide sequences that include a
heterologous domain. Such domains can be added to the
amino-terminus or at the carboxyl-terminus of the peptide sequence.
Heterologous domains can also be positioned within the peptide
sequence, and/or alternatively flanked by FGF19 and/or FGF21
derived amino acid sequences.
[0114] The term "peptide" also includes dimers or multimers
(oligomers) of peptides. In accordance with the invention, there
are also provided dimers or multimers (oligomers) of the
exemplified peptide sequences as well as subsequences, variants and
modified forms of the exemplified peptide sequences (e.g.,
sequences listed in Table 1-9 and FIG. 1).
[0115] The invention further provides nucleic acid molecules
encoding peptide sequences of the invention, including
subsequences, sequence variants and modified forms of the sequences
listed in Table 1-9 and FIG. 1, and vectors that include nucleic
acid that encodes the peptide. Accordingly, "nucleic acids" include
those that encode the exemplified peptide sequences disclosed
herein, as well as those encoding functional subsequences, sequence
variants and modified forms of the exemplified peptide sequences,
so long as the foregoing retain at least detectable or measureable
activity or function. For example, a subsequence, a variant or
modified form of an exemplified peptide sequence disclosed herein
(e.g., a sequence listed in Table 1-9 and FIG. 1) that retains some
ability to lower or reduce glucose, provide normal glucose
homeostasis, or reduce the histopathological conditions associated
with chronic or acute hyperglycemia in vivo, etc.
[0116] Nucleic acid, which can also be referred to herein as a
gene, polynucleotide, nucleotide sequence, primer, oligonucleotide
or probe refers to natural or modified purine- and
pyrimidine-containing polymers of any length, either
polyribonucleotides or polydeoxyribonucleotides or mixed
polyribo-polydeoxyribo nucleotides and .alpha.-anomeric forms
thereof. The two or more purine- and pyrimidine-containing polymers
are typically linked by a phosphoester bond or analog thereof. The
terms can be used interchangeably to refer to all forms of nucleic
acid, including deoxyribonucleic acid (DNA) and ribonucleic acid
(RNA). The nucleic acids can be single strand, double, or triplex,
linear or circular. Nucleic acids include genomic DNA and cDNA. RNA
nucleic acid can be spliced or unspliced mRNA, rRNA, tRNA or
antisense. Nucleic acids include naturally occurring, synthetic, as
well as nucleotide analogues and derivatives.
[0117] As a result of the degeneracy of the genetic code, nucleic
acid molecules include sequences degenerate with respect to nucleic
acid molecules encoding the peptide sequences of the invention.
Thus, degenerate nucleic acid sequences encoding peptide sequences,
including subsequences, variants and modified forms of the peptide
sequences exemplified herein (e.g., sequences listed in Table 1-9
and FIG. 1), are provided. The term "complementary," when used in
reference to a nucleic acid sequence, means the referenced regions
are 100% complementary, i.e., exhibit 100% base pairing with no
mismatches.
[0118] Nucleic acid can be produced using any of a variety of known
standard cloning and chemical synthesis methods, and can be altered
intentionally by site-directed mutagenesis or other recombinant
techniques known to one skilled in the art. Purity of
polynucleotides can be determined through sequencing, gel
electrophoresis, UV spectrometry.
[0119] Nucleic acids may be inserted into a nucleic acid construct
in which expression of the nucleic acid is influenced or regulated
by an "expression control element," referred to herein as an
"expression cassette." The term "expression control element" refers
to one or more nucleic acid sequence elements that regulate or
influence expression of a nucleic acid sequence to which it is
operatively linked. An expression control element can include, as
appropriate, promoters, enhancers, transcription terminators, gene
silencers, a start codon (e.g., ATG) in front of a protein-encoding
gene, etc.
[0120] An expression control element operatively linked to a
nucleic acid sequence controls transcription and, as appropriate,
translation of the nucleic acid sequence. The term "operatively
linked" refers to a juxtaposition wherein the referenced components
are in a relationship permitting them to function in their intended
manner. Typically, expression control elements are juxtaposed at
the 5' or the 3' ends of the genes but can also be intronic.
[0121] Expression control elements include elements that activate
transcription constitutively, that are inducible (i.e., require an
external signal or stimuli for activation), or derepressible (i.e.,
require a signal to turn transcription off; when the signal is no
longer present, transcription is activated or "derepressed"). Also
included in the expression cassettes of the invention are control
elements sufficient to render gene expression controllable for
specific cell-types or tissues (i.e., tissue-specific control
elements). Typically, such elements are located upstream or
downstream (i.e., 5' and 3') of the coding sequence. Promoters are
generally positioned 5' of the coding sequence. Promoters, produced
by recombinant DNA or synthetic techniques, can be used to provide
for transcription of the polynucleotides of the invention. A
"promoter" typically means a minimal sequence element sufficient to
direct transcription.
[0122] Nucleic acids may be inserted into a plasmid for
transformation into a host cell and for subsequent expression
and/or genetic manipulation. A plasmid is a nucleic acid that can
be stably propagated in a host cell; plasmids may optionally
contain expression control elements in order to drive expression of
the nucleic acid. For purposes of this invention, a vector is
synonymous with a plasmid. Plasmids and vectors generally contain
at least an origin of replication for propagation in a cell and a
promoter. Plasmids and vectors may also include an expression
control element for expression in a host cell, and are therefore
useful for expression and/or genetic manipulation of nucleic acids
encoding peptide sequences, expressing peptide sequences in host
cells and organisms (e.g., a subject in need of treatment), or
producing peptide sequences, for example.
[0123] As used herein, the term "transgene" means a polynucleotide
that has been introduced into a cell or organism by artifice. For
example, a cell having a transgene, the transgene has been
introduced by genetic manipulation or "transformation" of the cell.
A cell or progeny thereof into which the transgene has been
introduced is referred to as a "transformed cell" or
"transformant." Typically, the transgene is included in progeny of
the transformant or becomes a part of the organism that develops
from the cell. Transgenes may be inserted into the chromosomal DNA
or maintained as a self-replicating plasmid, YAC, minichromosome,
or the like.
[0124] Bacterial system promoters include T7 and inducible
promoters such as pL of bacteriophage .lamda., plac, ptrp, ptac
(ptrp-lac hybrid promoter) and tetracycline responsive promoters.
Insect cell system promoters include constitutive or inducible
promoters (e.g., ecdysone). Mammalian cell constitutive promoters
include SV40, RSV, bovine papilloma virus (BPV) and other virus
promoters, or inducible promoters derived from the genome of
mammalian cells (e.g., metallothionein IIA promoter; heat shock
promoter) or from mammalian viruses (e.g., the adenovirus late
promoter; the inducible mouse mammary tumor virus long terminal
repeat). Alternatively, a retroviral genome can be genetically
modified for introducing and directing expression of a peptide
sequence in appropriate host cells.
[0125] As methods and uses of the invention include in vivo
delivery, expression systems further include vectors designed for
in vivo use. Particular non-limiting examples include adenoviral
vectors (U.S. Pat. Nos. 5,700,470 and 5,731,172), adeno-associated
vectors (U.S. Pat. No. 5,604,090), herpes simplex virus vectors
(U.S. Pat. No. 5,501,979), retroviral vectors (U.S. Pat. Nos.
5,624,820, 5,693,508 and 5,674,703), BPV vectors (U.S. Pat. No.
5,719,054), CMV vectors (U.S. Pat. No. 5,561,063) and parvovirus,
rotavirus, Norwalk virus and lentiviral vectors (see, e.g., U.S.
Pat. No. 6,013,516). Vectors include those that deliver genes to
cells of the intestinal tract, including the stem cells (Croyle et
al., Gene Ther. 5:645 (1998); S. J. Henning, Adv. Drug Deliv. Rev.
17:341 (1997), U.S. Pat. Nos. 5,821,235 and 6,110,456). Many of
these vectors have been approved for human studies.
[0126] Yeast vectors include constitutive and inducible promoters
(see, e.g., Ausubel et al., In: Current Protocols in Molecular
Biology, Vol. 2, Ch. 13, ed., Greene Publish. Assoc. & Wiley
Interscience, 1988; Grant et al. Methods in Enzymology, 153:516
(1987), eds. Wu & Grossman; Bitter Methods in Enzymology,
152:673 (1987), eds. Berger & Kimmel, Acad. Press, N.Y.; and,
Strathern et al., The Molecular Biology of the Yeast Saccharomyces
(1982) eds. Cold Spring Harbor Press, Vols. I and II). A
constitutive yeast promoter such as ADH or LEU2 or an inducible
promoter such as GAL may be used (R. Rothstein In: DNA Cloning, A
Practical Approach, Vol. 11, Ch. 3, ed. D. M. Glover, IRL Press,
Wash., D.C., 1986). Vectors that facilitate integration of foreign
nucleic acid sequences into a yeast chromosome, via homologous
recombination for example, are known in the art. Yeast artificial
chromosomes (YAC) are typically used when the inserted
polynucleotides are too large for more conventional vectors (e.g.,
greater than about 12 Kb).
[0127] Expression vectors also can contain a selectable marker
conferring resistance to a selective pressure or identifiable
marker (e.g., beta-galactosidase), thereby allowing cells having
the vector to be selected for, grown and expanded. Alternatively, a
selectable marker can be on a second vector that is co-transfected
into a host cell with a first vector containing a nucleic acid
encoding a peptide sequence. Selection systems include but are not
limited to herpes simplex virus thymidine kinase gene (Wigler et
al., Cell 11:223 (1977)), hypoxanthine-guanine
phosphoribosyltransferase gene (Szybalska et al., Proc. Natl. Acad.
Sci. USA 48:2026 (1962)), and adenine phosphoribosyltransferase
(Lowy et al., Cell 22:817 (1980)) genes that can be employed in
tk-, hgprt- or aprt- cells, respectively. Additionally,
antimetabolite resistance can be used as the basis of selection for
dhfr, which confers resistance to methotrexate (O'Hare et al.,
Proc. Natl. Acad. Sci. USA 78:1527 (1981)); the gpt gene, which
confers resistance to mycophenolic acid (Mulligan et al., Proc.
Natl. Acad. Sci. USA 78:2072 (1981)); neomycin gene, which confers
resistance to aminoglycoside G-418 (Colberre-Garapin et al., J.
Mol. Biol. 150:1(1981)); puromycin; and hygromycin gene, which
confers resistance to hygromycin (Santerre et al., Gene 30:147
(1984)). Additional selectable genes include trpB, which allows
cells to utilize indole in place of tryptophan; hisD, which allows
cells to utilize histinol in place of histidine (Hartman et al.,
Proc. Natl. Acad. Sci. USA 85:8047 (1988)); and ODC (ornithine
decarboxylase), which confers resistance to the ornithine
decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO
(McConlogue (1987) In: Current Communications in Molecular Biology,
Cold Spring Harbor Laboratory).
[0128] In accordance with the invention, there are provided
transformed cell(s) (in vitro, ex vivo and in vivo) and host cells
that produce a variant or fusion of FGF19 and/or FGF21 as set forth
herein, where expression of the variant or fusion of FGF19 and/or
FGF21 is conferred by a nucleic acid encoding the variant or fusion
of FGF19 and/or FGF21. Transformed and host cells that express
invention peptide sequences typically include a nucleic acid that
encodes the invention peptide sequence. In one embodiment, a
transformed or host cell is a prokaryotic cell. In another
embodiment, a transformed or host cell is a eukaryotic cell. In
various aspects, the eukaryotic cell is a yeast or mammalian (e.g.,
human, primate, etc.) cell.
[0129] As used herein, a "transformed" or "host" cell is a cell
into which a nucleic acid is introduced that can be propagated
and/or transcribed for expression of an encoded peptide sequence.
The term also includes any progeny or subclones of the host
cell.
[0130] Transformed and host cells include but are not limited to
microorganisms such as bacteria and yeast; and plant, insect and
mammalian cells. For example, bacteria transformed with recombinant
bacteriophage nucleic acid, plasmid nucleic acid or cosmid nucleic
acid expression vectors; yeast transformed with recombinant yeast
expression vectors; plant cell systems infected with recombinant
virus expression vectors (e.g., cauliflower mosaic virus, CaMV;
tobacco mosaic virus, TMV) or transformed with recombinant plasmid
expression vectors (e.g., Ti plasmid); insect cell systems infected
with recombinant virus expression vectors (e.g., baculovirus); and
animal cell systems infected with recombinant virus expression
vectors (e.g., retroviruses, adenovirus, vaccinia virus), or
transformed animal cell systems engineered for transient or stable
propagation or expression.
[0131] For gene therapy uses and methods, a transformed cell can be
in a subject. A cell in a subject can be transformed with a nucleic
acid that encodes an invention peptide sequence as set forth herein
in vivo. Alternatively, a cell can be transformed in vitro with a
transgene or polynucleotide, and then transplanted into a tissue of
subject in order to effect treatment. Alternatively, a primary cell
isolate or an established cell line can be transformed with a
transgene or polynucleotide that encodes a variant of FGF19 and/or
FGF21 or a fusion/chimeric sequence (or variant) thereof, such as a
chimeric peptide sequence including all or a portion of FGF19, or
including all or a portion of FGF21, and then optionally
transplanted into a tissue of a subject.
[0132] Non-limiting target cells for expression of peptide
sequences, particularly for expression in vivo, include pancreas
cells (islet cells), muscle cells, mucosal cells and endocrine
cells. Such endocrine cells can provide inducible production
(secretion) of a variant of FGF19 and/or FGF21, or a
fusion/chimeric sequence (or variant) thereof, such as a chimeric
peptide sequence including all or a portion of FGF19, or including
all or a portion of FGF21. Additional cells to transform include
stem cells or other multipotent or pluripotent cells, for example,
progenitor cells that differentiate into the various pancreas cells
(islet cells), muscle cells, mucosal cells and endocrine cells.
Targeting stem cells provides longer term expression of peptide
sequences of the invention.
[0133] As used herein, the term "cultured," when used in reference
to a cell, means that the cell is grown in vitro. A particular
example of such a cell is a cell isolated from a subject, and grown
or adapted for growth in tissue culture. Another example is a cell
genetically manipulated in vitro, and transplanted back into the
same or a different subject.
[0134] The term "isolated," when used in reference to a cell, means
a cell that is separated from its naturally occurring in vivo
environment. "Cultured" and "isolated" cells may be manipulated by
the hand of man, such as genetically transformed. These terms
include any progeny of the cells, including progeny cells that may
not be identical to the parental cell due to mutations that occur
during cell division. The terms do not include an entire human
being.
[0135] Nucleic acids encoding invention peptide sequences can be
introduced for stable expression into cells of a whole organism.
Such organisms including non-human transgenic animals are useful
for studying the effect of peptide expression in a whole animal and
therapeutic benefit. For example, as disclosed herein, production
of a variant of FGF19 and/or FGF21 or a fusion/chimeric sequence
(or variant) thereof, such as a chimeric peptide sequence including
all or a portion of FGF19, or including all or a portion of FGF21
as set forth herein, in mice lowered glucose and is
anti-diabetic.
[0136] Mice strains that develop or are susceptible to developing a
particular disease (e.g., diabetes, degenerative disorders, cancer,
etc.) are also useful for introducing therapeutic proteins as
described herein in order to study the effect of therapeutic
protein expression in the disease susceptible mouse. Transgenic and
genetic animal models that are susceptible to particular disease or
physiological conditions, such as streptozotocin (STZ)-induced
diabetic (STZ) mice, are appropriate targets for expressing
variants of FGF19 and/or FGF21, fusions/chimeric sequences (or
variant) thereof, such as a chimeric peptide sequence including all
or a portion of FGF19, or including all or a portion of FGF21, as
set forth herein. Thus, in accordance with the invention, there are
provided non-human transgenic animals that produce a variant of
FGF19 and/or FGF21, or a fusion/chimeric sequence (or variant)
thereof, such as a chimeric peptide sequence including all or a
portion of FGF19, or including all or a portion of FGF21, the
production of which is not naturally occurring in the animal which
is conferred by a transgene present in somatic or germ cells of the
animal.
[0137] The term "transgenic animal" refers to an animal whose
somatic or germ line cells bear genetic information received,
directly or indirectly, by deliberate genetic manipulation at the
subcellular level, such as by microinjection or infection with
recombinant virus. The term "transgenic" further includes cells or
tissues (i.e., "transgenic cell," "transgenic tissue") obtained
from a transgenic animal genetically manipulated as described
herein. In the present context, a "transgenic animal" does not
encompass animals produced by classical crossbreeding or in vitro
fertilization, but rather denotes animals in which one or more
cells receive a nucleic acid molecule. Invention transgenic animals
can be either heterozygous or homozygous with respect to the
transgene. Methods for producing transgenic animals, including
mice, sheep, pigs and frogs, are well known in the art (see, e.g.,
U.S. Pat. Nos. 5,721,367, 5,695,977, 5,650,298, and 5,614,396) and,
as such, are additionally included.
[0138] Peptide sequences, nucleic acids encoding peptide sequences,
vectors and transformed host cells expressing peptide sequences
include isolated and purified forms. The term "isolated," when used
as a modifier of an invention composition, means that the
composition is separated, substantially completely or at least in
part, from one or more components in an environment. Generally,
compositions that exist in nature, when isolated, are substantially
free of one or more materials with which they normally associate
with in nature, for example, one or more protein, nucleic acid,
lipid, carbohydrate or cell membrane. The term "isolated" does not
exclude alternative physical forms of the composition, such as
variants, modifications or derivatized forms, fusions and chimeras,
multimers/oligomers, etc., or forms expressed in host cells. The
term "isolated" also does not exclude forms (e.g., pharmaceutical
compositions, combination compositions, etc.) in which there are
combinations therein, any one of which is produced by the hand of
man.
[0139] An "isolated" composition can also be "purified" when free
of some, a substantial number of, or most or all of one or more
other materials, such as a contaminant or an undesired substance or
material. Peptide sequences of the invention are generally not
known or believed to exist in nature. However, for a composition
that does exist in nature, an isolated composition will generally
be free of some, a substantial number of, or most or all other
materials with which it typically associates with in nature. Thus,
an isolated peptide sequence that also occurs in nature does not
include polypeptides or polynucleotides present among millions of
other sequences, such as proteins of a protein library or nucleic
acids in a genomic or cDNA library, for example. A "purified"
composition includes combinations with one or more other inactive
or active molecules. For example, a peptide sequence of the
invention combined with another drug or agent, such as a glucose
lowering drug or therapeutic agent, for example.
[0140] As used herein, the term "recombinant," when used as a
modifier of peptide sequences, nucleic acids encoding peptide
sequences, etc., means that the compositions have been manipulated
(i.e., engineered) in a fashion that generally does not occur in
nature (e.g., in vitro). A particular example of a recombinant
peptide would be where a peptide sequence of the invention is
expressed by a cell transfected with a nucleic acid encoding the
peptide sequence. A particular example of a recombinant nucleic
acid would be where a nucleic acid (e.g., genomic or cDNA) encoding
a peptide sequence cloned into a plasmid, with or without 5', 3' or
intron regions that the gene is normally contiguous within the
genome of the organism. Another example of a recombinant peptide or
nucleic acid is a hybrid or fusion sequence, such as a chimeric
peptide sequence comprising a portion of FGF19 and a portion of
FGF21.
[0141] In accordance with the invention, there are provided
compositions and mixtures of invention peptide sequences, including
subsequences, variants and modified forms of the exemplified
peptide sequences (including the FGF19 and FGF21 variants and
subsequences listed in Table 1-9 and FIG. 1, and the FGF19/FGF21
fusions and chimeras listed in Table 1-9 and FIG. 1). In one
embodiment, a mixture includes one or more peptide sequences and a
pharmaceutically acceptable carrier or excipient. In another
embodiment, a mixture includes one or more peptide sequences and an
adjunct drug or therapeutic agent, such as an anti-diabetic, or
glucose lowering, drug or therapeutic agent. Examples of drugs and
therapeutic agents are set forth hereafter. Combinations, such as
one or more peptide sequences in a pharmaceutically acceptable
carrier or excipient, with one or more of an anti-diabetic, or
glucose lowering drug or therapeutic agent are also provided. Such
combinations of peptide sequence of the invention with another drug
or agent, such as a glucose lowering drug or therapeutic agent, for
example are useful in accordance with the invention methods and
uses, for example, for treatment of a subject.
[0142] Combinations also include incorporation of peptide sequences
or nucleic acids of the invention into particles or a polymeric
substances, such as polyesters, carbohydrates, polyamine acids,
hydrogel, polyvinyl pyrrolidone, ethylene-vinylacetate,
methylcellulose, carboxymethylcellulose, protamine sulfate, or
lactide/glycolide copolymers, polylactide/glycolide copolymers, or
ethylenevinylacetate copolymers; entrapment in microcapsules
prepared by coacervation techniques or by interfacial
polymerization, for example, by the use of hydroxymethylcellulose
or gelatin-microcapsules, or poly (methylmethacrolate)
microcapsules, respectively; incorporation in colloid drug delivery
and dispersion systems such as macromolecule complexes,
nano-capsules, microspheres, beads, and lipid-based systems (e.g.,
N-fatty acyl groups such as N-lauroyl, N-oleoyl, fatty amines such
as dodecyl amine, oleoyl amine, etc., see U.S. Pat. No. 6,638,513),
including oil-in-water emulsions, micelles, mixed micelles, and
liposomes, for example.
[0143] Invention peptides including subsequences, variants and
modified forms of the exemplified peptide sequences (including the
FGF19 and FGF21 variants and subsequences listed in Table 1-9 and
FIG. 1, and the FGF19/FGF21 fusions and chimeras listed in Table
1-9 and FIG. 1) as set forth herein can be used to modulate glucose
metabolism and facilitate transport of glucose from the blood to
key metabolic organs such as muscle, liver and fat. Such peptide
sequences can be produced in amounts sufficient or effective to
restore glucose tolerance and/or to improve or provide normal
glucose homeostasis.
[0144] As disclosed herein, administration of various FGF19
and/FGF21 variants and fusion peptide sequences to mice
successfully reduced glucose levels. Furthermore, in contrast to
FGF19, certain peptide sequences did not stimulate or induce HCC
formation or tumorigenesis in mice. Thus, administration of
invention peptides, including subsequences, variants and modified
forms of the exemplified peptide sequences (including the FGF19 and
FGF21 variants and subsequences listed in Table 1-9 and FIG. 1, and
the FGF19/FGF21 fusions and chimeras listed in Table 1-9 and FIG.
1), into an animal, either by direct or indirect in vivo or by ex
vivo methods (e.g., administering the variant or fusion peptide, a
nucleic acid encoding the variant or fusion peptide, or a
transformed cell or gene therapy vector expressing the variant or
fusion peptide), can be used to treat various disorders.
[0145] Accordingly, the invention includes in vitro, ex vivo and in
vivo (e.g., on or in a subject) methods and uses. Such methods and
uses can be practiced with any of the peptide sequences of the
invention set forth herein.
[0146] In accordance with the invention, there are provided methods
of treating a subject having, or at risk of having, a disorder. In
various embodiments, a method includes administering a peptide
sequence, such as an FGF19 or FGF21 variant, fusion or chimera
listed in Table 1-9 and FIG. 1, or a subsequence, a variant or
modified form of an FGF19 or FGF21 variant, fusion or chimera
listed in Table 1-9 and FIG. 1, to a subject in an amount effective
for treating the disorder.
[0147] Exemplary disorders treatable, preventable, and the like
with invention peptides, and methods and uses, include metabolic
diseases and disorders. Non limiting examples of diseases and
disorders include: 1. Glucose utilization disorders and the
sequelae associated therewith, including diabetes mellitus (Type I
and Type-2), gestational diabetes, hyperglycemia, insulin
resistance, abnormal glucose metabolism, "pre-diabetes" (Impaired
Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)), and
other physiological disorders associated with, or that result from,
the hyperglycemic condition, including, for example,
histopathological changes such as pancreatic .beta.-cell
destruction. For treatment, invention peptide sequences can be
administered to subjects having a fasting plasma glucose (FPG)
level greater than about 100 mg/dl. Peptide sequences of the
invention may also be useful in other hyperglycemic-related
disorders, including kidney damage (e.g., tubule damage or
nephropathy), liver degeneration, eye damage (e.g., diabetic
retinopathy or cataracts), and diabetic foot disorders; 2.
Dyslipidemias and their sequelae such as, for example,
atherosclerosis, coronary artery disease, cerebrovascular disorders
and the like; 3. Other conditions which may be associated with the
metabolic syndrome, such as obesity and elevated body mass
(including the co-morbid conditions thereof such as, but not
limited to, nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS)),
and also include thromboses, hypercoagulable and prothrombotic
states (arterial and venous), hypertension, cardiovascular disease,
stroke and heart failure; 4. Disorders or conditions in which
inflammatory reactions are involved, including atherosclerosis,
chronic inflammatory bowel diseases (e.g., Crohn's disease and
ulcerative colitis), asthma, lupus erythematosus, arthritis, or
other inflammatory rheumatic disorders; 5. Disorders of cell cycle
or cell differentiation processes such as adipose cell tumors,
lipomatous carcinomas including, for example, liposarcomas, solid
tumors, and neoplasms; 6. Neurodegenerative diseases and/or
demyelinating disorders of the central and peripheral nervous
systems and/or neurological diseases involving neuroinflammatory
processes and/or other peripheral neuropathies, including
Alzheimer's disease, multiple sclerosis, Parkinson's disease,
progressive multifocal leukoencephalopathy and Guillian-Barre
syndrome; 7. Skin and dermatological disorders and/or disorders of
wound healing processes, including erythemato-squamous dermatoses;
and 8. Other disorders such as syndrome X, osteoarthritis, and
acute respiratory distress syndrome.
[0148] As used herein, the term "hyperglycemic" or "hyperglycemia,"
when used in reference to a condition of a subject means a
transient or chronic abnormally high level of glucose present in
the blood of a subject. The condition can be caused by a delay in
glucose metabolism or absorption such that the subject exhibits
glucose intolerance or a state of elevated glucose not typically
found in normal subjects (e.g., in glucose-intolerant pre-diabetic
subjects at risk of developing diabetes, or in diabetic subjects).
Fasting plasma glucose (FPG) levels for normoglycemia are less than
about 100 mg/dl, for impaired glucose metabolism, between about 100
and 126 mg/dl, and for diabetics greater than about 126 mg/dl.
[0149] As disclosed herein, the invention includes methods of
preventing (e.g., in subjects predisposed to having a particular
disorder(s)), delaying, slowing or inhibiting progression of, the
onset of, or treating (e.g., ameliorating) obesity or an
undesirable body mass (e.g., a greater than normal body mass index,
or "BMI" relative to an appropriate matched subject of comparable
age, gender, race, etc.). Thus, in various embodiments, a method of
the invention for, for example, treating obesity or an undesirable
body mass (including the co-morbid conditions of obesity, e.g.,
obstructive sleep apnea, arthritis, cancer (e.g., breast,
endometrial, and colon), gallstones or hyperglycemia, includes
contacting or administering a peptide of the invention as set forth
herein (e.g., a variant or fusion of FGF19 and/or FGF21 as set
forth in Table 1-9 or FIG. 1, for example) in an amount effective
to treat obesity or an undesirable body mass. In particular
aspects, a subject has a body mass index greater than 25, for
example, 25-30, 30-35, 35-40, or greater than 40.
[0150] Moreover, the invention includes methods of preventing
(e.g., in subjects predisposed to having a particular disorder(s)),
slowing or inhibiting the progression of, delaying the onset of, or
treating undesirable levels or abnormally elevated serum/plasma
LDL, VLDL, triglycerides or cholesterol, all of which, alone or in
combination, can lead to, for example, plaque formation, narrowing
or blockage of blood vessels, and increased risk of hypertension,
stroke and coronary artery disease. Such disorders can be due to,
for example, genetic predisposition or diet, for example.
[0151] The term "subject" refers to an animal. Typically, the
animal is a mammal that would benefit from treatment with a peptide
sequence of the invention. Particular examples include primates
(e.g., humans), dogs, cats, horses, cows, pigs, and sheep.
[0152] Subjects include those having a disorder, e.g., a
hyperglycemic disorder, such as diabetes, or subjects that do not
have a disorder but may be at risk of developing the disorder,
e.g., pre-diabetic subjects having FPG levels greater than 100
mg/dl, for example, between about 100 and 126 mg/dl. Subjects at
risk of developing a disorder include, for example, those whose
diet may contribute to development of acute or chronic
hyperglycemia (e.g., diabetes), undesirable body mass or obesity,
as well as those which may have a family history or genetic
predisposition towards development of acute or chronic
hyperglycemia, or undesirable body mass or obesity.
[0153] As disclosed herein, treatment methods include contacting or
administering a peptide of the invention as set forth herein (e.g.,
a variant or fusion of FGF19 and or FGF21 as set forth in Table 1-9
or FIG. 1, for example) in an amount effective to achieve a desired
outcome or result in a subject. A treatment that results in a
desired outcome or result includes decreasing, reducing or
preventing severity or frequency of one or more symptoms of the
condition in the subject, e.g., an improvement in the subject's
condition or a "beneficial effect" or "therapeutic effect."
Therefore, treatment can decrease or reduce or prevent the severity
or frequency of one or more symptoms of the disorder, stabilize or
inhibit progression or worsening of the disorder, and in some
instances, reverse the disorder, transiently (e.g., for 1-6, 6-12,
or 12-24 hours), for medium term (e.g., 1-6, 6-12, 12-24 or 24-48
days) or long term (e.g., for 1-6, 6-12, 12-24, 24-48 weeks, or
greater than 24-48 weeks). Thus, in the case of a hyperglycemic
disorder, for example, treatment can lower or reduce blood glucose,
improve glucose tolerance, improve glucose metabolism, provide
normal glucose homeostasis, lower or reduce insulin resistance,
lower or reduce insulin levels, or decrease, prevent, improve, or
reverse metabolic syndrome, or a histopathological change
associated with or that results from the hyperglycemic disorder,
such as diabetes.
[0154] For example, a peptide sequence, method or use can lower or
reduce glucose in one or more subjects having FPG levels greater
than 100 mg/dl, for example, between about 100 and 125 mg/dl, or
greater than 125 mg/dl, by 5-10%, 10-20%, 20-30%, or 30-50%, or
more, or for example from greater than 200 mg/dl to less than 200
mg/dl, for greater than 150 mg/dl to less than 150 mg/dl, from
greater than 125 mg/dl to less than 125 mg/dl, etc. In addition, a
peptide sequence, method or use can lower or reduce glucose, for
example, for pre-diabetes or for diabetes (e.g., Type 2) subjects
with baseline HbAIc levels greater than about 5%, 6%, 7%, 8%, 9% or
10%, in particular 5%, 6%, or 7%.
[0155] Non-limiting examples of an improvement of a
histopathological change associated with a hyperglycemic condition
include, for example, decreasing, inhibiting, reducing or
arresting: the destruction or degeneration of pancreas cells (e.g.,
(3-cells), kidney damage such as tubule calcification or
nephropathy, degeneration of liver, eye damage (e.g., diabetic
retinopathy, cataracts), diabetic foot, ulcerations in mucosa such
as mouth and gums, periodontitis, excess bleeding, slow or delayed
healing of injuries or wounds (e.g., that lead to diabetic
carbuncles), skin infections and other cutaneous disorders,
cardiovascular and coronary heart disease, peripheral vascular
disease, stroke, dyslipidemia, hypertension, obesity, or the risk
of developing any of the foregoing. Improvement in undesirable body
mass or obesity can include, for example, a reduction of body mass
(as reflected by BMI or the like) or an improvement in an
associated disorder, such as a decrease in triglyceride,
cholesterol, LDL or VLDL levels, a decrease in blood pressure, a
decrease in intimal thickening of the blood vessel, a decreased or
reduced risk of cardiovascular disease, or stroke, decrease in
resting heart rate, etc.
[0156] An "effective amount" or a "sufficient amount" for use
and/or for treating a subject refer to an amount that provides, in
single or multiple doses, alone, or in combination with one or more
other compositions (therapeutic agents such as a drug or treatment
for hyperglycemia), treatments, protocols, or therapeutic regimens
agents, a detectable response of any duration of time (transient,
medium or long term), a desired outcome in or an objective or
subjective benefit to a subject of any measurable or detectable
degree or for any duration of time (e.g., for hours, days, months,
years, or cured). Such amounts typically are effective to
ameliorate a disorder, or one, multiple or all adverse symptoms,
consequences or complications of the disorder, to a measurable
extent, although reducing or inhibiting a progression or worsening
of the disorder, is considered a satisfactory outcome.
[0157] As used herein, the term "ameliorate" means an improvement
in the subject's disorder, a reduction in the severity of the
disorder, or an inhibition of progression or worsening of the
disorder (e.g., stabilizing the disorder). In the case of a
hyperglycemic disorder (e.g., diabetes, insulin resistance, glucose
intolerance, metabolic syndrome, etc.), for example, an improvement
can be a lowering or a reduction in blood glucose, a reduction in
insulin resistance, a reduction in glucagon, an improvement in
glucose tolerance, or glucose metabolism or homeostasis. An
improvement in a hyperglycemic disorder also can include improved
pancreatic function (e.g., inhibit or prevent .beta.-cell/islet
destruction or enhance .beta.-cell number and/or function), a
decrease in a pathology associated with or resulting from the
disorder, such as an improvement in histopathology of an affected
tissue or organ, as set forth herein. In the case of undesirable
body mass or obesity, for example, an improvement can be a decrease
in weight gain, a reduction of body mass (as reflected in reduced
BMI, for example) or an improvement in a condition associated with
undesirable body mass obesity, for example, as set forth herein
(e.g., a lowering or a reduction of blood glucose, triglyceride,
cholesterol, LDL or VLDL levels, a decrease in blood pressure, a
decrease in intimal thickening of the blood vessel, etc.).
[0158] A therapeutic benefit or improvement therefore need not be
complete ablation of any one, most or all symptoms, complications,
consequences or underlying causes associated with the disorder or
disease. Thus, a satisfactory endpoint is achieved when there is a
transient, medium or long term, incremental improvement in a
subject's condition, or a partial reduction in the occurrence,
frequency, severity, progression, or duration, or inhibition or
reversal, of one or more associated adverse symptoms or
complications or consequences or underlying causes, worsening or
progression (e.g., stabilizing one or more symptoms or
complications of the condition, disorder or disease), of the
disorder or disease, over a duration of time (hours, days, weeks,
months, etc.).
[0159] Thus, in the case of a disorder treatable by a peptide
sequence of the invention, the amount of peptide sufficient to
ameliorate a disorder will depend on the type, severity and extent,
or duration of the disorder, the therapeutic effect or outcome
desired, and can be readily ascertained by the skilled artisan.
Appropriate amounts will also depend upon the individual subject
(e.g., the bioavailability within the subject, gender, age, etc.).
For example, a transient, or partial, restoration of normal glucose
homeostasis in a subject can reduce the dosage amount or frequency
of insulin injection, even though complete freedom from insulin has
not resulted.
[0160] An effective amount can be ascertained, for example, by
measuring one or more relevant physiological effects. In a
particular non-limiting example in the case of a hyperglycemic
condition, a lowering or reduction of blood glucose or an
improvement in glucose tolerance test can be used to determine
whether the amount of invention peptide sequence, including
subsequences, sequence variants and modified forms of the
exemplified peptide sequences (e.g., sequences listed in Table 1-9
and FIG. 1) is effective to treat a hyperglycemic condition. In
another particular non-limiting example, an effective amount is an
amount sufficient to reduce or decrease any level (e.g., a baseline
level) of FPG, wherein, for example, an amount sufficient to reduce
a FPG level greater than 200 mg/dl to less than 200 mg/dl, an
amount sufficient to reduce a FPG level between 175 mg/dl and 200
mg/dl to less than the pre-administration level, an amount
sufficient to reduce a FPG level between 150 mg/dl and 175 mg/dl to
less than the pre-administration level, an amount sufficient to
reduce a FPG level between 125 mg/dl and 150 mg/dl to less than the
pre-administration level, and so on (e.g., reducing FPG levels to
less than 125 mg/dl, to less than 120 mg/dl, to less than 115
mg/dl, to less than 110 mg/dl, etc.). In the case of HbAIc levels,
an effective amount includes an amount sufficient to reduce or
decrease levels by more than about 10% to 9%, by more than about 9%
to 8%, by more than about 8% to 7%, by more than about 7% to 6%, by
more than about 6% to 5%, and so on. More particularly, a reduction
or decrease of HbAIc levels by about 0.1%, 0.25%, 0.4%, 0.5%, 0.6%,
0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 33%,
35%, 40%, 45%, 50%, or more is an effective amount in accordance
with the invention. In yet another particular non-limiting example
in the case of undesirable body mass or obesity, an effective
amount is an amount sufficient to decrease or reduce the body mass
index (BMI) of a subject, a decrease or reduction of glucose, a
decrease or reduction in serum/plasma levels of triglyceride,
lipid, cholesterol, fatty acids, LDL and/or VLDL. In yet further
particular non-limiting examples, an amount is an amount sufficient
to decrease or reduce any of the aforementioned parameters by, for
example, about 0.1%, 0.25%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%,
1.5%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, or
more.
[0161] Methods and uses of the invention for treating a subject are
applicable for prophylaxis to prevent a disorder in a subject, such
as a hyperglycemic disorder, or development of undesirable body
mass or obesity. Alternatively, methods and uses can be practiced
during or following treatment of a subject. For example, prior to,
during or following treatment of a subject to lower glucose using
insulin or another glucose lowering drug or therapeutic agent, for
example, a method or use of the invention can, for example, a
peptide sequence of the invention can be administered to the
subject. In addition, a composition such as a peptide sequence of
the invention can be combined with another drug or agent, such as a
glucose lowering drug or therapeutic agent, for example.
[0162] Accordingly, methods and uses of the invention for treating
a subject can be practiced prior to, substantially
contemporaneously with or following another treatment, and can be
supplemented with other forms of therapy. Supplementary therapies
include other glucose lowering treatments, such as insulin, an
insulin sensitivity enhancer and other drug treatments, a change in
diet (low sugar, fats, etc.), weight loss surgery- (reducing
stomach volume by gastric bypass, gastrectomy), gastric banding,
gastric balloon, gastric sleeve, etc. For example, a method or use
of the invention for treating a hyperglycemic or insulin resistance
disorder can be used in combination with drugs or other
pharmaceutical compositions that lower glucose or increase insulin
sensitivity in a subject. Drugs for treating diabetes include, for
example, biguanides and sulphonylureas (e.g., tolbutamide,
chlorpropamide, acetohexamide, tolazamide, glibenclamide and
glipizide), thiazolidinediones (rosiglitazone, pioglitazone), GLP-1
analogues, Dipeptidyl peptidase-4 (DPP-4) inhibitors, bromocriptine
formulations (e.g. and bile acid sequestrants (e.g., colesevelam),
and insulin (bolus and basal analogs), metformin (e.g., metformin
hydrochloride) with or without a thiazolidinedione (TZD), and
SGLT-2 inhibitors. Appetite suppression drugs are also well known
and can be used in combination with the methods of the invention.
Supplementary therapies can be administered prior to,
contemporaneously with or following invention methods and uses.
[0163] Peptide sequences of the invention including subsequences,
sequence variants and modified forms of the exemplified peptide
sequences (sequences listed in Table 1-9 and FIG. 1), may be
formulated in a unit dose or unit dosage form. In a particular
embodiment, a peptide sequence is in an amount effective to treat a
subject in need of treatment, e.g., due to hyperglycemia. Exemplary
unit doses range from about 25-250, 250-500, 500-1000, 1000-2500 or
2500-5000, 5000-25,000, 25,000-50,000 ng; from about 25-250,
250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000,
25,000-50,000 .mu.g; and from about 25-250, 250-500, 500-1000,
1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 mg.
[0164] Peptide sequences of the invention including subsequences,
sequence variants and modified forms of the exemplified peptide
sequences (sequences listed in Table 1-9 and FIG. 1) can be
administered to provide the intended effect as a single dose or
multiple dosages, for example, in an effective or sufficient
amount. Exemplary doses range from about 25-250, 250-500, 500-1000,
1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 pg/kg; from
about 50-500, 500-5000, 5000-25,000 or 25,000-50,000 ng/kg; and
from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000,
5000-25,000, 25,000-50,000 .mu.g/kg. Single or multiple doses can
be administered, for example, multiple times per day, on
consecutive days, alternating days, weekly or intermittently (e.g.,
twice per week, once every 1, 2, 3, 4, 5, 6, 7 or 8 weeks, or once
every 2, 3, 4, 5 or 6 months).
[0165] Peptide sequences of the invention including subsequences,
variants and modified forms of the exemplified peptide sequences
(sequences listed in Table 1-9 and FIG. 1) can be administered and
methods may be practiced via systemic, regional or local
administration, by any route. For example, a peptide sequence can
be administered parenterally (e.g., subcutaneously, intravenously,
intramuscularly, or intraperitoneally), orally (e.g., ingestion,
buccal, or sublingual), inhalation, intradermally, intracavity,
intracranially, transdermally (topical), transmucosally or
rectally. Peptide sequences of the invention including
subsequences, variants and modified forms of the exemplified
peptide sequences (sequences listed in Table 1-9 and FIG. 1) and
methods of the invention including pharmaceutical compositions can
be administered via a (micro)encapsulated delivery system or
packaged into an implant for administration.
[0166] A particular non-limiting example of parenteral (e.g.,
subcutaneous) administration entails the use of Intarcia's
subcutaneous delivery system (Intarcia Therapeutics, Inc.; Hayward,
Calif.). The system comprises a miniature osmotic pump that
delivers a consistent amount of a therapeutic agent over a desired
period of time. In addition to maintaining drug levels within an
appropriate therapeutic range, the system can be used with
formulations that maintain the stability of proteinaceous
therapeutic agents at human body temperature for extended periods
of time. The subcutaneous system is being evaluated for the
continuous, subcutaneous delivery of exenatide (marketed as
Byetta.TM.) in a once-yearly, injection-free GLP-1 therapy for
treatment of type 2 diabetes.
[0167] The invention further provides "pharmaceutical
compositions," which include a peptide sequence (or sequences) of
the invention, including subsequences, variants and modified forms
of the exemplified peptide sequences (sequences listed in Table 1-9
and FIG. 1), and one or more pharmaceutically acceptable or
physiologically acceptable diluent, carrier or excipient. In
particular embodiments, a peptide sequence or sequences are present
in a therapeutically acceptable amount. The pharmaceutical
compositions may be used in accordance with the invention methods
and uses. Thus, for example, the pharmaceutical compositions can be
administered ex vivo or in vivo to a subject in order to practice
treatment methods and uses of the invention.
[0168] Pharmaceutical compositions of the invention can be
formulated to be compatible with the intended method or route of
administration; exemplary routes of administration are set forth
herein. In addition, the pharmaceutical compositions may further
comprise other therapeutically active agents or compounds disclosed
herein (e.g., glucose lowering agents) or known to the skilled
artisan which can be used in the treatment or prevention of various
diseases and disorders as set forth herein.
[0169] Pharmaceutical compositions typically comprise a
therapeutically effective amount of at least one of the peptide
sequences of the invention, including subsequences, variants and
modified forms of the exemplified peptide sequences (sequences
listed in Table 1-9 and FIG. 1) and one or more pharmaceutically
and physiologically acceptable formulation agents. Suitable
pharmaceutically acceptable or physiologically acceptable diluents,
carriers or excipients include, but are not limited to,
antioxidants (e.g., ascorbic acid and sodium bisulfate),
preservatives (e.g., benzyl alcohol, methyl parabens, ethyl or
n-propyl, p-hydroxybenzoate), emulsifying agents, suspending
agents, dispersing agents, solvents, fillers, bulking agents,
buffers, vehicles, diluents, and/or adjuvants. For example, a
suitable vehicle may be physiological saline solution or citrate
buffered saline, possibly supplemented with other materials common
in pharmaceutical compositions for parenteral administration.
Neutral buffered saline or saline mixed with serum albumin are
further exemplary vehicles. Those skilled in the art will readily
recognize a variety of buffers that could be used in the
pharmaceutical compositions and dosage forms used in the invention.
Typical buffers include, but are not limited to pharmaceutically
acceptable weak acids, weak bases, or mixtures thereof. Buffer
components also include water soluble materials such as phosphoric
acid, tartaric acids, lactic acid, succinic acid, citric acid,
acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts
thereof.
[0170] A primary solvent in a vehicle may be either aqueous or
non-aqueous in nature. In addition, the vehicle may contain other
pharmaceutically acceptable excipients for modifying or maintaining
the pH, osmolarity, viscosity, sterility or stability of the
pharmaceutical composition. In certain embodiments, the
pharmaceutically acceptable vehicle is an aqueous buffer. In other
embodiments, a vehicle comprises, for example, sodium chloride
and/or sodium citrate.
[0171] Pharmaceutical compositions of the invention may contain
still other pharmaceutically-acceptable formulation agents for
modifying or maintaining the rate of release of an invention
peptide. Such formulation agents include those substances known to
artisans skilled in preparing sustained release formulations. For
further reference pertaining to pharmaceutically and
physiologically acceptable formulation agents, see, for example,
Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack
Publishing Co., Easton, Pa. 18042) pages 1435-1712, The Merck
Index, 12th Ed. (1996, Merck Publishing Group, Whitehouse, N.J.);
and Pharmaceutical Principles of Solid Dosage Forms (1993,
Technonic Publishing Co., Inc., Lancaster, Pa.). Additional
pharmaceutical compositions appropriate for administration are
known in the art and are applicable in the methods and compositions
of the invention.
[0172] A pharmaceutical composition may be stored in a sterile vial
as a solution, suspension, gel, emulsion, solid, or dehydrated or
lyophilized powder. Such compositions may be stored either in a
ready to use form, a lyophilized form requiring reconstitution
prior to use, a liquid form requiring dilution prior to use, or
other acceptable form. In some embodiments, a pharmaceutical
composition is provided in a single-use container (e.g., a
single-use vial, ampoule, syringe, or autoinjector (similar to,
e.g., an EpiPen.RTM.)), whereas a multi-use container (e.g., a
multi-use vial) is provided in other embodiments. Any drug delivery
apparatus may be used to deliver invention peptides, including
implants (e.g., implantable pumps) and catheter systems, both of
which are known to the skilled artisan. Depot injections, which are
generally administered subcutaneously or intramuscularly, may also
be utilized to release invention peptides over a defined period of
time. Depot injections are usually either solid- or oil-based and
generally comprise at least one of the formulation components set
forth herein. The skilled artisan is familiar with possible
formulations and uses of depot injections.
[0173] A pharmaceutical composition can be formulated to be
compatible with its intended route of administration. Thus,
pharmaceutical compositions include carriers, diluents, or
excipients suitable for administration by routes including
parenteral (e.g., subcutaneous (s.c.), intravenous, intramuscular,
or intraperitoneal), intradermal, oral (e.g., ingestion),
inhalation, intracavity, intracranial, and transdermal
(topical).
[0174] Pharmaceutical compositions may be in the form of a sterile
injectable aqueous or oleagenous suspension. This suspension may be
formulated using suitable dispersing or wetting agents and
suspending agents disclosed herein or known to the skilled artisan.
The sterile injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally-acceptable
diluent or solvent, for example, as a solution in 1,3-butane diol.
Acceptable diluents, solvents and dispersion media that may be
employed include water, Ringer's solution, isotonic sodium chloride
solution, Cremophor EL.TM. (BASF, Parsippany, N.J.) or phosphate
buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene
glycol, and liquid polyethylene glycol), and suitable mixtures
thereof. In addition, sterile, fixed oils are conventionally
employed as a solvent or suspending medium. For this purpose any
bland fixed oil may be employed including synthetic mono- or
diglycerides. Moreover, fatty acids such as oleic acid find use in
the preparation of injectables. Prolonged absorption of particular
injectable formulations can be achieved by including an agent that
delays absorption (e.g., aluminum monostearate or gelatin).
[0175] Pharmaceutical compositions may be in a form suitable for
oral use, for example, as tablets, capsules, troches, lozenges,
aqueous or oily suspensions, dispersible powders or granules,
emulsions, hard or soft capsules, or syrups, solutions, microbeads
or elixirs. Pharmaceutical compositions intended for oral use may
be prepared according to any method known to the art for the
manufacture of pharmaceutical compositions. Such compositions may
contain one or more agents such as sweetening agents, flavoring
agents, coloring agents and preserving agents in order to provide
pharmaceutically elegant and palatable preparations. Tablets
containing an invention peptide may be in admixture with non-toxic
pharmaceutically acceptable excipients suitable for the manufacture
of tablets. These excipients include, for example, diluents, such
as calcium carbonate, sodium carbonate, lactose, calcium phosphate
or sodium phosphate; granulating and disintegrating agents, for
example, corn starch, or alginic acid; binding agents, for example
starch, gelatin or acacia, and lubricating agents, for example
magnesium stearate, stearic acid or talc.
[0176] Tablets, capsules and the like suitable for oral
administration may be uncoated or they may be coated by known
techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate may be employed. They
may also be coated by techniques known in the art to form osmotic
therapeutic tablets for controlled release. Additional agents
include biodegradable or biocompatible particles or a polymeric
substance such as polyesters, polyamine acids, hydrogel, polyvinyl
pyrrolidone, polyanhydrides, polyglycolic acid,
ethylene-vinylacetate, methylcellulose, carboxymethylcellulose,
protamine sulfate, or lactide/glycolide copolymers,
polylactide/glycolide copolymers, or ethylenevinylacetate
copolymers in order to control delivery of an administered
composition. For example, the oral agent can be entrapped in
microcapsules prepared by coacervation techniques or by interfacial
polymerization, by the use of hydroxymethylcellulose or
gelatin-microcapsules or poly (methylmethacrolate) microcapsules,
respectively, or in a colloid drug delivery system. Colloidal
dispersion systems include macromolecule complexes, nano-capsules,
microspheres, microbeads, and lipid-based systems, including
oil-in-water emulsions, micelles, mixed micelles, and liposomes.
Methods for preparation of such formulations are known to those
skilled in the art and are commercially available.
[0177] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate, kaolin or microcrystalline cellulose, or as soft gelatin
capsules wherein the active ingredient is mixed with water or an
oil medium, for example peanut oil, liquid paraffin, or olive
oil.
[0178] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture thereof.
Such excipients are suspending agents, for example sodium
carboxymethylcellulose, methylcellulose,
hydroxy-propylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents may be a naturally-occurring phosphatide, for
example lecithin, or condensation products of an alkylene oxide
with fatty acids, for example polyoxy-ethylene stearate, or
condensation products of ethylene oxide with long chain aliphatic
alcohols, for example heptadecaethyleneoxycetanol, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived
from fatty acids and hexitol anhydrides, for example polyethylene
sorbitan monooleate. The aqueous suspensions may also contain one
or more preservatives.
[0179] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation.
[0180] Dispersible powders and granules suitable for preparation of
an aqueous suspension by addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified herein.
[0181] Pharmaceutical compositions of the invention may also be in
the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, for example olive oil or arachis oil, or a mineral
oil, for example, liquid paraffin, or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example,
gum acacia or gum tragacanth; naturally-occurring phosphatides, for
example, soy bean, lecithin, and esters or partial esters derived
from fatty acids; hexitol anhydrides, for example, sorbitan
monooleate; and condensation products of partial esters with
ethylene oxide, for example, polyoxyethylene sorbitan
monooleate.
[0182] Pharmaceutical compositions can also include carriers to
protect the composition against rapid degradation or elimination
from the body, such as a controlled release formulation, including
implants, liposomes, hydrogels, prodrugs and microencapsulated
delivery systems. For example, a time delay material such as
glyceryl monostearate or glyceryl stearate alone, or in combination
with a wax, may be employed. Prolonged absorption of injectable
pharmaceutical compositions can be achieved by including an agent
that delays absorption, for example, aluminum monostearate or
gelatin. Prevention of the action of microorganisms can be achieved
by various antibacterial and antifungal agents, for example,
parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the
like.
[0183] The invention also includes invention peptides in the form
of suppositories for rectal administration. The suppositories can
be prepared by mixing an invention peptide with a suitable
non-irritating excipient which is solid at ordinary temperatures
but liquid at the rectal temperature and will therefore melt in the
rectum to release the drug. Such materials include, but are not
limited to, cocoa butter and polyethylene glycols.
[0184] In accordance with the invention, there are provided methods
of identifying a peptide (or a subsequence, variant or modified
form as set forth herein) having glucose lowering activity without
substantial HCC activity. In one embodiment, a method includes:
screening (e.g., assaying or measuring) a peptide sequence (or a
subsequence, variant or modified form as set forth herein) for
glucose lowering activity; and screening (e.g., assaying or
measuring) a peptide sequence (or a subsequence, variant or
modified form as set forth herein) for HCC activity, or expression
of a marker correlating with HCC activity. A peptide having glucose
lowering activity and reduced or absent HCC activity thereby
identifies the peptide. In particular aspects, the marker
correlating with HCC activity comprises lipid profile--a peptide
that has less lipid increasing activity compared to FGF19 indicates
the peptide has reduced or absent HCC activity; or the marker
correlating with HCC activity comprises aldo-keto reductase gene
expression--a peptide that down-regulates or decreases aldo-keto
reductase gene expression compared to FGF19 indicates that the
peptide has reduced or absent HCC activity; or the marker
indicative of HCC activity comprises Slc1a2 gene expression--a
peptide that up-regulates or increases Slc1a2 gene expression
compared to FGF19 indicates that the peptide has reduced or absent
HCC activity.
[0185] The terms "assaying" and "measuring" and grammatical
variations thereof are used interchangeably herein and refer to
either qualitative or quantitative determinations, or both
qualitative and quantitative determinations. When the terms are
used in reference to detection, any means of assessing the relative
amount is contemplated, including the various methods set forth
herein and known in the art. For example, gene expression can be
assayed or measured by a Northern blot, Western blot,
immunoprecipitation assay, or by measuring activity, function or
amount of the expressed protein (e.g., aldo-keto reductase or
Slc1a2).
[0186] Risk factors for HCC, the most common type of liver cancer,
include type 2 diabetes (probably exacerbated by obesity). The risk
of HCC in type 2 diabetics is greater (from .about.2.5 to .about.7
times the non-diabetic risk) depending on the duration of diabetes
and treatment protocol.
[0187] Various methodologies can be used in the screening and
diagnosis of HCC and are well known to the skilled artisan.
Indicators for HCC include detection of a tumor maker such as
elevated alpha-fetoprotein (AFP) or des-gamma carboxyprothrombin
(DCP) levels. A number of different scanning and imaging techniques
are also helpful, including ultrasound, CT scans and MRI. In
relation to the invention, evaluation of whether a peptide (e.g., a
candidate peptide) exhibits evidence of inducing HCC may be
determined in vivo by, for example, quantifying HCC nodule
formation in an animal model, such as db/db mice, administered a
peptide, compared to HCC nodule formation by wild type FGF19.
Macroscopically, liver cancer may be nodular, where the tumor
nodules (which are round-to-oval, grey or green, well circumscribed
but not encapsulated) appear as either one large mass or multiple
smaller masses. Alternatively, HCC may be present as an
infiltrative tumor which is diffuse and poorly circumscribed and
frequently infiltrates the portal veins.
[0188] Pathological assessment of hepatic tissue samples is
generally performed after the results of one or more of the
aforementioned techniques indicate the likely presence of HCC.
Thus, methods of the invention may further include assessing a
hepatic tissue sample from an in vivo animal model (e.g., a db/db
mouse) useful in HCC studies in order to determine whether a
peptide sequence exhibits evidence of inducing HCC. By microscopic
assessment, a pathologist can determine whether one of the four
general architectural and cytological types (patterns) of HCC are
present (i.e., fibrolamellar, pseudoglandular (adenoid),
pleomorphic (giant cell) and clear cell).
[0189] The invention also includes the generation and use of
antibodies, and fragments thereof, that bind the peptide sequences
of the invention, including subsequences, sequence variants and
modified forms of the exemplified peptide sequences (including the
peptides listed in Table 1-9 and FIG. 1).
[0190] As used herein, the terms "antibodies" (Abs) and
"immunoglobulins" (Igs) refer to glycoproteins having the same
structural characteristics. While antibodies exhibit binding
specificity to an antigen, immunoglobulins include both antibodies
and other antibody-like molecules which may lack antigen
specificity.
[0191] The term "antibody" includes intact monoclonal antibodies,
polyclonal antibodies, multispecific antibodies (e.g., bispecific
antibodies) formed from at least two intact antibodies, and
antibody binding fragments including Fab and F(ab) .sub.2, provided
that they exhibit the desired biological activity. The basic
antibody structural unit comprises a tetramer, and each tetramer is
composed of two identical pairs of polypeptide chains, each pair
having one "light" chain (about 25 kDa) and one "heavy" chain
(about 50-70 kDa). The amino-terminal portion of each chain
includes a variable region of about 100 to 110 or more amino acids
primarily responsible for antigen recognition. In contrast, the
carboxy-terminal portion of each chain defines a constant region
primarily responsible for effector function. Human light chains are
classified as kappa and lambda light chains, whereas human heavy
chains are classified as mu, delta, gamma, alpha, or epsilon, and
define the antibody's isotype as IgM, IgD, IgA, and IgE,
respectively. Binding fragments are produced by recombinant DNA
techniques, or by enzymatic or chemical cleavage of intact
antibodies. Binding fragments include Fab, Fab', F(ab').sub.2, Fv,
and single-chain antibodies.
[0192] Each heavy chain has at one end a variable domain (VH)
followed by a number of constant domains. Each light chain has a
variable domain at one end (VL) and a constant domain at its other
end; the constant domain of the light chain is aligned with the
first constant domain of the heavy chain, and the light chain
variable domain is aligned with the variable domain of the heavy
chain. Within light and heavy chains, the variable and constant
regions are joined by a "J" region of about 12 or more amino acids,
with the heavy chain also including a "D" region of about 10 more
amino acids. The antibody chains all exhibit the same general
structure of relatively conserved framework regions (FR) joined by
three hyper-variable regions, also called
complementarity-determining regions or CDRs. The CDRs from the two
chains of each pair are aligned by the framework regions, enabling
binding to a specific epitope. From N-terminal to C-terminal, both
light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2,
FR3, CDR3 and FR4.
[0193] An intact antibody has two binding sites and, except in
bifunctional or bispecific antibodies, the two binding sites are
the same. A bispecific or bifunctional antibody is an artificial
hybrid antibody having two different heavy/light chain pairs and
two different binding sites. Bispecific antibodies can be produced
by a variety of methods including fusion of hybridomas or linking
of Fab' fragments.
[0194] As used herein, the term "monoclonal antibody" refers to an
antibody obtained from a population of substantially homogeneous
antibodies, that is, the individual antibodies comprising the
population are identical except for possible naturally occurring
mutations that may be present in minor amounts. Monoclonal
antibodies are highly specific, being directed against a single
antigenic site. In contrast to polyclonal antibody preparations
which include different antibodies directed against different
determinants (epitopes), each monoclonal antibody is directed
against a single determinant on the antigen.
[0195] A "neutralizing antibody" is an antibody molecule that is
able to eliminate or significantly reduce an effector function of a
target antigen to which it binds.
[0196] Antibody binding fragments may be produced by enzymatic or
chemical cleavage of intact antibodies. Digestion of antibodies
with the enzyme papain results in two identical antigen-binding
fragments, also known as "Fab" fragments, and an "Fc" fragment
which has no antigen-binding activity. Digestion of antibodies with
the enzyme pepsin results in a F(ab').sub.2 fragment in which the
two arms of the antibody molecule remain linked and comprise
two-antigen binding sites. The F(ab').sub.2 fragment has the
ability to crosslink antigen.
[0197] The term "Fab" refers to a fragment of an antibody that
comprises the constant domain of the light chain and the CH1 domain
of the heavy chain. The term "Fv" when used herein refers to the
minimum fragment of an antibody that retains both
antigen-recognition and antigen-binding sites. In a two-chain Fv
species, this region consists of a dimer of one heavy-chain and one
light-chain variable domain in non-covalent association. In a
single-chain Fv species, one heavy-chain and one light-chain
variable domain can be covalently linked by a flexible peptide
linker such that the light and heavy chains can associate in a
"dimeric" structure analogous to that in a two-chain Fv species. It
is in this configuration that the three CDRs of each variable
domain interact to define an antigen-binding site on the surface of
the VH-VL dimer. While the six CDRs, collectively, confer
antigen-binding specificity to the antibody, even a single variable
domain (or half of an Fv comprising only three CDRs specific for an
antigen) has the ability to recognize and bind antigen.
[0198] The term "complementarity determining regions" or "CDRs"
refers to parts of immunological receptors that make contact with a
specific ligand and determine its specificity. The term
"hypervariable region" refers to the amino acid residues of an
antibody which are responsible for antigen-binding. The
hypervariable region generally comprises amino acid residues from a
"complementarity determining region" or "CDR" and/or those residues
from a "hypervariable loop".
[0199] As used herein, the term "epitope" refers to binding sites
for antibodies on protein antigens. Epitopic determinants usually
consist of chemically active surface groupings of molecules such as
amino acids or sugar side chains, as well as specific three
dimensional structural and charge characteristics. An antibody is
said to bind an antigen when the dissociation constant is .ltoreq.1
.mu.M, preferably .ltoreq.100 nM, and most preferably .ltoreq.10
nM. An increased equilibrium constant ("K.sub.D") means that there
is less affinity between the epitope and the antibody, whereas a
decreased equilibrium constant means that there is a higher
affinity between the epitope and the antibody. An antibody with a
K.sub.D of "no more than" a certain amount means that the antibody
will bind to the epitope with the given K.sub.D or more strongly.
Whereas K.sub.D describes the binding characteristics of an epitope
and an antibody, "potency" describes the effectiveness of the
antibody itself for a function of the antibody. There is not
necessarily a correlation between an equilibrium constant and
potency; thus, for example, a relatively low K.sub.D does not
automatically mean a high potency.
[0200] The term "selectively binds" in reference to an antibody
does not mean that the antibody only binds to a single substance,
but rather that the K.sub.D of the antibody to a first substance is
less than the K.sub.D of the antibody to a second substance. An
antibody that exclusively binds to an epitope only binds to that
single epitope.
[0201] When administered to humans, antibodies that contain rodent
(murine or rat) variable and/or constant regions are sometimes
associated with, for example, rapid clearance from the body or the
generation of an immune response by the body against the antibody.
In order to avoid the utilization of rodent-derived antibodies,
fully human antibodies can be generated through the introduction of
human antibody function into a rodent so that the rodent produces
fully human antibodies. Unless specifically identified herein,
"human" and "fully human" antibodies can be used interchangeably
herein. The term "fully human" can be useful when distinguishing
antibodies that are only partially human from those that are
completely, or fully human. The skilled artisan is aware of various
methods of generating fully human antibodies.
[0202] In order to address possible human anti-mouse antibody
responses, chimeric or otherwise humanized antibodies can be
utilized. Chimeric antibodies have a human constant region and a
murine variable region, and, as such, human anti-chimeric antibody
responses may be observed in some patients. Therefore, it is
advantageous to provide fully human antibodies against multimeric
enzymes in order to avoid possible human anti-mouse antibody or
human anti-chimeric antibody responses.
[0203] Fully human monoclonal antibodies can be prepared, for
example, by the generation of hybridoma cell lines by techniques
known to the skilled artisan. Other preparation methods involve the
use of sequences encoding particular antibodies for transformation
of a suitable mammalian host cell, such as a CHO cell.
Transformation can be by any known method for introducing
polynucleotides into a host cell, including, for example, packaging
the polynucleotide in a virus (or into a viral vector) and
transducing a host cell with the virus (or vector) or by
transfection procedures known in the art. Methods for introducing
heterologous polynucleotides into mammalian cells are well known in
the art and include dextran-mediated transfection, calcium
phosphate precipitation, polybrene-mediated transfection,
protoplast fusion, electroporation, encapsulation of the
polynucleotide(s) in liposomes, and direct microinjection of the
DNA into nuclei. Mammalian cell lines available as hosts for
expression are well known in the art and include, but are not
limited to CHO cells, HeLa cells, and human hepatocellular
carcinoma cells.
[0204] Antibodies can be used diagnostically and/or
therapeutically. For example, the antibodies can be used as a
diagnostic by detecting the level of one or more peptides of the
invention in a subject, and either comparing the detected level to
standard control level or to a baseline level in a subject
determined previously (e.g., prior to any illness). The antibodies
can be used as a therapeutic to modulate the activity of one or
more peptides of the invention, thereby having an effect on a
condition or disorder.
[0205] The invention provides kits including, but not limited to,
peptide sequences of the invention, optionally in combination with
one or more therapeutic agents, compositions and pharmaceutical
compositions thereof, packaged into suitable packaging material. A
kit optionally includes a label or packaging insert including a
description of the components or instructions for use in vitro, in
vivo, or ex vivo, of the components therein. Exemplary instructions
include instructions for reducing or lowering blood glucose,
treatment of hyperglycemia, treatment of diabetes, etc.
[0206] A kit can contain a collection of such components, e.g., two
or more peptide sequences alone, or a combination of a peptide
sequence with another therapeutically useful composition (e.g., an
anti-diabetic drug, such as a gastrin compound).
[0207] The term "packaging material" refers to a physical structure
housing the components of the kit. The packaging material can
maintain the components sterilely, and can be made of material
commonly used for such purposes (e.g., paper, corrugated fiber,
glass, plastic, foil, ampules, vials, tubes, etc.).
[0208] Kits of the invention can include labels or inserts. Labels
or inserts include "printed matter," e.g., paper or cardboard,
separate or affixed to a component, a kit or packing material
(e.g., a box), or attached to, for example, an ampule, tube or vial
containing a kit component. Labels or inserts can additionally
include a computer readable medium, such as a disk (e.g., hard
disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM,
DVD, MP3, magnetic tape, or an electrical storage media such as RAM
and ROM or hybrids of these such as magnetic/optical storage media,
FLASH media or memory type cards.
[0209] Labels or inserts can include identifying information of one
or more components therein, dose amounts, clinical pharmacology of
the active ingredient(s) including mechanism of action,
pharmacokinetics and pharmacodynamics. Labels or inserts can
include information identifying manufacturer information, lot
numbers, manufacturer location and date.
[0210] Labels or inserts can include information on a condition,
disorder, disease or symptom for which a kit component may be used.
Labels or inserts can include instructions for the clinician or for
a subject for using one or more of the kit components in a method,
treatment protocol or therapeutic regimen. Instructions can include
dosage amounts, frequency or duration, and instructions for
practicing any of the methods, treatment protocols or therapeutic
regimes set forth herein. Exemplary instructions include
instructions for treatment or use of a peptide sequence as set
forth herein. Kits of the invention therefore can additionally
include labels or instructions for practicing any of the methods
and uses of the invention described herein including treatment
methods and uses.
[0211] Labels or inserts can include information on any benefit
that a component may provide, such as a prophylactic or therapeutic
benefit. Labels or inserts can include information on potential
adverse side effects, such as warnings to the subject or clinician
regarding situations where it would not be appropriate to use a
particular composition. Adverse side effects could also occur when
the subject has, will be or is currently taking one or more other
medications that may be incompatible with the composition, or the
subject has, will be or is currently undergoing another treatment
protocol or therapeutic regimen which would be incompatible with
the composition and, therefore, instructions could include
information regarding such incompatibilities.
[0212] Invention kits can additionally include other components.
Each component of the kit can be enclosed within an individual
container and all of the various containers can be within a single
package. Invention kits can be designed for cold storage. Invention
kits can further be designed to contain peptide sequences of the
invention, or that contain nucleic acids encoding peptide
sequences. The cells in the kit can be maintained under appropriate
storage conditions until ready to use.
[0213] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the invention,
suitable methods and materials are described herein.
[0214] All applications, publications, patents and other
references, GenBank citations and ATCC citations cited herein are
incorporated by reference in their entirety. In case of conflict,
the specification, including definitions, will control. As used
herein, the singular forms "a", "and," and "the" include plural
referents unless the context clearly indicates otherwise. Thus, for
example, reference to "a peptide sequence" or a "treatment,"
includes a plurality of such sequences, treatments, and so
forth.
[0215] As used herein, numerical values are often presented in a
range format throughout this document. The use of a range format is
merely for convenience and brevity and should not be construed as
an inflexible limitation on the scope of the invention unless the
context clearly indicates otherwise. Accordingly, the use of a
range expressly includes all possible subranges, all individual
numerical values within that range, and all numerical values or
numerical ranges including integers within such ranges and
fractions of the values or the integers within ranges unless the
context clearly indicates otherwise. This construction applies
regardless of the breadth of the range and in all contexts
throughout this patent document. Thus, for example, reference to a
range of 90-100% includes 91-99%, 92-98%, 93-95%, 91-98%, 91-97%,
91-96%, 91-95%, 91-94%, 91-93%, and so forth. Reference to a range
of 90-100% also includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc.,
as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%,
92.3%, 92.4%, 92.5%, etc., and so forth.
[0216] In addition, reference to a range of 1-3, 3-5, 5-10, 10-20,
20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110,
110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180,
180-190, 190-200, 200-225, 225-250 includes 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. In a further
example, reference to a range of 25-250, 250-500, 500-1000,
1000-2500 or 2500-5000, 5000-25,000, 5000-50,000 includes any
numerical value or range within or encompassing such values, e.g.,
25, 26, 27, 28, 29 . . . 250, 251, 252, 253, 254 . . . 500, 501,
502, 503, 504 . . . , etc.
[0217] As also used herein a series of ranges are disclosed
throughout this document. The use of a series of ranges include
combinations of the upper and lower ranges to provide another
range. This construction applies regardless of the breadth of the
range and in all contexts throughout this patent document. Thus,
for example, reference to a series of ranges such as 5-10, 10-20,
20-30, 30-40, 40-50, 50-75, 75-100, 100-150, includes ranges such
as 5-20, 5-30, 5-40, 5-50, 5-75, 5-100, 5-150, and 10-30, 10-40,
10-50, 10-75, 10-100, 10-150, and 20-40, 20-50, 20-75, 20-100,
20-150, and so forth.
[0218] For the sake of conciseness, certain abbreviations are used
herein. One example is the single letter abbreviation to represent
amino acid residues. The amino acids and their corresponding three
letter and single letter abbreviations are as follows:
TABLE-US-00002 alanine Ala (A) arginine Arg (R) asparagine Asn (N)
aspartic acid Asp (D) cysteine Cys (C) glutamic acid Glu (E)
glutamine Gln (Q) glycine Gly (G) histidine His (H) isoleucine Ile
(I) leucine Leu (L) lysine Lys (K) methionine Met (M) phenylalanine
Phe (F) proline Pro (P) serine Ser (S) threonine Thr (T) tryptophan
Trp (W) tyrosine Tyr (Y) valine Val (V)
[0219] The invention is generally disclosed herein using
affirmative language to describe the numerous embodiments. The
invention also specifically includes embodiments in which
particular subject matter is excluded, in full or in part, such as
substances or materials, method steps and conditions, protocols,
procedures, assays or analysis. Thus, even though the invention is
generally not expressed herein in terms of what the invention does
not include, aspects that are not expressly included in the
invention are nevertheless disclosed herein.
[0220] A number of embodiments of the invention have been
described. Nevertheless, it will be understood that various
modifications may be made without departing from the spirit and
scope of the invention. Accordingly, the following examples are
intended to illustrate but not limit the scope of invention
described in the claims.
EXAMPLES
Example 1
[0221] The following is a description of various methods and
materials used in the studies herein.
[0222] Animals. db/db mice were purchased from The Jackson
Laboratory (Bar Harbor, Me.), Mice were kept in accordance with
welfare guidelines under controlled light (12 hr light and 12 hr
dark cycle, dark 6:30 pm-6:30 am), temperature (22.+-.4.degree. C.)
and humidity (50%.+-.20%) conditions. They had free access to water
(autoclaved distilled water) and were fed ad libitum on a
commercial diet (Harlan Laboratories, Indianapolis, Ind.,
Irradiated 2018 Teklad Global 18% Protein Rodent Diet) containing
17 kcal % fat, 23 kcal % protein and 60 kcal % carbohydrate. For
diet-induced obesity, C57BL6/J mice (Jackson Laboratory) were
maintained on a high-fat diet (D12492, Research Diet, New
Brunswick, N.J. USA) containing 60 kcal % fat, 20 kcal % protein
and 20 kcal % carbohydrate for 16-20 weeks. All animal studies were
approved by the NGM Institutional Animal Care and Use
Committee.
[0223] DNA and amino acid sequences. cDNA of ORF encoding human
FGF19 (Homo sapiens FGF19, GenBank Accession No. NM_005117.2)
variants. Protein sequence encoded by the cDNA (GenBank Accession
No. NP_005108.1)
PCR. FGF19 ORF was amplified with polymerase chain reaction (PCR)
using recombinant DNA (cDNA) prepared from human small intestinal
tissue. PCR reagents kits with Phusion high-fidelity DNA polymerase
were purchased from New England BioLabs (F-530L, Ipswich, Mass.).
The following primers were used:
TABLE-US-00003 forward PCR primer: (SEQ ID NO: 136) 5'
CCGACTAGTCACCatgcggagcgggtgtgtgg and reverse PCR primer: (SEQ ID
NO: 137) 5' ATAAGAATGCGGCCGCTTACTTCTCAAAGCTGGGACTCCTC.
Amplified DNA fragment was digested with restriction enzymes Spe I
and Not I (the restriction sites were included in the 5' or 3' PCR
primers, respectively) and was then ligated with AAV transgene
vectors that had been digested with the same restriction enzymes.
The vector used for expression contained a selectable marker and an
expression cassette composed of a strong eukaryotic promoter 5' of
a site for insertion of the cloned coding sequence, followed by a
3' untranslated region and bovine growth hormone polyadenylation
tail. The expression construct is also flanked by internal terminal
repeats at the 5' and 3' ends.
[0224] Production and purification of AAV. AAV293 cells (obtained
from Agilent Technologies, Santa Clara, Calif.) were cultured in
Dulbeco's Modification of Eagle's Medium (DMEM, Mediatech, Inc.
Manassas, Va.) supplemented with 10% fetal bovine serum and
1.times. antibiotic-antimycotic solution (Mediatech, Inc. Manassas,
Va.). The cells were plated at 50% density on day 1 in 150 mm cell
culture plates and transfected on day 2, using calcium phosphate
precipitation method with the following 3 plasmids (20 .mu.g/plate
of each): AAV transgene plasmid, pHelper plasmids (Agilent
Technologies) and AAV2/9 plasmid (Gao et al., J. Virol. 78:6381
(2004)). 48 hours after transfection, the cells were scraped off
the plates, pelleted by centrifugation at 3000.times.g and
resuspended in buffer containing 20 mM Tris pH 8.5, 100 mM NaCl and
1 mM MgCl.sub.2. The suspension was frozen in an alcohol dry ice
bath and was then thawed in 37.degree. C. water bath. The freeze
and thaw cycles were repeated three times; Benzonase.RTM.
(Sigma-aldrich, St. Louis, Mo.) was added to 50 units/ml;
deoxycholate was added to a final concentration of 0.25%. After an
incubation at 37.degree. C. for 30 min, cell debris was pelleted by
centrifugation at 5000.times.g for 20 min. Viral particles in the
supernatant were purified using a discontinued iodixanal
(Sigma-aldrich, St. Louis, Mo.) gradient as previously described
(Zolotukhin S. et al (1999) Gene Ther. 6:973). The viral stock was
concentrated using Vivaspin Benzonase.RTM. 20 (MW cutoff 100,000
Dalton, Sartorius Stedim Biotech, Aubagne, France) and re-suspended
in phosphate-buffered saline (PBS) with 10% glycerol and stored at
-80.degree. C. To determine the viral genome copy number, 2 .mu.l
of viral stock were incubated in 6 .mu.l of solution containing 50
units/ml Benzonase.RTM., 50 mM Tris-HCl pH 7.5, 10 mM MgCl.sub.2
and 10 mM CaCl.sub.2 at 37.degree. C. for 30 minutes.
[0225] Afterwards, 15 .mu.l of the solution containing 2 mg/ml of
Proteinase K, 0.5% SDS and 25 mM EDTA were added and the mixture
was incubated for additional 20 min at 55.degree. C. to release
viral DNA. Viral DNA was cleaned with mini DNeasy.RTM. Kit (Qiagen,
Valencia, Calif.) and eluted with 40 .mu.l of water. Viral genome
copy (GC) was determined by using quantitative PCR.
[0226] Viral stock was diluted with PBS to desirable GC/ml. Viral
working solution (200 .mu.l) was delivered into mice via tail vein
injection.
[0227] Blood glucose assay. Blood glucose in mouse tail snip was
measured using ACCU-CHEK Active test strips read by ACCU-CHEK
Active meter (Roche Diagnostics, Indianapolis, Ind.) following
manufacturer's instruction.
[0228] Lipid profile assay. Whole blood from mouse tail snips was
collected into plain capillary tubes (BD Clay Adams SurePrep.TM.,
Becton Dickenson and Co. Sparks, Md.). Serum and blood cells were
separated by spinning the tubes in an Autocrit.TM. Ultra 3 (Becton
Dickinson and Co. Sparks, Md.). Serum samples were assayed for
lipid profile (triglyceride, total cholesterol, HDL, and non-HDL)
using Integra.TM. 400 Clinical Analyzer (Roche Diagnostics,
Indianapolis, Ind.) following the manufacturer's instructions.
[0229] Serum FGF19/FGF21/variants exposure level assay. Whole blood
(about 50 IA/mouse) from mouse tail snips was collected into plain
capillary tubes (BD Clay Adams SurePrep, Becton Dickenson and Co.
Sparks, Md.). Serum and blood cells were separated by spinning the
tubes in an Autocrit.TM. Ultra 3 (Becton Dickinson and Co. Sparks,
Md.). FGF19, FGF21, and variant exposure levels in serum were
determined using EIA kits (Biovendor) by following the
manufacturer's instructions.
[0230] Hepatocellular carcinoma (HCC) assay. Liver specimen was
harvested from db/db mice 6 months after AAV injection. HCC score
is recorded as the number of HCC nodules on the surface of the
entire liver from variants-injected mice divided by the number of
HCC nodules from wild type FGF19-injected mice.
[0231] Liver gene expression assay. Liver specimen was harvested
and homogenized in TRIzol.RTM. reagent (Invitrogen). Total RNA was
extracted following manufacturer's instruction. RNA was treated
with DNase (Ambion) followed by quantitative RT-PCR analysis using
TaqMane primers and reagents from Applied Biosystems. Relative mRNA
levels of aldo-keto reductase and slc1a2 in the liver was
calculated using .DELTA..DELTA.Ct method.
[0232] FGFR4 binding and activity assays. Solid phase ELISA
(binding) and ERK phosphorylation assay can be performed using
purified recombinant proteins. FGFR binding assay can be conducted
using solid phase ELISA. Briefly, a 96-well plate can be coated
with 2 .mu.g/ml anti-hFc antibody and can be incubated with 1
.mu.g/ml FGFR1-hFc or FGFR4-hFc. Binding to FGF19 variants in the
presence of 1 .mu.g/ml soluble .beta.-klotho and 20 .mu.g/ml
heparin can be detected by biotinylated anti-FGF19 antibodies (0.2
.mu.g/mL), followed by streptavidin-HRP incubation (100 ng/mL). For
FGFR4 activation assay, Hep3B cells can be stimulated with FGF19
variants for 10 minutes at 37.degree. C., then can be immediately
lysed and assayed for ERK phosphorylation using a commercially
available kit from Cis-Bio.
Example 2
[0233] The following is a description of studies showing the
glucose lowering activity of various sequence variants of FGF19 and
FGF21, and FGF19/FGF21 fusion constructs.
[0234] FIG. 2 illustrates exemplary FGF19/FGF21 fusion constructs,
and the segments from each of FGF19 and FGF21 present in the fusion
peptides. These peptides were analyzed for glucose lowering
activity and statistically significant lipid elevating or
increasing activity (Table 1-9 and FIG. 1).
[0235] Mice (db/db) were injected with viral vector expressing
FGF19, FGF21 or variants, and analyzed after injection.
Glucose-lowering activity of each sequence is represented by a "+"
symbol (a "-" symbol means no glucose lowering activity, a "+/-"
symbol means variants retain minimal glucose-lowering activity);
lipid elevating activity is represented by a "+" symbol (a "-"
symbol means no lipid elevating activity, a "+/-" symbol means
variants retain minimal lipid-elevating activity, FIG. 2).
[0236] Two fusions of FGF21 and FGF19, denoted variant M5 and
variant 45 (M45), exhibited glucose lowering activity and an
absence of statistically significant lipid elevating or increasing
activity. Variants denoted M1, M2 and M69, respectively (FIG. 1,
also exhibited glucose lowering activity (FIGS. 3B and 3C, Table
5). Data comparing M5, M1, M2 and M69 glucose lowering activity and
lipid elevating or increasing activity to FGF19 and FGF21 are
illustrated in FIGS. 3A-3C and 4A-4C.
Example 3
[0237] The following is a description of studies showing that
variants M5, M1, M2 and M69 are not tumorigenic, as determined by
HCC formation, and that variants M5, M2 and M69 also do not reduce
lean muscle and fat mass.
[0238] Animals (db/db) were injected with AAV vectors expressing
FGF19, FGF21, M5, M1, M2, or M69, or injected with saline, and
analyzed 6 months after injection. The data indicate that variants
M5, M1, M2, and M69 did not induce (HCC) formation significantly
(FIGS. 5A-5C).
[0239] Animals (db/db mice) were also injected with viral vector
expressing FGF19, FGF21, M5, M1, M2 or M69, or injected with
saline, and analyzed 6 months after injection for the effect of on
lean mass and fat mass. The data indicate that M5, M2 and M69
peptides did not cause a statistically significant reduction in
lean mass or fat mass, in contrast to FGF21, and that M1 peptide
reduces lean mass (FIGS. 6A-6C).
Example 4
[0240] The following is a data summary of 25 additional variant
peptides analyzed for lipid elevating activity and tumorigenesis.
The data clearly show a positive correlation between lipid
elevation and tumorigenesis, as determined by HCC formation in
db/db mice.
[0241] Tables 1 to 3 summarize data for 26 different variant
peptides. Such exemplified variant peptides have FGF19 C-terminal
sequence:
PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGL
LQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:188) at the
C-terminal portion, e.g., following the "TSG" amino acid residues.
Notably, variant peptides (7 total, including M5) that did not
cause a statistically significant elevation of lipids did not
induce HCC formation. In contrast, all variant peptides (17 total)
that caused a statistically significant elevation of lipids also
caused HCC formation in mice. This data indicates that there is a
strong positive correlation between lipid elevating activity and
HCC formation. Accordingly, lipid elevating activity can be used as
an indicator and/or predictor of HCC formation in animals.
TABLE-US-00004 TABLE 1 Elevated Triglyceride and Cholesterol in
db/db Mice Appears to Positively Correlate With HCC Formation (see
SEQ ID NOs:99, 5 and 74 to 81). ##STR00001## SEQ ID NO. Core SEQ ID
NO. Lipid Eleva- tion HCC Forma- tion FGF19 RPLAFSDAGPHVHYGWGDPI 99
(aa 1-20) RLRHLYTSG 185 + + FGF21 HPIPDSSPLLQ--FGGQV 100 (aa 1-16)
RQRYLYTDD 186 - - M5 R-HPIPDSSPLLQ--FGGQV 5 (aa 1-17) RLRHLYTSG 185
- - M74 R-----------DAGPHVHYGWGDPI 74 (aa 1-15) RLRHLYTSG 185 + +
M75 R----------------VHYGWGDPI 75 (aa 1-10) RLRHLYTSG 185 - - M76
R---------------------GDPI 76 (aa 1-5) RLRHLYTSG 185 - - M77
R------------------------- 77 (aa 1) RLRHLYTSG 185 - - M78
R------------AGPHVHYGWGDPI 78 (aa 1-14) RLRHLYTSG 185 + + M79
R-------------GPHVHYGWGDPI 79 (aa 1-13) RLRHLYTSG 185 + + M80
R--------------PHVHYGWGDPI 80 (aa 1-12) RLRHLYTSG 185 - - M81
R---------------HVHYGWGDPI 81 (aa 1-11) RLRHLYTSG 185 - -
TABLE-US-00005 TABLE 2 Elevated Triglyceride and Cholesterol in
db/db Mice Appears to Positively Correlate with HCC Formation (see
SEQ ID NOs: 99, 100 and 82 to 98). ##STR00002## SEQ ID NO. Core SEQ
ID NO. Lipid Eleva- tion HCC Forma- tion FGF19 RPLAFSDAGPHVHYGWGDPI
99 (aa 1-20) RLRHLYTSG 185 + + FGF21 HPIPDSSPLLQ--FGGQV 100 (aa
1-16) RQRYLYTDD 186 - - M82 RPLAFSAAGPHVHYGWGDPI 82 (aa 1-20)
RLRHLYTSG 185 + + M83 RPLAFSDAAPHVHYGWGDPI 83 (aa 1-20) RLRHLYTSG
185 +/- +/ M84 RPLAFSDAGAHVHYGWGDPI 84 (aa 1-20) RLRHLYTSG 185 +/-
+/ M85 RPLAFSDAGPHVHYGAGDPI 85 (aa 1-20) RLRHLYTSG 185 - - M86
RPLAFSDAGPHVHYGWGAPI 86 (aa 1-20) RLRHLYTSG 185 + + M87
RPLAFSDAGPHVHYGWGDAI 87 (aa 1-20) RLRHLYTSG 185 + +
TABLE-US-00006 TABLE 3 Elevated Triglyceride and Cholesterol in
db/db Mice Appears to Positively Correlate with HCC Formation (see
SEQ ID NOs: 99, 100 and 88 to 98) ##STR00003## Core SEQ ID NO Lipid
Elevation HCC Formation FGF19 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG 99 (aa
1-29) + + FGF21 HPIPDSSPLLQ--FGGQV RQRYLYTDD 100 (aa 1-25) - -
H31A/S141A(M88) FGF19 + + H31A/H142A(M89) FGF19 + +
K127A/R129A(M90) FGF19 + + K127A/S141A(M91) FGF19 + +
K127A/H142A(M92) FGF19 + + R129A/S141A(M93) FGF19 + +
S141A/H142A(M94) FGF19 + + K127A/H142A(M95) FGF19 + +
K127A/R129A/S141A(M96) FGF19 + + K127A/R129A/H142A(M97) FGF19 + +
K127A/R129A/S141A/H142A(M98) FGF19 + +
TABLE-US-00007 M88 (H31A/S141A): (SEQ ID NO: 88)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPAGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLAHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M89 (H31A/H142A): (SEQ ID
NO: 89) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPAGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M90 (K127A/R129A): (SEQ
ID NO: 90) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M91 (K127A/S141A): (SEQ
ID NO: 91) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGFLPLAHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M92 (K127A/H142A): (SEQ
ID NO: 92) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGELPLSAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M93 (R129A/S141A): (SEQ
ID NO: 93) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQAQLYKNRGFLPLAHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M94 (S141A/H142A): (SEQ
ID NO: 94) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLAAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M95 (K127A/H142A): (SEQ
ID NO: 95) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGFLPLSAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M96 (K127A/R129A/S141A):
(SEQ ID NO: 96) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLAHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M97 (K127A/R129A/H142A):
(SEQ ID NO: 97) RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLSAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M98
(K127A/R129A/S141A/H142A): (SEQ ID NO: 98)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLAAFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
Example 5
[0242] The following is a data summary of additional FGF19 variant
peptides analyzed for glucose lowering activity and lipid elevating
activity.
[0243] Table 4 illustrates the peptide "core sequences" of 35
additional FGF19 variants, denoted M5 to M40. Such exemplified
variant peptides have FGF19 C-terminal sequence,
PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGL
LQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO: 188) at the
C-terminal portion, e.g., following the "TSG" amino acid residues
of the core sequence. The data clearly show that variants M6, M7,
M8, mM38 and M39 have the desired characteristics of glucose
lowering activity and not statistically significant lipid elevating
activity in db/db mice.
TABLE-US-00008 TABLE 4 Additional Variants and Fine Mapping of the
N-terminal Domain (see SEQ ID NOs: 99, 100, and 5 to 40) SEQ ID NO
of N-term- SEQ ID Glucose Lipid N-terminal Domain Domain Core NO.
Lowering Elevation FGF19 RPLAFSDAGPHVHYGWGDPI 99 (aa 1-20)
RLRHLYTSG 185 + + FGF21 -HPIPDSSPLLQ--FGGQV 100 (aa 1-16) RQRYLYTDD
186 + - M5 RHPIPDSSPLLQ--FGGQV 5 (aa 1-17) RLRHLYTSG 185 + - M6
R----DSSPLLQ--FGGQV 6 (aa 1-18) RLRHLYTSG 185 + - M7
RPLAFSDSSPLLQ--FGGQV 7 (aa 1-18) RLRHLYTSG 185 + - M8
R-HPIPDSSPLLQ--WGDPI 8 (aa 1-17) RLRHLYTSG 185 + - M9
R-HPIPDSSPLLQFGWGDPI 9 (aa 1-19) RLRHLYTSG 185 + + M10
R-HPIPDSSPHVHYGWGDPI 10 (aa 1-19) RLRHLYTSG 185 - + M11
RPLAFSDAGPLLQ--WGDPI 11 (aa 1-18) RLRHLYTSG 185 N/D N/D M12
RPLAFSDAGPLLQFGWGDPI 12 (aa 1-20) RLRHLYTSG 185 - + M13
RPLAFSDAGPLLQ--FGGQV 13 (aa 1-18) RLRHLYTSG 185 - - M14
R-HPIPDSSPHVHYG--GQV 14 (aa 1-17) RLRHLYTSG 185 - - M15
RPLAFSDAGPHVHYG--GQV 15 (aa 1-18) RLRHLYTSG 185 + + M16
RPLAFSDAGPHVH--WGDPI 16 (aa 1-18) RLRHLYTSG 185 N/D N/D M17
RPLAFSDAGPHV--GWGDPI 17 (aa 1-18) RLRHLYTSG 185 N/D N/D M18
RPLAFSDAGPH--YGWGDPI 18 (aa 1-18) RLRHLYTSG 185 N/D N/D M19
RPLAFSDAGP-V-YGWGDPI 19 (aa 1-18) RLRHLYTSG 185 N/D N/D M20
RPLAFSDAGP-VH-GWGDPI 20 (aa 1-18) RLRHLYTSG 185 N/D N/D M21
RPLAFSDAGP-VHY-WGDPI 21 (aa 1-18) RLRHLYTSG 185 N/D N/D M22
RPLAFSDAGPHVH-GWGDPI 22 (aa 1-18) RLRHLYTSG 185 N/D N/D M23
RPLAFSDAGPH-H-GWGDPI 23 (aa 1-18) RLRHLYTSG 185 N/D N/D M24
RPLAFSDAGPH-HY-WGDPI 24 (aa 1-18) RLRHLYTSG 185 N/D N/D M25
RPLAFSDAGPHV-Y-WGDPI 25 (aa 1-18) RLRHLYTSG 185 N/D N/D M26
RPLAFSDSSPLVH--WGDPI 26 (aa 1-18) RLRHLYTSG 185 N/D N/D M27
RPLAFSDSSPHVH--WGDPI 27 (aa 1-18) RLRHLYTSG 185 N/D N/D M28
RPLAFSDAPHV----WGDPI 28 (aa 1-16) RLRHLYTSG 185 N/D N/D M29
RPLAFSDAGPHVHY-WGDPI 29 (aa 1-19) RLRHLYTSG 185 N/D N/D M30
RPLAFSDAGPHVHYAWGDPI 30 (aa 1-20) RLRHLYTSG 185 N/D N/D M31
R-HPIPDSSPLLQ--FGAQV 31 (aa 1-17) RLRHLYTSG 185 +/- - M32
R-HPIPDSSPLLQ--FGIYQV 32 (aa 1-18) RLRHLYTSG 185 - - M33
R-HPIPDSSPLLQ--FGGQV 33 (aa 1-17) RLRHLYTSG 185 - - M34
R-HPIPDSSPLLQ--FGGAV 34 (aa 1-17) RLRHLYTSG 185 +/- - M35
R-HPIPDSSPLLQ--FGGEV 35 (aa 1-17) RLRHLYTSG 185 +/- +/ M36
R-HPIPDSSPLLQ--FGGQV 36 (aa 1-17) RLRHLYTSG 185 +/- - M37
R-HPIPDSSPLLQ--FGGUA 37 (aa 1-17) RLRHLYTSG 185 - - M38
R-HPIPDSSPLLQ--FGGQT 38 (aa 1-17) RLRHLYTSG 185 + - M39
R-HPIPDSSPLLQ--FGGQT 39 (aa 1-17) RLRHLYTSG 185 + - M40
R-HPIPDSSPLLQFGWGQP 40 (aa 1-16) RLRHLYTSG 185 - +
TABLE-US-00009 TABLE 4a (see SEQ ID NOs: 99, 100, 5, 9, 8, 12, 10,
13, 15, 14, 43, 6 and 7) ##STR00004## Core SEQ ID NO. Glucose
Lowering Lipid Elevation HCC Formation FGF19 RPLAFSDAGPHVHYGWGDPI
RLRHLYTSG 99 (aa 1-29) + + + FGF21 HPIPDSSPLLQ--FGGQV RQRYLYTDD 100
(aa 1-25) + - - M5 R-HPIPDSSPLLQ--FGGQV RLRHLYTSG 5 (aa 1-26) + - -
M9 R-HPIPDSSPLLQFGWGDPI RLRHLYTSG 9 (aa 1-28) + + + M8
R-HPIPDSSPLLQ--WGDPI RLRHLYTSG 8 (aa 1-26) + + + M12
RPLAFSDAGPLLQFGWGDPI RLRHLYTSG 12 (aa 1-29) - + + M10
R-HPIPDSSPHVHYGWGDPI RLRHLYTSG 10 (aa 1-28) - + + M13
RPLAFSDAGPLLQ--FGGQV RLRHLYTSG 13 (aa 1-27) - + + M15
RPLAFSDAGPHVHYG--GQV RLRHLYTSG 15 (aa 1-27) - - +/- M14
R-HPIPDSSPHVHYG--GQV RLRHLYTSG 14 (aa 1-26) - - +/- M43
RPLAFSDAGPHVHYG-GD-I RLRHLYTSG 43 (aa 1-27) + - +/- M6
R-----DSSPLLQ--FGGQV RLRHLYTSG 6 (aa 1-22) + - - M7
RPLAFSDSSPLLQ--FGGQV RLRHLYTSG 7 (aa 1-27) - - -
TABLE-US-00010 TABLE 4b (see SEQ ID NOs: 99, 5 and 31 to 40)
##STR00005## Core SEQ ID NO Glucose Lowering Lipid Elevation HCC
Formation FGF19 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG 99 (aa 1-29) + + +
FGF21 HPIPDSSPLLQ--FGGQV RQRYLYTDD 100 (aa 1-25) + - - M5
R-HPIPDSSPLLQ--FGGQV RLRHLYTSG 5 (aa 1-26) + - - M31
R-HPIPDSSPLLQ--FGAQV RLRHLYTSG 31 (aa 1-26) + - + M32
R-HPIPDSSPLLQ--FGDQV RLRHLYTSG 32 (aa 1-26) + - - M33
R-HPIPDSSPLLQ--FGPQV RLRHLYTSG 33 (aa 1-26) - - + M34
R-HPIPDSSPLLQ--FGGAV RLRHLYTSG 34 (aa 1-26) - - + M35
R-HPIPDSSPLLQ--FGGEV RLRHLYTSG 35 (aa 1-26) - - + M36
R-HPIPDSSPLLQ--FGGNV RLRHLYTSG 36 (aa 1-26) + - +/- M37
R-HPIPDSSPLLQ--FGGQA RLRHLYTSG 37 (aa 1-26) - - + M38
R-HPIPDSSPLLQ--FGGQI RLRHLYTSG 38 (aa 1-26) - - + M39
R-HPIPDSSPLLQ--FGGQT RLRHLYTSG 39 (aa 1-26) - - + M40
R-HPIPDSSPLLQFGWGQPV RLRHLYTSG 40 (aa 1-28) - + +
TABLE-US-00011 TABLE 4c (see SEQ ID NOs: 99, 100, 5, 52, 54, to 68,
4, 69, 70 and 53) ##STR00006## Core SEQ ID NO. Glucose Lowering
Lipid Elevation HCC Formation FGF19 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG
99 (aa 1-29) + + + FGF21 HPIPDSSPLLQ--FGGQV RQRYLYTDD 100 (aa 1-25)
+ - - M5 R-HPIPDSSPLLQ--FGGQV RLRHLYTSG 5 (aa 1-26) + - - M52
R-----DSSPLLQ--WGDPI RLRHLYTSG 52 (aa 1-22) + + - M54
RPLAFSDAGPLLQ--WGDPI RLRHLYTSG 54 (aa 1-27) - + + M55
RPLAFSDAGPH--YGWGDPI RLRHLYTSG 55 (aa 1-27) - + + M56
RPLAFSDAGP-V-YGWGDPI RLRHLYTSG 56 (aa 1-27) - + + M57
RPLAFSDAGP-VT-GWGDPI RLRHLYTSG 57 (aa 1-27) - + + M58
RPLAFSDAGP-VHY-WGDPI RLRHLYTSG 58 (aa 1-27) - + + M59
RPLAFSDAGPH-H-GWGDPI RLRHLYTSG 59 (aa 1-27) - + + M60
RPLAFSDAGPH-HY-WGDPI RLRHLYTSG 60 (aa 1-27) - + + M61
RPLAFSDAGPHV--GWGDPI RLRHLYTSG 61 (aa 1-27) - + + M62
RPLAFSDAGPHV-Y-WGDPI RLRHLYTSG 62 (aa 1-27) - + + M63
RPLAFSDAGPHVH--WGDPI RLRHLYTSG 63 (aa 1-27) + + + M64
RPLAFSDSSPLVH--WGDPI RLRHLYTSG 64 (aa 1-27) + + + M65
RPLAFSDSSPHVH--WGDPI RLRHLYTSG 65 (aa 1-27) - + + M66
RPLAFSDAGPHLQ--WGDPI RLRHLYTSG 66 (aa 1-27) + + + M67
RPLAFSDAGPHV---WGDPI RLRHLYTSG 67 (aa 1-26) - - +/- M68
RPLAFSDAGPHVHY-WGDPI RLRHLYTSG 68 (aa 1-28) - + - M4
RPLAFSDAGPHVHYAWGDPI RLRHLYTSG 4 (aa 1-29) + + + M69
R-----DSSPLVHYGWGDPI RLRHLYTSG 69 (aa 1-24) + + - M70
MR----DSSPLVHYGWGDPI RLRHLYTSG 70 (aa 1-25) + + - M53
M-----DSSPLLQ--WGDPI RLRHLYTSG 192 (aa 1-22) + + -
[0244] Table 5 illustrates the peptide sequences of 3 FGF19
variants, denoted M1, M2 and M69. The data clearly show that these
three variants have the desired characteristics of glucose lowering
activity in db/db mice. These three variants appear to elevate
lipids in db/db mice.
TABLE-US-00012 TABLE 5 Additional Variants (SEQ ID NOs: 1, 2 and
69) M1: RPLAFSDASPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO: 1 or 139) M2:
RPLAFSDSSPLVHYGWGDPIRLRHYLTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO: 2 or 140)
M69: RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHS
LLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPD
GYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLR
GHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO: 69)
Example 6
[0245] The following is a data summary showing that FGF19 reduces
body weight in diet-induced obese mice and in ob/ob mice, and liver
tumor formation activity and body weight in db/db mice.
[0246] Mice were injected with FGF19 or FGF21 in AAV vector. Body
weight was recorded 4 weeks after injection.
TABLE-US-00013 TABLE 6 FGF19 reduces body weight in diet-induced
obese mice and in ob/ob mice (sequences correspond to aa 1-29 of
SEQ ID NO: 99 and aa 1-25 of SEQ ID NO: 100, respectively)
##STR00007## Core Body weight - Lowering in DIO Body Weight -
Lowering in Ob/ob FGF19 RPLAFSDAGTHWYGWGDPI RLRHLYTSG + + FGF21
HPIPDSSPLLQ--FGGQV PQRYZYTDD + +
TABLE-US-00014 TABLE 7 Correlation of body weight and liver tumor
formation of FGF19, FGF21 and selected variants in db/db mice (see,
e.g., SEQ ID NOs: 99, 100, 5, 6, 32, 52 and 69) ##STR00008## core
SEQ ID NO Liver Tumor Nodule Body Weight FGF19 RPLAFSDAGPHVHYGWGDPI
RLRHLYTSG 99 (aa 1-29) + Increased FGF21 HPIPDSSPLLQ--FGGQV
RQRYLYTDD 100 (aa 1-25) - Decreased M5 R-HPIPDSSPLLQ--FGGQV
RLRHLYTSG 5 (aa 1-26) - Increased M6 R-----DSSPLLQ--FGGQV RLRHLYTSG
6 (aa 1-22) - Decreased M32 R-HPIPDSSPLLQ--FGDQV RLRHLYTSG 32 (aa
1-26) - Decreased M52 R-----DSSPLLQ--WGDPI RLRHLYTSG 52 (aa 1-22) -
Decreased M69 R-----DSSPLVHYGWGDPI RLRHLYTSG 69 (aa 1-24) -
Increased
Example 7
[0247] The following is a study showing that variant M5 and variant
M69 peptides reduce blood glucose.
[0248] Mice (ob/ob) were injected (subcutaneously) with M5 (0.1 and
1 mg/kg, s.c.) or FGF19 (1 mg/kg, s.c.), or variant M69 (0.1 and 1
mg/kg, s.c.) or FGF19 (1 mg/kg, s.c.). Plasma glucose levels were
measured at 2, 4, 7, and 24 hours after injection, and the results
are shown in FIG. 7. M5 (FIG. 7A) and variant M69 (FIG. 7B) showed
similar glucose lowering effects as wild type FGF19.
Example 8
[0249] This example sets forth several variant polypeptides and
particular characteristics thereof, including the variants' effect
on glucose lowering, lipid profile parameters, and HCC
formation.
[0250] In particular, Table 8 compares data generated for variants
M5 (SEQ ID NO:5), M6 (SEQ ID NO:6) and M50 (SEQ ID NO:50) with data
generated for corresponding variant polypeptides (denoted as M144,
M145, and M146, respectively) having N-terminal Arg (R) deletions.
Only certain sequence domains for each variant are listed:
N-terminal domain, Core, and Sheet-8/Loop-8/Sheet-9 region.
TABLE-US-00015 TABLE 8 ##STR00009## Core Sheet- 8/Loop8/Sheet-9
region Glu- cose Lower- ing Body Weight Re- duct- ion HDL Ele- va-
tion Tri- gly- cer- ide Ele- va- tion HCC Form- ation FGF19
RPLAFSDAGPHVHYGWGDPI RLRHLYTSG //EEIRPDGYNVY// + - + + + (aa 1-20
of SEQ ID (aa 21-29 of (aa 102-112 of SEQ NO: 99) SEQ ID NO: 99) ID
NO: 99) FGF21 HPIPDSSPLLQ--FGGQV RQRYLYTDD //ELLLEDGYNVY// + + - -
- (aa 1-20 of SEQ ID (aa 21-29 of (aa 97-107 of SEQ NO: 100) SEQ ID
NO: 100) ID NO: 100) M5 R-HPIPDSSPLLQ--FGGQV RLRHLYTSG
//EEIRPDGYNVY// + - - - - (aa 1-17 of SEQ ID (aa 18-26 of (aa
99-109 of SEQ NO: 5) SEQ ID NO: 5) ID NO: 5) M6
R-------DSSPLLQ--FGGQV RLRHLYTSG //EEIRPDGYNVY// + - - - - (aa 1-14
of SEQ ID (aa 15-23 of (aa 95-105 of SEQ NO: 6) SEQ ID NO: 6) ID
NO:6) M50 R-HPIPDSSPLLQ--FGDQV RLRHLYTSG //EEIRPDGYNVY// + + - - -
(aa 1-17 of SEQ ID (aa 18-26 of (aa 99-109 of SEQ NO: 50) SEQ ID
NO: 50) ID NO: 50) M144 --HPIPDSSPLLQ--FGGQV RLRHLYTSG
//EEIRPDGYNVY// + - - - - (aa 2-17 of SEQ ID (aa 18-26 of (aa
99-109 of SEQ NO: 5) SEQ ID NO: 5) ID NO: 5) M145
------DSSPLLQ--FGGQV RLRHLYTSG(a //EEIRPDGYNVY// + - - - - (aa 2-14
of SEQ ID a 15-23 of (aa 95-105 of SEQ NO: 6) SEQ ID NO: 6) ID NO:
6) M146 --HPIPDSSPLLQ--FGDQV RLRHLYTSG(a //EEIRPDGYNVY// + + - - -
(aa 2-17 of SEQ ID a 18-26 of (aa 99-109 of SEQ NO: 50) SEQ ID NO:
50) ID NO: 50)
[0251] As the data in Table 8 indicate, the deletion of the
N-terminal Arg (R) did not significantly impact glucose lowering,
body weight reduction, HDL and triglyceride elevation, and HCC
formation.
Example 9
[0252] This example sets forth several variant peptides having
amino acid substitutions in the Loop 8 region of FGF19, along with
the variants' effect on body weight, certain metabolic parameters,
and HCC formation.
[0253] The data in Table 9 are associated with variant polypeptides
denoted as M3, M139, M140, M141 and M160. The amino acid sequence
for M3 is set forth elsewhere herein, and the amino acid sequences
for M139, M140, M141 and M160 are as follows:
TABLE-US-00016 (M139) (SEQ ID NO: 193)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EILPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK; (M140) (SEQ ID NO: 194)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIREDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK; (M141) (SEQ ID NO: 195)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EILCDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK; and (M160) (SEQ ID NO:
196) RPLAFSDAGPHVHYGWGDPIRQRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK.
[0254] Only the following sequence domains for each of the
aforementioned variants are listed in Table 9: N-terminal domain,
Core, and Sheet-8/Loop-8/Sheet-9 region. While the particular amino
acid residues making up the Loop 8 region are not universally
accepted in the literature, FGF19 residues 127-129 are defined
herein as constituting the Loop-8 region.
TABLE-US-00017 TABLE 9 ##STR00010## Glu- cose Lower- ing Body
Weight Re- duct- ion HDL Ele- va- tion Tri- gly- cer- ide Ele- va-
tion HCC Form- ation FGF19 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG
//EEIRPDGYNVY// + - + + + (aa 1-20 of SEQ ID NO: 99) (aa 21-29 of
(aa 102-112 of SEQ SEQ ID NO: 99) ID NO: 99) FGF21
HPIPDSSPLLQ--FGGQV RQRYLYTDD //ELLLEDGYNVY// + + - - - (aa 1-20 of
SEQ ID NO: 100) (aa 21-29 of (aa 97-107 of SEQ SEQ ID ID NO: 100)
NO: 100) M3 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG //EEILEDGYNVY//( + + + +
+/- (aa 1-20 of SEQ ID NO: 3) (aa 21-29 of aa 102-112 of SEQ SEQ ID
NO: 3) ID NO: 3) M139 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG
//EEILPDGYNVY// + - + + + (aa 1-20 of SEQ ID NO. 193) (aa 21-29 of
(aa 102-112 of SEQ SEQ ID ID NO: 193) NO: 193) M140
RPLAFSDAGPHVHYGWGDPI RLRHLYTSG //EEIREDGYNVY//( + + + + +/- (aa
1-20 of SEQ ID NO: 194) (aa 21-29 of aa 102-112 of SEQ SEQ ID ID
NO: 194) NO: 194) M141 RPLAFSDAGPHVHYGWGDPI RLRHLYTSG
//EEILCDGYNVY// + - + + + (aa 1-20 of SEQ ID NO: 195) (aa 21-29 of
(aa 102-112 of SEQ SEQ ID ID NO: 195) NO: 195) M160
RPLAFSDAGPHVHYGWGDPI RQRHLYTSG //EEILEDGYNVY//( + + + + - (aa 1-20
of SEQ ID NO: 196) (aa 21-29 of aa 102-112 of SEQ SEQ ID ID NO:
196) NO: 196)
[0255] Referring to Table 9, the P128E substitution appears
necessary to significantly prevent HCC formation, but is
insufficient by itself to prevent HCC formation. In particular, an
improvement in preventing HCC formation is observed with the P128E
substitution in M140. Conversely, by itself the R127L substitution
does not prevent HCC formation (see M139). As indicated in
comparison to M3, a combination of the R127L and P128E
substitutions decreases HCC formation but does not eliminate HCC
formation. Surprisingly, however, a combination of the R127L and
P128E substitutions along with a substitution of Gln (Q) for Leu
(L) in the FGF19 core region does significantly prevent HCC
formation (see M160).
[0256] These data indicate that the FGF19 Loop 8 region plays a
role in HCC formation. Amino acid residues outside of the Loop 8
region (e.g., substitutions in the core region) may enhance the
prevention of HCC formation.
TABLE-US-00018 M1 (SEQ ID NO: 1)
RPLAFSDASPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M2 (SEQ ID NO: 2)
RPLAFSDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M3 (SEQ ID NO: 3)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M5 (SEQ ID NO: 5)
RHPIPDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA
HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIR
PDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPED
LRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M5-R (SEQ ID NO: 160)
HPIPDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAH
SLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRP
DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL
RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M48 (SEQ ID NO: 48)
RDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL
EIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGY
NVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH
LESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M49 (SEQ ID NO: 49)
RPLAFSDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQS
AHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEI
RPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPE
DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M50 (SEQ ID NO: 50)
RHPIPDSSPLLQFGDQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA
HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIL
EDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPED
VLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M51 (SEQ ID NO: 51)
RHPIPDSSPLLQFGGNVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA
HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIR
PDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPED
LRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M52 (SEQ ID NO: 52)
RDSSPLLQWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL
EIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGY
NVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH
LESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M53 (SEQ ID NO: 192)
MDSSPLLQWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL
EIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGY
NVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH
LESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M69 (SEQ ID NO: 69)
RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHS
LLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPD
GYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLR
GHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M70 (SEQ ID NO: 70)
MRDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAH
SLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRP
DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL
RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M71 (SEQ ID NO: 71)
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPES
LLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLED
GYNVYQSEAHSLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGIL
APQPPDVGSSDPLSMVGPSQGRSPSYAS M72 (SEQ ID NO: 72)
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPES
LLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLED
GYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPAPPEPPGIL
APQPPDVGSSDPLSMVGPSQGRSPSYAS M73 (SEQ ID NO: 73)
HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPES
LLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLED
GYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGIL
APQPPDVGSSDPLSMVVQDELQGVGGEGCHMHPENCKTLLTDIDRTHTEKP VWDGITGE M75
(SEQ ID NO: 75) RVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK
AVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVY
RSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLES
DMFSSPLETDSMDPFGLVTGLEAVRSPSFEK M76 (SEQ ID NO: 76)
RGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKH
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSS
PLETDSMDPFGLVTGLEAVRSPSFEK FGF19 (SEQ ID NO: 99)
RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG
QSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE
EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
Example 10
[0257] This example shows activation of mouse FGFR4-.beta.-klotho
signaling by FGF19, M3, and M70 in a rat myoblast cell line
[0258] Methods: An ELK luciferase assay was performed in L6 cells
transiently transfected with mouse FGFR4, b-klotho, and reporter
constructs containing 5.times.UAS luciferase and GAL4-DNA-binding
domain (DBD) fused to ELK1. In this system, luciferase activity is
regulated by the endogenous phosphorylated extracellular
signal-regulated kinase (ERK). Cells were incubated with ligands
for 6 hours before lysed for luciferase activity measurements.
[0259] A cell-based receptor activation assay was used to evaluate
the ability of mouse FGFR4 to mediate ligand-dependent signaling in
the presence of .beta.-klotho. To this end, a rat L6 myoblast cell
line, which lacks endogenous expression of these proteins, was
transfected with DNAs encoding FGFR4 and .beta.-klotho from mouse,
as well as plasmids containing an Elk1-dependent chimeric
transcription factor-based reporter system.
[0260] Following transfection, concentration response of
ligand-dependent luciferase expression was analyzed in whole-cell
lysates in the presence of luciferin substrate.
[0261] Results: Co-expression of FGFR4 and .beta.-klotho in L6
cells was found to potentiate activation of intracellular signaling
pathways by both M3, M70 and FGF19 (EC.sub.50=20, 38 and 53 pM,
respectively (see Table 10 and FIG. 8).
TABLE-US-00019 TABLE 10 Co-expression of Mouse FGFR4/.beta.-klotho
complex in L6 Cells Potentiates Activation of Intracellular
Signaling Pathways by FGF19, M3 and M70. FGFR4/.beta.klotho
E.sub.max Ligand EC.sub.50 (pM) (fold potentiation) FGF19 52.5 .+-.
0.01 1.82 .+-. 0.09 M3 19.8 .+-. 0.04 1.68 .+-. 0.04 M70 38.3 .+-.
0.12 1.85 .+-. 0.14 EC.sub.50 = half-maximal effective
concentration; E.sub.max = maximum efficacy. Data are expressed as
mean .+-. SD
[0262] These data suggest that the formation of a ternary complex
between the FGFR4-.beta.-klotho co-receptors and cognate ligands is
important for potent activation of intracellular signaling.
SEQUENCE LISTING
[0263] The present specification is being filed with a computer
readable form (CRF) copy of the Sequence Listing. The CRF entitled
13370-116-999_SEQLIST.txt, which was created on Aug. 5, 2020 and is
241,720 bytes in size, is identical to the paper copy of the
Sequence Listing and is incorporated herein by reference in its
entirety.
Sequence CWU 1
1
1961194PRTHomo sapiens 1Arg Pro Leu Ala Phe Ser Asp Ala Ser Pro His
Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser
Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120
125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys2194PRTHomo sapiens
2Arg Pro Leu Ala Phe Ser Asp Ser Ser Pro Leu Val His Tyr Gly Trp1 5
10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155
160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp
165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro
Ser Phe 180 185 190Glu Lys3194PRTHomo sapiens 3Arg Pro Leu Ala Phe
Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser
Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg
Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu
Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75
80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Leu Glu Asp Gly Tyr Asn Val
Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu
Lys4194PRTHomo sapiens 4Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His
Val His Tyr Ala Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser
Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120
125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys5191PRTHomo sapiens
5Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln1 5
10 15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155
160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly
165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu
Lys 180 185 1906187PRTHomo sapiens 6Arg Asp Ser Ser Pro Leu Leu Gln
Phe Gly Gly Gln Val Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser Gly Pro
His Gly Leu Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp Gly Val
Val Asp Cys Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu Glu Ile
Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val His Ser
Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75 80Gln Gly
Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu 85 90 95Ile
Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu 100 105
110Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg
115 120 125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro Met
Val Pro 130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser
Asp Met Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp Ser Met Asp
Pro Phe Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val Arg Ser Pro
Ser Phe Glu Lys 180 1857192PRTHomo sapiens 7Arg Pro Leu Ala Phe Ser
Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly1 5 10 15Gln Val Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
1908191PRTHomo sapiens 8Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu
Gln Trp Gly Asp Pro1 5 10 15Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120
125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu
130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu
Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 185 1909193PRTHomo sapiens 9Arg His Pro
Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Trp Gly1 5 10 15Asp Pro
Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser
Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala 35 40
45Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
50 55 60Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met65 70 75 80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser Leu
Ser Ser Ala Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe
Leu Pro Leu Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val Pro
Glu Glu Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser Asp
Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170 175Phe
Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185
190Lys10193PRTHomo sapiens 10Arg His Pro Ile Pro Asp Ser Ser Pro
His Val His Tyr Gly Trp Gly1 5 10 15Asp Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala 35 40 45Arg Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu 50 55 60Arg Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met65 70 75 80Gly Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp 85 90 95Cys Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg 100 105
110Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro 130 135 140Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185 190Lys11192PRTHomo
sapiens 11Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro Leu Leu Gln Trp
Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150
155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro
Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser
Phe Glu Lys 180 185 19012194PRTHomo sapiens 12Arg Pro Leu Ala Phe
Ser Asp Ala Gly Pro Leu Leu Gln Phe Gly Trp1 5 10 15Gly Asp Pro Ile
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser
Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg
Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu
Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75
80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu
Lys13192PRTHomo sapiens 13Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
Leu Leu Gln Phe Gly Gly1 5 10 15Gln Val Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120
125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met
130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185 19014191PRTHomo sapiens 14Arg
His Pro Ile Pro Asp Ser Ser Pro His Val His Tyr Gly Gly Gln1 5 10
15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser
20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg
Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu
Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe
Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro
Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155 160Asp
Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170
175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185 19015192PRTHomo sapiens 15Arg Pro Leu Ala Phe Ser Asp Ala Gly
Pro His Val His Tyr Gly Gly1 5 10 15Gln Val Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19016192PRTHomo sapiens
16Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Trp Gly Asp1
5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155
160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19017192PRTHomo sapiens 17Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro His Val Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19018192PRTHomo sapiens 18Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
His Tyr Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120
125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185 19019192PRTHomo sapiens 19Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro Val Tyr Gly Trp Gly Asp1 5 10
15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155 160Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170
175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys
180 185 19020192PRTHomo sapiens 20Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro Val His Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19021192PRTHomo sapiens
21Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro Val His Tyr Trp Gly Asp1
5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155
160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19022193PRTHomo sapiens 22Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro His Val His Gly Trp Gly1 5 10 15Asp Pro Ile Arg Leu
Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser Ser Cys Phe
Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala 35 40 45Arg Gly Gln
Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu 50 55 60Arg Thr
Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met65 70 75
80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp
85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr
Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala
Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu
Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val Pro Glu Glu Pro
Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe Ser
Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu Val
Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185
190Lys23192PRTHomo sapiens 23Arg Pro Leu Ala Phe Ser Asp Ala Gly
Pro His His Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19024192PRTHomo sapiens
24Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His His Tyr Trp Gly Asp1
5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155
160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19025192PRTHomo sapiens 25Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro His Val Tyr Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19026192PRTHomo sapiens 26Arg Pro Leu Ala Phe Ser Asp Ser Ser Pro
Leu Val His Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19027192PRTHomo sapiens 27Arg Pro Leu Ala Phe Ser Asp Ser Ser Pro
His Val His Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120
125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185 19028191PRTHomo sapiens 28Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val Trp Gly Asp Pro1 5 10
15Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser
20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg
Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu
Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe
Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro
Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155 160Asp
Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170
175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185 19029193PRTHomo sapiens 29Arg Pro Leu Ala Phe Ser Asp Ala Gly
Pro His Val His Tyr Trp Gly1 5 10 15Asp Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala 35 40 45Arg Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu 50 55 60Arg Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met65 70 75 80Gly Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp 85 90 95Cys Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg 100 105
110Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro 130 135 140Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185 190Lys30194PRTHomo
sapiens 30Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Ala Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys31191PRTHomo sapiens 31Arg His Pro
Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Ala Gln1 5 10 15Val Arg
Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys
Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40
45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr
50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly
Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19032191PRTHomo sapiens 32Arg His Pro Ile Pro Asp Ser Ser Pro Leu
Leu Gln Phe Gly Asp Gln1 5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met
Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu
Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys
His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120
125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu
130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu
Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 185 19033191PRTHomo sapiens 33Arg His
Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Pro Gln1 5 10 15Val
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25
30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly
35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg
Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met
Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn
Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser
Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu
Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu
Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155 160Asp Met
Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170
175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185 19034191PRTHomo sapiens 34Arg His Pro Ile Pro Asp Ser Ser Pro
Leu Leu Gln Phe Gly Gly Ala1 5 10 15Val Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105
110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu
115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr
Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala
Val Arg Ser Pro Ser Phe Glu Lys 180 185 19035191PRTHomo sapiens
35Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Glu1
5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155
160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly
165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu
Lys 180 185 19036191PRTHomo sapiens 36Arg His Pro Ile Pro Asp Ser
Ser Pro Leu Leu Gln Phe Gly Gly Asn1 5 10 15Val Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90
95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu
100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19037191PRTHomo
sapiens 37Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly
Gly Gln1 5 10 15Ala Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro
Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150
155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19038191PRTHomo sapiens 38Arg His Pro Ile Pro Asp
Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln1 5 10 15Ile Arg Leu Arg His
Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg
Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala
His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala
Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75
80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala
85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser
Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19039191PRTHomo
sapiens 39Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly
Gly Gln1 5 10 15Thr Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90
95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu
100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19040193PRTHomo
sapiens 40Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly
Trp Gly1 5 10 15Gln Pro Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro
His Gly Leu 20 25 30Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val
Val Asp Cys Ala 35 40 45Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile
Lys Ala Val Ala Leu 50 55 60Arg Thr Val Ala Ile Lys Gly Val His Ser
Val Arg Tyr Leu Cys Met65 70 75 80Gly Ala Asp Gly Lys Met Gln Gly
Leu Leu Gln Tyr Ser Glu Glu Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile
Arg Pro Asp Gly Tyr Asn Val Tyr Arg 100 105 110Ser Glu Lys His Arg
Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg 115 120 125Gln Leu Tyr
Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro 130 135 140Met
Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu145 150
155 160Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp
Pro 165 170 175Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro
Ser Phe Glu 180 185 190Lys41182PRTHomo sapiens 41Arg Pro Leu Ala
Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro
Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser
Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala
Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55
60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65
70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn
Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser
Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu
Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Glu Pro Pro Gly
Ile Leu Ala Pro Gln Pro Pro Asp145 150 155 160Val Gly Ser Ser Asp
Pro Leu Ser Met Val Gly Pro Ser Gln Gly Arg 165 170 175Ser Pro Ser
Tyr Ala Ser 18042178PRTHomo sapiens 42His Pro Ile Pro Asp Ser Ser
Pro Leu Leu Gln Phe Gly Gly Gln Val1 5 10 15Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser Ser Cys 20 25 30Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln 35 40 45Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val 50 55 60Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp65 70 75 80Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe 85 90
95Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys
100 105 110His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
Leu Tyr 115 120 125Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met Leu Pro 130 135 140Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro
Pro Asp Val Gly Ser Ser145 150 155 160Asp Pro Leu Ser Met Val Gly
Pro Ser Gln Gly Arg Ser Pro Ser Tyr 165 170 175Ala Ser43192PRTHomo
sapiens 43Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Gly Gly1 5 10 15Asp Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150
155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro
Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser
Phe Glu Lys 180 185 19044185PRTHomo sapiens 44Arg Pro Leu Ala Phe
Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile
Arg Gln Arg Tyr Leu Tyr Thr Asp Asp Ala Gln Gln 20 25 30Thr Glu Ala
His Leu Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala 35 40 45Ala Asp
Gln Ser Pro Glu Ser Leu Leu Gln Leu Lys Ala Leu Lys Pro 50 55 60Gly
Val Ile Gln Ile Leu Gly Val Lys Thr Ser Arg Phe Leu Cys Gln65 70 75
80Arg Pro Asp Gly Ala Leu Tyr Gly Ser Leu His Phe Asp Pro Glu Ala
85 90 95Cys Ser Phe Arg Glu Leu Leu Leu Glu Asp Gly Tyr Asn Val Tyr
Gln 100 105 110Ser Glu Ala His Gly Leu Pro Leu His Leu Pro Gly Asn
Lys Ser Pro 115 120 125His Arg Asp Pro Ala Pro Arg Gly Pro Ala Arg
Phe Leu Pro Leu Pro 130 135 140Gly Leu Pro Pro Ala Leu Pro Glu Pro
Pro Gly Ile Leu Ala Pro Gln145 150 155 160Pro Pro Asp Val Gly Ser
Ser Asp Pro Leu Ser Met Val Gly Pro Ser 165 170 175Gln Gly Arg Ser
Pro Ser Tyr Ala Ser 180 18545193PRTHomo sapiens 45His Pro Ile Pro
Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln Val1 5 10 15Arg Gln Arg
Tyr Leu Tyr Thr Asp Asp Ala Gln Gln Thr Glu Ala His 20 25 30Leu Glu
Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Gln Ser 35 40 45Pro
Glu Ser Leu Leu Gln Leu Lys Ala Leu Lys Pro Gly Val Ile Gln 50 55
60Ile Leu Gly Val Lys Thr Ser Arg Phe Leu Cys Gln Arg Pro Asp Gly65
70 75 80Ala Leu Tyr Gly Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe
Arg 85 90 95Glu Leu Leu Leu Glu Asp Gly Tyr Asn Val Tyr Gln Ser Glu
Ala His 100 105 110Gly Leu Pro Leu His Leu Pro Gly Asn Lys Ser Pro
His Arg Asp Pro 115 120 125Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro
Leu Pro Gly Leu Pro Pro 130 135 140Ala Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185
190Lys46232PRTHomo sapiens 46Arg Pro Leu Ala Phe Ser Asp Ala Gly
Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Gln Arg Tyr
Leu Tyr Thr Asp Asp Ala Gln Gln 20 25 30Thr Glu Ala His Leu Glu Ile
Arg Glu Asp Gly Thr Val Gly Gly Ala 35 40 45Ala Asp Gln Ser Pro Glu
Ser Leu Leu Gln Leu Lys Ala Leu Lys Pro 50 55 60Gly Val Ile Gln Ile
Leu Gly Val Lys Thr Ser Arg Phe Leu Cys Gln65 70 75 80Arg Pro Asp
Gly Ala Leu Tyr Gly Ser Leu His Phe Asp Pro Glu Ala 85 90 95Cys Ser
Phe Arg Glu Leu Leu Leu Glu Asp Gly Tyr Asn Val Tyr Gln 100 105
110Ser Glu Ala His Gly Leu Pro Leu His Leu Pro Gly Asn Lys Ser Pro
115 120 125His Arg Asp Pro Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro
Leu Pro 130 135 140Gly Leu Pro Pro Ala Leu Pro Glu Pro Pro Gly Ile
Leu Ala Pro Gln145 150 155 160Pro Pro Asp Val Gly Ser Ser Asp Pro
Leu Ser Met Val Gly Pro Ser 165 170 175Gln Gly Arg Ser Pro Ser Tyr
Ala Ser Pro Met Val Pro Glu Glu Pro 180 185 190Glu Asp Leu Arg Gly
His Leu Glu Ser Asp Met Phe Ser Ser Pro Leu 195 200 205Glu Thr Asp
Ser Met Asp Pro Phe Gly Leu Val Thr Gly Leu Glu Ala 210 215 220Val
Arg Ser Pro Ser Phe Glu Lys225 23047190PRTHomo sapiens 47His Pro
Ile Pro Asp Ser Ser Pro Leu Leu Gln Trp Gly Asp Pro Ile1 5 10 15Arg
Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys 20 25
30Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln
35 40 45Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr
Val 50 55 60Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly
Ala Asp65 70 75 80Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp Cys Ala Phe 85 90 95Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg Ser Glu Lys 100 105 110His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg Gln Leu Tyr 115 120 125Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro Met Leu Pro 130 135 140Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp145 150 155 160Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu 165 170
175Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19048187PRTHomo sapiens 48Arg Asp Ser Ser Pro Leu Leu Gln Phe Gly
Gly Gln Val Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75 80Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu 85 90 95Ile Arg Pro
Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu 100 105 110Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg 115 120
125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro
130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met
Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 18549192PRTHomo sapiens 49Arg Pro Leu Ala Phe Ser Asp
Ser Ser Pro Leu Leu Gln Phe Gly Gly1 5 10 15Gln Val Arg Leu Arg His
Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg
Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala
His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala
Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala
Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90
95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser
100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19050191PRTHomo
sapiens 50Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly
Asp Gln1 5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Leu Glu
Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150
155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19051191PRTHomo sapiens 51Arg His Pro Ile Pro Asp
Ser Ser Pro Leu Leu Gln Phe Gly Gly Asn1 5 10 15Val Arg Leu Arg His
Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg
Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala
His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala
Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75
80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala
85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser
Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His Leu Glu Ser145 150
155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19052187PRTHomo sapiens 52Arg Asp Ser Ser Pro Leu
Leu Gln Trp Gly Asp Pro Ile Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75
80Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu
85 90 95Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg
Leu 100 105 110Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr
Lys Asn Arg 115 120 125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
Leu Pro Met Val Pro 130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu Ser Asp Met Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 18553189PRTHomo sapiens 53Met Asp
Ser Ser Pro Leu Val His Tyr Gly Trp Gly Asp Pro Ile Arg1 5 10 15Leu
Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe 20 25
30Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln Ser
35 40 45Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val
Ala 50 55 60Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala
Asp Gly65 70 75 80Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp
Cys Ala Phe Glu 85 90 95Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr
Arg Ser Glu Lys His 100 105 110Arg Leu Pro Val Ser Leu Ser Ser Ala
Lys Gln Arg Gln Leu Tyr Lys 115 120 125Asn Arg Gly Phe Leu Pro Leu
Ser His Phe Leu Pro Met Leu Pro Met 130 135 140Val Pro Glu Glu Pro
Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met145 150 155 160Phe Ser
Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val 165 170
175Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
18554192PRTHomo sapiens 54Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
Leu Leu Gln Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120
125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185 19055192PRTHomo sapiens 55Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Tyr Gly Trp Gly Asp1 5 10
15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155 160Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170
175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys
180 185 19056192PRTHomo sapiens 56Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro Val Tyr Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19057192PRTHomo sapiens
57Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro Val His Gly Trp Gly Asp1
5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155
160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19058192PRTHomo sapiens 58Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro Val His Tyr Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19059192PRTHomo sapiens 59Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
His His Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120
125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185 19060192PRTHomo sapiens 60Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His His Tyr Trp Gly Asp1 5 10
15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155 160Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170
175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys
180 185 19061192PRTHomo sapiens 61Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro His Val Gly Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19062192PRTHomo sapiens
62Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val Tyr Trp Gly Asp1
5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155
160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 19063192PRTHomo sapiens 63Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro His Val His Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19064192PRTHomo sapiens 64Arg Pro Leu Ala Phe Ser Asp Ser Ser Pro
Leu Val His Trp Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100
105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 19065192PRTHomo
sapiens 65Arg Pro Leu Ala Phe Ser Asp Ser Ser Pro His Val His Trp
Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150
155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro
Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser
Phe Glu Lys 180 185 19066192PRTHomo sapiens 66Arg Pro Leu Ala Phe
Ser Asp Ala Gly Pro His Leu Gln Trp Gly Asp1 5 10 15Pro Ile Arg Leu
Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe
Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln
Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr
Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75
80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys
85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg
Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys
Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser
His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu
Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser
Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr
Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19067191PRTHomo sapiens 67Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
His Val Trp Gly Asp Pro1 5 10 15Ile Arg Leu Arg His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met
Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu
Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys
His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120
125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu
130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu
Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 185 19068193PRTHomo sapiens 68Arg Pro
Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Trp Gly1 5 10 15Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25
30Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
35 40 45Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu 50 55 60Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met65 70 75 80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170
175Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu
180 185 190Lys69189PRTHomo sapiens 69Arg Asp Ser Ser Pro Leu Val
His Tyr Gly Trp Gly Asp Pro Ile Arg1 5 10 15Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser Ser Cys Phe 20 25 30Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg Gly Gln Ser 35 40 45Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val Ala 50 55 60Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly65 70 75 80Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu 85 90
95Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His
100 105 110Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu
Tyr Lys 115 120 125Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met Leu Pro Met 130 135 140Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
His Leu Glu Ser Asp Met145 150 155 160Phe Ser Ser Pro Leu Glu Thr
Asp Ser Met Asp Pro Phe Gly Leu Val 165 170 175Thr Gly Leu Glu Ala
Val Arg Ser Pro Ser Phe Glu Lys 180 18570190PRTHomo sapiens 70Met
Arg Asp Ser Ser Pro Leu Val His Tyr Gly Trp Gly Asp Pro Ile1 5 10
15Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys
20 25 30Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly
Gln 35 40 45Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg
Thr Val 50 55 60Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met
Gly Ala Asp65 70 75 80Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu Asp Cys Ala Phe 85 90 95Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn
Val Tyr Arg Ser Glu Lys 100 105 110His Arg Leu Pro Val Ser Leu Ser
Ser Ala Lys Gln Arg Gln Leu Tyr 115 120 125Lys Asn Arg Gly Phe Leu
Pro Leu Ser His Phe Leu Pro Met Leu Pro 130 135 140Met Val Pro Glu
Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp145 150 155 160Met
Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu 165 170
175Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
19071181PRTHomo sapiens 71His Pro Ile Pro Asp Ser Ser Pro Leu Leu
Gln Phe Gly Gly Gln Val1 5 10 15Arg Gln Arg Tyr Leu Tyr Thr Asp Asp
Ala Gln Gln Thr Glu Ala His 20 25 30Leu Glu Ile Arg Glu Asp Gly Thr
Val Gly Gly Ala Ala Asp Gln Ser 35 40 45Pro Glu Ser Leu Leu Gln Leu
Lys Ala Leu Lys Pro Gly Val Ile Gln 50 55 60Ile Leu Gly Val Lys Thr
Ser Arg Phe Leu Cys Gln Arg Pro Asp Gly65 70 75 80Ala Leu Tyr Gly
Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe Arg 85 90 95Glu Leu Leu
Leu Glu Asp Gly Tyr Asn Val Tyr Gln Ser Glu Ala His 100 105 110Ser
Leu Pro Leu His Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro 115 120
125Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Leu Pro Pro
130 135 140Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro
Asp Val145 150 155 160Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro
Ser Gln Gly Arg Ser 165 170 175Pro Ser Tyr Ala Ser 18072181PRTHomo
sapiens 72His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly
Gln Val1 5 10 15Arg Gln Arg Tyr Leu Tyr Thr Asp Asp Ala Gln Gln Thr
Glu Ala His 20 25 30Leu Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala
Ala Asp Gln Ser 35 40 45Pro Glu Ser Leu Leu Gln Leu Lys Ala Leu Lys
Pro Gly Val Ile Gln 50 55 60Ile Leu Gly Val Lys Thr Ser Arg Phe Leu
Cys Gln Arg Pro Asp Gly65 70 75 80Ala Leu Tyr Gly Ser Leu His Phe
Asp Pro Glu Ala Cys Ser Phe Arg 85 90 95Glu Leu Leu Leu Glu Asp Gly
Tyr Asn Val Tyr Gln Ser Glu Ala His 100 105 110Gly Leu Pro Leu His
Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro 115 120 125Ala Pro Arg
Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Leu Pro Pro 130 135 140Ala
Pro Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val145 150
155 160Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Gln Gly Arg
Ser 165 170 175Pro Ser Tyr Ala Ser 18073212PRTHomo sapiens 73His
Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln Val1 5 10
15Arg Gln Arg Tyr Leu Tyr Thr Asp Asp Ala Gln Gln Thr Glu Ala His
20 25 30Leu Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Gln
Ser 35 40 45Pro Glu Ser Leu Leu Gln Leu Lys Ala Leu Lys Pro Gly Val
Ile Gln 50 55 60Ile Leu Gly Val Lys Thr Ser Arg Phe Leu Cys Gln Arg
Pro Asp Gly65 70 75 80Ala Leu Tyr Gly Ser Leu His Phe Asp Pro Glu
Ala Cys Ser Phe Arg 85 90 95Glu Leu Leu Leu Glu Asp Gly Tyr Asn Val
Tyr Gln Ser Glu Ala His 100 105 110Gly Leu Pro Leu His Leu Pro Gly
Asn Lys Ser Pro His Arg Asp Pro 115 120 125Ala Pro Arg Gly Pro Ala
Arg Phe Leu Pro Leu Pro Gly Leu Pro Pro 130 135 140Ala Leu Pro Glu
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val145 150 155 160Gly
Ser Ser Asp Pro Leu Ser Met Val Val Gln Asp Glu Leu Gln Gly 165 170
175Val Gly Gly Glu Gly Cys His Met His Pro Glu Asn Cys Lys Thr Leu
180 185 190Leu Thr Asp Ile Asp Arg Thr His Thr Glu Lys Pro Val Trp
Asp Gly 195 200 205Ile Thr Gly Glu 21074189PRTHomo sapiens 74Arg
Asp Ala Gly Pro His Val His Tyr Gly Trp Gly Asp Pro Ile Arg1 5 10
15Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe
20 25 30Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln
Ser 35 40 45Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr
Val Ala 50 55 60Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly
Ala Asp Gly65 70 75 80Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp Cys Ala Phe Glu 85 90 95Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg Ser Glu Lys His 100 105 110Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg Gln Leu Tyr Lys 115 120 125Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro Met Leu Pro Met 130 135 140Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met145 150 155 160Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val 165 170
175Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
18575184PRTHomo sapiens 75Arg Val His Tyr Gly Trp Gly Asp Pro Ile
Arg Leu Arg His Leu Tyr1 5 10 15Thr Ser Gly Pro His Gly Leu Ser Ser
Cys Phe Leu Arg Ile Arg Ala 20 25 30Asp Gly Val Val Asp Cys Ala Arg
Gly Gln Ser Ala His Ser Leu Leu 35 40 45Glu Ile Lys Ala Val Ala Leu
Arg Thr Val Ala Ile Lys Gly Val His 50 55 60Ser Val Arg Tyr Leu Cys
Met Gly Ala Asp Gly Lys Met Gln Gly Leu65 70 75 80Leu Gln Tyr Ser
Glu Glu Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro 85 90 95Asp Gly Tyr
Asn Val Tyr Arg Ser Glu Lys His Arg Leu Pro Val Ser 100 105 110Leu
Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu 115 120
125Pro Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro Glu Glu Pro
130 135 140Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met Phe Ser Ser
Pro Leu145 150 155 160Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val
Thr Gly Leu Glu Ala 165 170 175Val Arg Ser Pro Ser Phe Glu Lys
18076179PRTHomo sapiens 76Arg Gly Asp Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His1 5 10 15Gly Leu Ser Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp 20 25 30Cys Ala Arg Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val 35 40 45Ala Leu Arg Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu 50 55 60Cys Met Gly Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu65 70 75 80Glu Asp Cys Ala
Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val 85 90 95Tyr Arg Ser
Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys 100 105 110Gln
Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe 115 120
125Leu Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
130 135 140His Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp
Ser Met145 150 155 160Asp Pro Phe Gly Leu Val Thr Gly Leu Glu Ala
Val Arg Ser Pro Ser 165 170 175Phe Glu Lys77175PRTHomo sapiens
77Arg Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser1
5 10 15Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg
Gly 20 25 30Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
Arg Thr 35 40 45Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met Gly Ala 50 55 60Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu Asp Cys Ala65 70 75 80Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg Ser Glu 85
90 95Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
Leu 100 105 110Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met Leu 115 120 125Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu Ser 130 135 140Asp Met Phe Ser Ser Pro Leu Glu Thr
Asp Ser Met Asp Pro Phe Gly145 150 155 160Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 165 170 17578188PRTHomo sapiens
78Arg Ala Gly Pro His Val His Tyr Gly Trp Gly Asp Pro Ile Arg Leu1
5 10 15Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe
Leu 20 25 30Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln
Ser Ala 35 40 45His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr
Val Ala Ile 50 55 60Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly
Ala Asp Gly Lys65 70 75 80Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp Cys Ala Phe Glu Glu 85 90 95Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg Ser Glu Lys His Arg 100 105 110Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg Gln Leu Tyr Lys Asn 115 120 125Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro Met Leu Pro Met Val 130 135 140Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met Phe145 150 155
160Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val Thr
165 170 175Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
18579187PRTHomo sapiens 79Arg Gly Pro His Val His Tyr Gly Trp Gly
Asp Pro Ile Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75 80Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu 85 90 95Ile Arg Pro
Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu 100 105 110Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg 115 120
125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro
130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met
Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 18580186PRTHomo sapiens 80Arg Pro His Val His Tyr Gly
Trp Gly Asp Pro Ile Arg Leu Arg His1 5 10 15Leu Tyr Thr Ser Gly Pro
His Gly Leu Ser Ser Cys Phe Leu Arg Ile 20 25 30Arg Ala Asp Gly Val
Val Asp Cys Ala Arg Gly Gln Ser Ala His Ser 35 40 45Leu Leu Glu Ile
Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys Gly 50 55 60Val His Ser
Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met Gln65 70 75 80Gly
Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu Ile 85 90
95Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu Pro
100 105 110Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn
Arg Gly 115 120 125Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro
Met Val Pro Glu 130 135 140Glu Pro Glu Asp Leu Arg Gly His Leu Glu
Ser Asp Met Phe Ser Ser145 150 155 160Pro Leu Glu Thr Asp Ser Met
Asp Pro Phe Gly Leu Val Thr Gly Leu 165 170 175Glu Ala Val Arg Ser
Pro Ser Phe Glu Lys 180 18581185PRTHomo sapiens 81Arg His Val His
Tyr Gly Trp Gly Asp Pro Ile Arg Leu Arg His Leu1 5 10 15Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser Cys Phe Leu Arg Ile Arg 20 25 30Ala Asp
Gly Val Val Asp Cys Ala Arg Gly Gln Ser Ala His Ser Leu 35 40 45Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys Gly Val 50 55
60His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met Gln Gly65
70 75 80Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu Ile
Arg 85 90 95Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu
Pro Val 100 105 110Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys
Asn Arg Gly Phe 115 120 125Leu Pro Leu Ser His Phe Leu Pro Met Leu
Pro Met Val Pro Glu Glu 130 135 140Pro Glu Asp Leu Arg Gly His Leu
Glu Ser Asp Met Phe Ser Ser Pro145 150 155 160Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly Leu Val Thr Gly Leu Glu 165 170 175Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 18582194PRTHomo sapiens 82Arg Pro Leu
Ala Phe Ser Ala Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys83194PRTHomo sapiens 83Arg Pro Leu Ala Phe Ser Asp Ala
Ala Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly
Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp
Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105
110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys84194PRTHomo
sapiens 84Arg Pro Leu Ala Phe Ser Asp Ala Gly Ala His Val His Tyr
Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys85194PRTHomo sapiens 85Arg Pro Leu
Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Ala1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys86194PRTHomo sapiens 86Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Ala Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly
Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp
Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105
110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys87167PRTHomo
sapiens 87Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Gly Trp1 5 10 15Gly Asp Ala Ile Cys Ala Arg Gly Gln Ser Ala His Ser
Leu Leu Glu 20 25 30Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys
Gly Val His Ser 35 40 45Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys
Met Gln Gly Leu Leu 50 55 60Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu
Glu Glu Ile Arg Pro Asp65 70 75 80Gly Tyr Asn Val Tyr Arg Ser Glu
Lys His Arg Leu Pro Val Ser Leu 85 90 95Ser Ser Ala Lys Gln Arg Gln
Leu Tyr Lys Asn Arg Gly Phe Leu Pro 100 105 110Leu Ser His Phe Leu
Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu 115 120 125Asp Leu Arg
Gly His Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu 130 135 140Thr
Asp Ser Met Asp Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val145 150
155 160Arg Ser Pro Ser Phe Glu Lys 16588194PRTHomo sapiens 88Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10
15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro Ala Gly
20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro
Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ala His Phe Leu 130 135 140Pro Met Leu Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu
Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170
175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
180 185 190Glu Lys89194PRTHomo sapiens 89Arg Pro Leu Ala Phe Ser
Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg
Leu Arg His Leu Tyr Thr Ser Gly Pro Ala Gly 20 25 30Leu Ser Ser Cys
Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly
Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg
Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75
80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser Ala Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu
Lys90194PRTHomo sapiens 90Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro
His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu
Ser Ser Ala Ala Gln 115 120 125Ala Gln Leu Tyr Lys Asn Arg Gly Phe
Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro
Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser Asp
Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe
Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys91194PRTHomo sapiens 91Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly
Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp
Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105
110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Ala Gln
115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ala His
Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys92194PRTHomo
sapiens 92Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Ala Gln 115 120 125Arg Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser Ala Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys93194PRTHomo sapiens 93Arg Pro Leu
Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln 115 120 125Ala Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ala His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys94194PRTHomo sapiens 94Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly
Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp
Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105
110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ala Ala
Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys95194PRTHomo
sapiens 95Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Ala Gln 115 120 125Arg Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser Ala Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys96194PRTHomo sapiens 96Arg Pro Leu
Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Ala Gln 115 120 125Ala Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ala His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys97194PRTHomo sapiens 97Arg Pro Leu Ala Phe Ser Asp Ala
Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg
His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu
Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly
Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp
Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105
110Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Ala Gln
115 120 125Ala Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser Ala
Phe Leu 130 135 140Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His145 150 155 160Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp 165 170 175Pro Phe Gly Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185 190Glu Lys98194PRTHomo
sapiens 98Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr
Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Ala Gln 115 120 125Ala Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ala Ala Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys99194PRTHomo sapiens 99Arg Pro Leu
Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys100181PRTHomo sapiens 100His Pro Ile Pro Asp Ser Ser Pro
Leu Leu Gln Phe Gly Gly Gln Val1 5 10 15Arg Gln Arg Tyr Leu Tyr Thr
Asp Asp Ala Gln Gln Thr Glu Ala His 20 25 30Leu Glu Ile Arg Glu Asp
Gly Thr Val Gly Gly Ala Ala Asp Gln Ser 35 40 45Pro Glu Ser Leu Leu
Gln Leu Lys Ala Leu Lys Pro Gly Val Ile Gln 50 55 60Ile Leu Gly Val
Lys Thr Ser Arg Phe Leu Cys Gln Arg Pro Asp Gly65 70 75 80Ala Leu
Tyr Gly Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe Arg 85 90 95Glu
Leu Leu Leu Glu Asp Gly Tyr Asn Val Tyr Gln Ser Glu Ala His 100 105
110Gly Leu Pro Leu His Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro
115 120 125Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Leu
Pro Pro 130 135 140Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln
Pro Pro Asp Val145 150 155 160Gly Ser Ser Asp Pro Leu Ser Met Val
Gly Pro Ser Gln Gly Arg Ser 165 170 175Pro Ser Tyr Ala Ser
1801014PRTHomo sapiens 101Val His Tyr Gly11029PRTHomo sapiens
102Asp Ala Ser Pro His Val His Tyr Gly1 51039PRTHomo sapiens 103Asp
Ser Ser Pro Leu Val His Tyr Gly1 51047PRTHomo sapiens 104Asp Ser
Ser Pro Leu Leu Gln1 510512PRTHomo sapiens 105Asp Ser Ser Pro Leu
Leu Gln Phe Gly Gly Gln Val1 5 101065PRTHomo sapiens 106Arg His Pro
Ile Pro1 51074PRTHomo sapiens 107His Pro Ile Pro11085PRTHomo
sapiens 108Arg Pro Leu Ala Phe1 51094PRTHomo sapiens 109Pro Leu Ala
Phe11106PRTHomo sapiens 110Met Asp Ser Ser Pro Leu1 51117PRTHomo
sapiens 111Met Ser Asp Ser Ser Pro Leu1 51126PRTHomo sapiens 112Ser
Asp Ser Ser Pro Leu1 51135PRTHomo sapiens 113Met Ser Ser Pro Leu1
51144PRTHomo sapiens 114Ser Ser Pro Leu11154PRTHomo sapiens 115Arg
Asp Ser Ser11164PRTHomo sapiens 116Met Asp Ser Ser11175PRTHomo
sapiens 117Met Arg Asp Ser Ser1 51185PRTHomo sapiens 118Met Ser Ser
Pro Leu1 51196PRTHomo sapiens 119Met Asp Ser Ser Pro Leu1
51207PRTHomo sapiens 120Met Ser Asp Ser Ser Pro Leu1 51215PRTHomo
sapiens 121Asp Ser Ser Pro Leu1 51225PRTHomo sapiens 122Asp Ala Ser
Pro His1 51234PRTHomo sapiens 123Arg Asp Ser Ser11244PRTHomo
sapiens 124Met Asp Ser Ser11255PRTHomo sapiens 125Met Arg Asp Ser
Ser1 51266PRTHomo sapiens 126Met Asp Ser Ser Pro Leu1 51277PRTHomo
sapiens 127Met Ser Asp Ser Ser Pro Leu1 51285PRTHomo sapiens 128Met
Ser Ser Pro Leu1 51295PRTArtificial SequenceDescription of
Artificial Sequence Linker sequence 129Gly Ser Gly Gly Ser1
51304PRTArtificial SequenceDescription of Artificial Sequence
Linker sequence 130Gly Gly Gly Ser11314PRTArtificial
SequenceDescription of Artificial Sequence Linker sequence 131Gly
Gly Ser Gly11325PRTArtificial SequenceDescription of Artificial
Sequence Linker sequence 132Gly Gly Ser Gly Gly1 51335PRTArtificial
SequenceDescription of Artificial Sequence Linker sequence 133Gly
Ser Gly Ser Gly1 51345PRTArtificial SequenceDescription of
Artificial Sequence Linker sequence 134Gly Ser Gly Gly Gly1
51355PRTArtificial SequenceDescription of Artificial Sequence
Linker sequence 135Gly Ser Ser Ser Gly1 513632DNAArtificial
SequenceDescription of Artificial Sequence Forward primer
136ccgactagtc accatgcgga gcgggtgtgt gg 3213741DNAArtificial
SequenceDescription of Artificial Sequence Reverse primer
137ataagaatgc ggccgcttac ttctcaaagc tgggactcct c 41138186PRTHomo
sapiens 138Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln Val Arg Leu
Arg His1 5 10
15Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe Leu Arg Ile
20 25 30Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln Ser Ala His
Ser 35 40 45Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile
Lys Gly 50 55 60Val His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly
Lys Met Gln65 70 75 80Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala
Phe Glu Glu Glu Ile 85 90 95Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser
Glu Lys His Arg Leu Pro 100 105 110Val Ser Leu Ser Ser Ala Lys Gln
Arg Gln Leu Tyr Lys Asn Arg Gly 115 120 125Phe Leu Pro Leu Ser His
Phe Leu Pro Met Leu Pro Met Val Pro Glu 130 135 140Glu Pro Glu Asp
Leu Arg Gly His Leu Glu Ser Asp Met Phe Ser Ser145 150 155 160Pro
Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val Thr Gly Leu 165 170
175Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185139194PRTHomo
sapiens 139Arg Pro Leu Ala Phe Ser Asp Ala Ser Pro His Val His Tyr
Gly Trp1 5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His
Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu
Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro
Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150
155 160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp 165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe 180 185 190Glu Lys140194PRTHomo sapiens 140Arg Pro Leu
Ala Phe Ser Asp Ser Ser Pro Leu Val His Tyr Gly Trp1 5 10 15Gly Asp
Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25 30Leu
Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys 35 40
45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170 175Pro
Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe 180 185
190Glu Lys141188PRTHomo sapiens 141Asp Ser Ser Pro Leu Val His Tyr
Gly Trp Gly Asp Pro Ile Arg Leu1 5 10 15Arg His Leu Tyr Thr Ser Gly
Pro His Gly Leu Ser Ser Cys Phe Leu 20 25 30Arg Ile Arg Ala Asp Gly
Val Val Asp Cys Ala Arg Gly Gln Ser Ala 35 40 45His Ser Leu Leu Glu
Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile 50 55 60Lys Gly Val His
Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys65 70 75 80Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu 85 90 95Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg 100 105
110Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn
115 120 125Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro
Met Val 130 135 140Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu
Ser Asp Met Phe145 150 155 160Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp Pro Phe Gly Leu Val Thr 165 170 175Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe Glu Lys 180 185142193PRTHomo sapiens 142Arg His Pro Ile
Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Trp Gly1 5 10 15Asp Pro Ile
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser Ser
Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala 35 40 45Arg
Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu 50 55
60Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met65
70 75 80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185
190Lys143191PRTHomo sapiens 143Arg His Pro Ile Pro Asp Ser Ser Pro
Leu Leu Gln Trp Gly Asp Pro1 5 10 15Ile Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105
110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu
115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr
Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala
Val Arg Ser Pro Ser Phe Glu Lys 180 185 190144194PRTHomo sapiens
144Arg Pro Leu Ala Phe Ser Asp Ala Gly Pro Leu Leu Gln Phe Gly Trp1
5 10 15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly 20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155
160Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp
165 170 175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro
Ser Phe 180 185 190Glu Lys145193PRTHomo sapiens 145Arg His Pro Ile
Pro Asp Ser Ser Pro His Val His Tyr Gly Trp Gly1 5 10 15Asp Pro Ile
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25 30Ser Ser
Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala 35 40 45Arg
Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu 50 55
60Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met65
70 75 80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu
Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val
Tyr Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser
Ala Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro
Leu Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val Pro Glu Glu
Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser Asp Met Phe
Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170 175Phe Gly Leu
Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu 180 185
190Lys146192PRTHomo sapiens 146Arg Pro Leu Ala Phe Ser Asp Ala Gly
Pro Leu Leu Gln Phe Gly Gly1 5 10 15Gln Val Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 190147191PRTHomo
sapiens 147Arg His Pro Ile Pro Asp Ser Ser Pro His Val His Tyr Gly
Gly Gln1 5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro
Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150
155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 190148187PRTHomo sapiens 148Arg Asp Ser Ser Pro Leu
Leu Gln Phe Gly Gly Gln Val Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75
80Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu
85 90 95Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg
Leu 100 105 110Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr
Lys Asn Arg 115 120 125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met
Leu Pro Met Val Pro 130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His
Leu Glu Ser Asp Met Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp
Ser Met Asp Pro Phe Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val
Arg Ser Pro Ser Phe Glu Lys 180 185149192PRTHomo sapiens 149Arg Pro
Leu Ala Phe Ser Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly1 5 10 15Gln
Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25
30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg
35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu Pro Val Ser Leu
Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys Asn Arg Gly Phe
Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu Pro Met Val Pro
Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150 155 160Ser Asp
Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe 165 170
175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys
180 185 190150191PRTHomo sapiens 150Arg His Pro Ile Pro Asp Ser Ser
Pro Leu Leu Gln Phe Gly Ala Gln1 5 10 15Val Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe
Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105
110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu
115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
190151191PRTHomo sapiens 151Arg His Pro Ile Pro Asp Ser Ser Pro Leu
Leu Gln Phe Gly Asp Gln1 5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met
Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu
Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys
His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120
125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu
130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu
Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 185 190152191PRTHomo sapiens 152Arg His
Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Pro Gln1 5 10 15Val
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25
30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly
35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg
Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met
Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn
Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser
Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu
Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu
Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155 160Asp Met
Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170
175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185 190153191PRTHomo sapiens 153Arg His Pro Ile Pro Asp Ser Ser Pro
Leu Leu Gln Phe Gly Gly Ala1 5 10 15Val Arg Leu Arg His Leu Tyr Thr
Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala
Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu
Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly
Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys
Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105
110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu
115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro
Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly
His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr
Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala
Val Arg Ser Pro Ser Phe Glu Lys 180 185 190154191PRTHomo sapiens
154Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Glu1
5 10 15Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser
Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150 155
160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly
165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu
Lys 180 185 190155191PRTHomo sapiens 155Arg His Pro Ile Pro Asp Ser
Ser Pro Leu Leu Gln Phe Gly Gly Asn1 5 10 15Val Arg Leu Arg His Leu
Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile
Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His
Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile
Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp
Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90
95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu
100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 190156191PRTHomo
sapiens 156Arg His Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly
Gly Gln1 5 10 15Ala Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu Glu Ile Arg Pro
Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120 125Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu 130 135 140Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser145 150
155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185 190157191PRTHomo sapiens 157Arg His Pro Ile Pro Asp
Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln1 5 10 15Ile Arg Leu Arg His
Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg
Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala
His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala
Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75
80Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala
85 90 95Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser
Glu 100 105 110Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln
Arg Gln Leu 115 120 125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His
Phe Leu Pro Met Leu 130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp
Leu Arg Gly His Leu Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro
Leu Glu Thr Asp Ser Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly
Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185
190158191PRTHomo sapiens 158Arg His Pro Ile Pro Asp Ser Ser Pro Leu
Leu Gln Phe Gly Gly Gln1 5 10 15Thr Arg Leu Arg His Leu Tyr Thr Ser
Gly Pro His Gly Leu Ser Ser 20 25 30Cys Phe Leu Arg Ile Arg Ala Asp
Gly Val Val Asp Cys Ala Arg Gly 35 40 45Gln Ser Ala His Ser Leu Leu
Glu Ile Lys Ala Val Ala Leu Arg Thr 50 55 60Val Ala Ile Lys Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala65 70 75 80Asp Gly Lys Met
Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala 85 90 95Phe Glu Glu
Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu 100 105 110Lys
His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu 115 120
125Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu
130 135 140Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu
Glu Ser145 150 155 160Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser
Met Asp Pro Phe Gly 165 170 175Leu Val Thr Gly Leu Glu Ala Val Arg
Ser Pro Ser Phe Glu Lys 180 185 190159193PRTHomo sapiens 159Arg His
Pro Ile Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Trp Gly1 5 10 15Gln
Pro Val Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu 20 25
30Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala
35 40 45Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala
Leu 50 55 60Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu
Cys Met65 70 75 80Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr
Ser Glu Glu Asp 85 90 95Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly
Tyr Asn Val Tyr Arg 100 105 110Ser Glu Lys His Arg Leu Pro Val Ser
Leu Ser Ser Ala Lys Gln Arg 115 120 125Gln Leu Tyr Lys Asn Arg Gly
Phe Leu Pro Leu Ser His Phe Leu Pro 130 135 140Met Leu Pro Met Val
Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu145 150 155 160Glu Ser
Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro 165 170
175Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu
180 185 190Lys160190PRTHomo sapiens 160His Pro Ile Pro Asp Ser Ser
Pro Leu Leu Gln Phe Gly Gly Gln Val1 5 10 15Arg Leu Arg His Leu Tyr
Thr Ser Gly Pro His Gly Leu Ser Ser Cys 20 25 30Phe Leu Arg Ile Arg
Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln 35 40 45Ser Ala His Ser
Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val 50 55 60Ala Ile Lys
Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp65 70 75 80Gly
Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe 85 90
95Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys
100 105 110His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
Leu Tyr 115 120 125Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met Leu Pro 130 135 140Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu Ser Asp145 150 155 160Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe Gly Leu 165 170 175Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 190161186PRTHomo
sapiens 161Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln Val Arg Leu
Arg His1 5 10 15Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe
Leu Arg Ile 20 25 30Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln
Ser Ala His Ser 35 40 45Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr
Val Ala Ile Lys Gly 50 55 60Val His Ser Val Arg Tyr Leu Cys Met Gly
Ala Asp Gly Lys Met Gln65 70 75 80Gly Leu Leu Gln Tyr Ser Glu Glu
Asp Cys Ala Phe Glu Glu Glu Ile 85 90 95Arg Pro Asp Gly Tyr Asn Val
Tyr Arg Ser Glu Lys His Arg Leu Pro 100 105 110Val Ser Leu Ser Ser
Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg Gly 115 120 125Phe Leu Pro
Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro Glu 130 135 140Glu
Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met Phe Ser Ser145 150
155 160Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val Thr Gly
Leu 165 170 175Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185162190PRTHomo sapiens 162His Pro Ile Pro Asp Ser Ser Pro Leu Leu
Gln Trp Gly Asp Pro Ile1 5 10 15Arg Leu Arg His Leu Tyr Thr Ser Gly
Pro His Gly Leu Ser Ser Cys 20 25 30Phe Leu Arg Ile Arg Ala Asp Gly
Val Val Asp Cys Ala Arg Gly Gln 35 40 45Ser Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala Leu Arg Thr Val 50 55 60Ala Ile Lys Gly Val His
Ser Val Arg Tyr Leu Cys Met Gly Ala Asp65 70 75 80Gly Lys Met Gln
Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe 85 90 95Glu Glu Glu
Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys 100 105 110His
Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr 115 120
125Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro
130 135 140Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu
Ser Asp145 150 155 160Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met
Asp Pro Phe Gly Leu 165 170 175Val Thr Gly Leu Glu Ala Val Arg Ser
Pro Ser Phe Glu Lys 180 185 190163192PRTHomo sapiens 163His Pro Ile
Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Trp Gly Asp1 5 10 15Pro Ile
Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser 20 25 30Ser
Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg 35 40
45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg
50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met
Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu
Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn
Val Tyr Arg Ser 100 105
110Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln
115 120 125Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu
Pro Met 130 135 140Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg
Gly His Leu Glu145 150 155 160Ser Asp Met Phe Ser Ser Pro Leu Glu
Thr Asp Ser Met Asp Pro Phe 165 170 175Gly Leu Val Thr Gly Leu Glu
Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 190164192PRTHomo
sapiens 164His Pro Ile Pro Asp Ser Ser Pro His Val His Tyr Gly Trp
Gly Asp1 5 10 15Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His
Gly Leu Ser 20 25 30Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val
Asp Cys Ala Arg 35 40 45Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys
Ala Val Ala Leu Arg 50 55 60Thr Val Ala Ile Lys Gly Val His Ser Val
Arg Tyr Leu Cys Met Gly65 70 75 80Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu Asp Cys 85 90 95Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr Asn Val Tyr Arg Ser 100 105 110Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln 115 120 125Leu Tyr Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met 130 135 140Leu
Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu145 150
155 160Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro
Phe 165 170 175Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser
Phe Glu Lys 180 185 190165190PRTHomo sapiens 165His Pro Ile Pro Asp
Ser Ser Pro His Val His Tyr Gly Gly Gln Val1 5 10 15Arg Leu Arg His
Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys 20 25 30Phe Leu Arg
Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln 35 40 45Ser Ala
His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val 50 55 60Ala
Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala Asp65 70 75
80Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe
85 90 95Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu
Lys 100 105 110His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln Arg
Gln Leu Tyr 115 120 125Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe
Leu Pro Met Leu Pro 130 135 140Met Val Pro Glu Glu Pro Glu Asp Leu
Arg Gly His Leu Glu Ser Asp145 150 155 160Met Phe Ser Ser Pro Leu
Glu Thr Asp Ser Met Asp Pro Phe Gly Leu 165 170 175Val Thr Gly Leu
Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180 185 190166188PRTHomo
sapiens 166Asp Ala Gly Pro His Val His Tyr Gly Trp Gly Asp Pro Ile
Arg Leu1 5 10 15Arg His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser
Cys Phe Leu 20 25 30Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg
Gly Gln Ser Ala 35 40 45His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu
Arg Thr Val Ala Ile 50 55 60Lys Gly Val His Ser Val Arg Tyr Leu Cys
Met Gly Ala Asp Gly Lys65 70 75 80Met Gln Gly Leu Leu Gln Tyr Ser
Glu Glu Asp Cys Ala Phe Glu Glu 85 90 95Glu Ile Arg Pro Asp Gly Tyr
Asn Val Tyr Arg Ser Glu Lys His Arg 100 105 110Leu Pro Val Ser Leu
Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn 115 120 125Arg Gly Phe
Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro Met Val 130 135 140Pro
Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met Phe145 150
155 160Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe Gly Leu Val
Thr 165 170 175Gly Leu Glu Ala Val Arg Ser Pro Ser Phe Glu Lys 180
185167183PRTHomo sapiens 167Val His Tyr Gly Trp Gly Asp Pro Ile Arg
Leu Arg His Leu Tyr Thr1 5 10 15Ser Gly Pro His Gly Leu Ser Ser Cys
Phe Leu Arg Ile Arg Ala Asp 20 25 30Gly Val Val Asp Cys Ala Arg Gly
Gln Ser Ala His Ser Leu Leu Glu 35 40 45Ile Lys Ala Val Ala Leu Arg
Thr Val Ala Ile Lys Gly Val His Ser 50 55 60Val Arg Tyr Leu Cys Met
Gly Ala Asp Gly Lys Met Gln Gly Leu Leu65 70 75 80Gln Tyr Ser Glu
Glu Asp Cys Ala Phe Glu Glu Glu Ile Arg Pro Asp 85 90 95Gly Tyr Asn
Val Tyr Arg Ser Glu Lys His Arg Leu Pro Val Ser Leu 100 105 110Ser
Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro 115 120
125Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu
130 135 140Asp Leu Arg Gly His Leu Glu Ser Asp Met Phe Ser Ser Pro
Leu Glu145 150 155 160Thr Asp Ser Met Asp Pro Phe Gly Leu Val Thr
Gly Leu Glu Ala Val 165 170 175Arg Ser Pro Ser Phe Glu Lys
180168174PRTHomo sapiens 168Arg Leu Arg His Leu Tyr Thr Ser Gly Pro
His Gly Leu Ser Ser Cys1 5 10 15Phe Leu Arg Ile Arg Ala Asp Gly Val
Val Asp Cys Ala Arg Gly Gln 20 25 30Ser Ala His Ser Leu Leu Glu Ile
Lys Ala Val Ala Leu Arg Thr Val 35 40 45Ala Ile Lys Gly Val His Ser
Val Arg Tyr Leu Cys Met Gly Ala Asp 50 55 60Gly Lys Met Gln Gly Leu
Leu Gln Tyr Ser Glu Glu Asp Cys Ala Phe65 70 75 80Glu Glu Glu Ile
Arg Pro Asp Gly Tyr Asn Val Tyr Arg Ser Glu Lys 85 90 95His Arg Leu
Pro Val Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr 100 105 110Lys
Asn Arg Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro 115 120
125Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp
130 135 140Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly Leu145 150 155 160Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser
Phe Glu Lys 165 17016914PRTArtificial SequenceSynthetic peptide
169Trp Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly1 5
101705PRTArtificial SequenceSynthetic peptide 170Trp Gly Asp Pro
Ile1 51714PRTArtificial SequenceSynthetic peptide 171Trp Gly Pro
Ile11725PRTArtificial SequenceSynthetic peptide 172Trp Gly Asp Pro
Val1 51734PRTArtificial SequenceSynthetic peptide 173Trp Gly Asp
Ile11744PRTArtificial SequenceSynthetic peptide 174Gly Asp Pro
Ile11755PRTArtificial SequenceSynthetic peptide 175Trp Gly Gln Pro
Ile1 51765PRTArtificial SequenceSynthetic peptide 176Trp Gly Ala
Pro Ile1 51775PRTArtificial SequenceSynthetic peptide 177Ala Gly
Asp Pro Ile1 51785PRTArtificial SequenceSynthetic peptide 178Trp
Ala Asp Pro Ile1 51795PRTArtificial SequenceSynthetic peptide
179Trp Gly Asp Ala Ile1 51805PRTArtificial SequenceSynthetic
peptide 180Trp Gly Asp Pro Ala1 51814PRTArtificial
SequenceSynthetic peptide 181Trp Asp Pro Ile11824PRTArtificial
SequenceSynthetic peptide 182Trp Gly Asp Ile11834PRTArtificial
SequenceSynthetic peptide 183Trp Gly Asp Pro11845PRTArtificial
SequenceSynthetic peptide 184Phe Gly Asp Pro Ile1
51859PRTArtificial SequenceSynthetic peptide 185Arg Leu Arg His Leu
Tyr Thr Ser Gly1 51869PRTArtificial Sequencecore sequence 186Arg
Gln Arg Tyr Leu Tyr Thr Asp Asp1 518713PRTArtificial
SequenceSynthetic peptide 187Ala Gly Pro His Val His Tyr Gly Trp
Gly Asp Pro Ile1 5 10188165PRTHomo sapiensFGF19 C-terminal sequence
188Pro His Gly Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val1
5 10 15Val Asp Cys Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile
Lys 20 25 30Ala Val Ala Leu Arg Thr Val Ala Ile Lys Gly Val His Ser
Val Arg 35 40 45Tyr Leu Cys Met Gly Ala Asp Gly Lys Met Gln Gly Leu
Leu Gln Tyr 50 55 60Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu Ile Arg
Pro Asp Gly Tyr65 70 75 80Asn Val Tyr Arg Ser Glu Lys His Arg Leu
Pro Val Ser Leu Ser Ser 85 90 95Ala Lys Gln Arg Gln Leu Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser 100 105 110His Phe Leu Pro Met Leu Pro
Met Val Pro Glu Glu Pro Glu Asp Leu 115 120 125Arg Gly His Leu Glu
Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp 130 135 140Ser Met Asp
Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser145 150 155
160Pro Ser Phe Glu Lys 1651895PRTArtificial SequenceLinker sequence
189Gly Gly Gly Ser Gly1 519011PRTHomo sapiensSheet-8/Loop-8/Sheet-9
region of FGF19 190Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr1 5
1019111PRTHomo sapiensSheet-8/Loop-8/Sheet-9 region of FGF21 191Glu
Leu Leu Leu Glu Asp Gly Tyr Asn Val Tyr1 5 10192187PRTArtificial
SequenceM53 sequence 192Met Asp Ser Ser Pro Leu Leu Gln Trp Gly Asp
Pro Ile Arg Leu Arg1 5 10 15His Leu Tyr Thr Ser Gly Pro His Gly Leu
Ser Ser Cys Phe Leu Arg 20 25 30Ile Arg Ala Asp Gly Val Val Asp Cys
Ala Arg Gly Gln Ser Ala His 35 40 45Ser Leu Leu Glu Ile Lys Ala Val
Ala Leu Arg Thr Val Ala Ile Lys 50 55 60Gly Val His Ser Val Arg Tyr
Leu Cys Met Gly Ala Asp Gly Lys Met65 70 75 80Gln Gly Leu Leu Gln
Tyr Ser Glu Glu Asp Cys Ala Phe Glu Glu Glu 85 90 95Ile Arg Pro Asp
Gly Tyr Asn Val Tyr Arg Ser Glu Lys His Arg Leu 100 105 110Pro Val
Ser Leu Ser Ser Ala Lys Gln Arg Gln Leu Tyr Lys Asn Arg 115 120
125Gly Phe Leu Pro Leu Ser His Phe Leu Pro Met Leu Pro Met Val Pro
130 135 140Glu Glu Pro Glu Asp Leu Arg Gly His Leu Glu Ser Asp Met
Phe Ser145 150 155 160Ser Pro Leu Glu Thr Asp Ser Met Asp Pro Phe
Gly Leu Val Thr Gly 165 170 175Leu Glu Ala Val Arg Ser Pro Ser Phe
Glu Lys 180 185193194PRTArtificial SequenceM139 sequence 193Arg Pro
Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10 15Gly
Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly 20 25
30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp Cys
35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala Val
Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg Tyr
Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu Gln
Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Leu Pro Asp
Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro Val
Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn Arg
Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro Met
Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu Glu
Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170
175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
180 185 190Glu Lys194194PRTArtificial SequenceM140 sequence 194Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10
15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Arg Glu
Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu
Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170
175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
180 185 190Glu Lys195194PRTArtificial SequenceM141 sequence 195Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10
15Gly Asp Pro Ile Arg Leu Arg His Leu Tyr Thr Ser Gly Pro His Gly
20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Leu Cys
Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu
Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170
175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
180 185 190Glu Lys196194PRTArtificial SequenceM160 sequence 196Arg
Pro Leu Ala Phe Ser Asp Ala Gly Pro His Val His Tyr Gly Trp1 5 10
15Gly Asp Pro Ile Arg Gln Arg His Leu Tyr Thr Ser Gly Pro His Gly
20 25 30Leu Ser Ser Cys Phe Leu Arg Ile Arg Ala Asp Gly Val Val Asp
Cys 35 40 45Ala Arg Gly Gln Ser Ala His Ser Leu Leu Glu Ile Lys Ala
Val Ala 50 55 60Leu Arg Thr Val Ala Ile Lys Gly Val His Ser Val Arg
Tyr Leu Cys65 70 75 80Met Gly Ala Asp Gly Lys Met Gln Gly Leu Leu
Gln Tyr Ser Glu Glu 85 90 95Asp Cys Ala Phe Glu Glu Glu Ile Leu Glu
Asp Gly Tyr Asn Val Tyr 100 105 110Arg Ser Glu Lys His Arg Leu Pro
Val Ser Leu Ser Ser Ala Lys Gln 115 120 125Arg Gln Leu Tyr Lys Asn
Arg Gly Phe Leu Pro Leu Ser His Phe Leu 130 135 140Pro Met Leu Pro
Met Val Pro Glu Glu Pro Glu Asp Leu Arg Gly His145 150 155 160Leu
Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp Ser Met Asp 165 170
175Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg Ser Pro Ser Phe
180 185 190Glu Lys
* * * * *